[
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "pentazocine",
    "entity2": "tripelennamine",
    "text": "Twelve strains of Staphylococcus aureus (a frequent cause of infection in heroin, but not in <drug>pentazocine</drug> and <drug>tripelennamine</drug>, addicts) were completely inhibited by the drug combination. ",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "tripelennamine",
    "entity2": "pentazocine",
    "text": "Dose-response curves (derived from the results of using the tablets as well as pure powders) showed that <drug>tripelennamine</drug> was responsible for the inhibitory activity, which was partially antagonized by <drug>pentazocine</drug>. ",
    "source": "MedLine"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "cobalt",
    "entity2": "iron",
    "text": "Interactions of <drug>cobalt</drug> and <drug>iron</drug> in absorption and retention.\r\n",
    "source": "MedLine"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "iron",
    "entity2": "cobalt",
    "text": "Additional <drug>iron</drug> significantly inhibited the absorption of <drug>cobalt</drug> in both dietary cobalt treatments. ",
    "source": "MedLine"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "iron",
    "entity2": "cobalt",
    "text": "Additional <drug>iron</drug> significantly inhibited the absorption of cobalt in both dietary <drug>cobalt</drug> treatments. ",
    "source": "MedLine"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Fe",
    "entity2": "cobalt",
    "text": "The lower rate of absorption in the groups receiving 446 mg <drug>Fe</drug> instead of 48 mg of Fe per kg diet resulted in a decreased renal excretion of <drug>cobalt</drug>. ",
    "source": "MedLine"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "iron",
    "entity2": "cobalt",
    "text": "Consequently, the effect of <drug>iron</drug> on the retention of <drug>cobalt</drug> was lower than on absorption. ",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "cisplatin",
    "entity2": "sodium thiosulfate",
    "text": "High-dose <drug>cisplatin</drug> with <drug>sodium thiosulfate</drug> protection.\r\n",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Sodium thiosulfate",
    "entity2": "cisplatin",
    "text": "<drug>Sodium thiosulfate</drug> is a neutralizing agent for <drug>cisplatin</drug> that protects against renal damage. ",
    "source": "MedLine"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "thiosulfate",
    "entity2": "cisplatin",
    "text": "This study demonstrates that concurrent administration of <drug>thiosulfate</drug> permits at least a twofold increase in dose and total exposure to <drug>cisplatin</drug>.",
    "source": "MedLine"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "indinavir",
    "entity2": "didanosine",
    "text": "Concurrent administration of <drug>indinavir</drug> and <drug>didanosine</drug> significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. ",
    "source": "MedLine"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "indinavir",
    "entity2": "didanosine",
    "text": "Median gastric pH was significantly higher when <drug>indinavir</drug> was taken after <drug>didanosine</drug> administration; ",
    "source": "MedLine"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "Indinavir",
    "entity2": "didanosine",
    "text": "<drug>Indinavir</drug> may be taken with a light meal 1 h following the administration of 400 mg of <drug>didanosine</drug>.",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "neomycin",
    "entity2": "ACTH",
    "text": "Studies in rats have shown that <drug>neomycin</drug> administration attenuates certain types of adrenocortical steroid dependent hypertension, including <drug>ACTH</drug> hypertension. ",
    "source": "MedLine"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Cholestyramine",
    "entity2": "fluvastatin",
    "text": "<drug>Cholestyramine</drug>, an anionic-binding resin, has a considerable effect in lowering the rate and extent of <drug>fluvastatin</drug> bioavailability. ",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "cholestyramine",
    "entity2": "fluvastatin",
    "text": "Although this effect was noted even when <drug>cholestyramine</drug> was given 4 hours prior to <drug>fluvastatin</drug>, this regimen did not result in diminished efficacy. ",
    "source": "MedLine"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "diltiazem",
    "entity2": "sirolimus",
    "text": "Pharmacokinetic interaction between single oral doses of <drug>diltiazem</drug> and <drug>sirolimus</drug> in healthy volunteers.\r\n",
    "source": "MedLine"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "sirolimus",
    "entity2": "diltiazem",
    "text": "RESULTS: The geometric mean (90% confidence interval) whole blood <drug>sirolimus</drug> area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with <drug>diltiazem</drug> coadministration, whereas the mean elimination half-life of sirolimus decreased slightly, from 79 to 67 hours. ",
    "source": "MedLine"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "sirolimus",
    "entity2": "diltiazem",
    "text": "Apparent oral clearance and volume of distribution of sirolimus decreased with 38% and 45%, respectively, when <drug>sirolimus</drug> was given with <drug>diltiazem</drug>. ",
    "source": "MedLine"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "diltiazem",
    "entity2": "sirolimus",
    "text": "CONCLUSIONS: Single-dose <drug>diltiazem</drug> coadministration leads to higher <drug>sirolimus</drug> exposure, presumably by inhibition of the first-pass metabolism of sirolimus. ",
    "source": "MedLine"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "sirolimus",
    "entity2": "diltiazem",
    "text": "Because of the pronounced intersubject variability in the extent of the <drug>sirolimus</drug>-<drug>diltiazem</drug> interaction, whole blood sirolimus concentrations should be monitored closely in patients treated with the two drugs.",
    "source": "MedLine"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "trovafloxacin",
    "entity2": "morphine",
    "text": "Previous studies have demonstrated a significant reduction in the oral bioavailability of <drug>trovafloxacin</drug> and ciprofloxacin when administered concomitantly with an intravenous opiate such as <drug>morphine</drug>. ",
    "source": "MedLine"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "ciprofloxacin",
    "entity2": "morphine",
    "text": "Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and <drug>ciprofloxacin</drug> when administered concomitantly with an intravenous opiate such as <drug>morphine</drug>. ",
    "source": "MedLine"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Acetaminophen",
    "entity2": "theophylline",
    "text": "<drug>Acetaminophen</drug> diminished the binding of <drug>theophylline</drug> to human serum by a net change of 5.7% (percentage increase in free drug fraction [FDF], 11.0%) at 662 micromol/L and by a net change of 7.1% (percentage increase in FDF, 13.7%) at 1324 micromol/L. ",
    "source": "MedLine"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Theophylline",
    "entity2": "acetaminophen",
    "text": "<drug>Theophylline</drug> decreased the binding of <drug>acetaminophen</drug> by a net change of 6.8% (percentage increase in FDF, 8.8%) at 277.5 micromol/L; ",
    "source": "MedLine"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Valproic acid",
    "entity2": "phenobarbital",
    "text": "<drug>Valproic acid</drug> diminished binding of <drug>phenobarbital</drug> by a net change of 9.9% (percentage increase in FDF, 21.2%) at 1732 micromol/L. ",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "acetaminophen",
    "entity2": "theophylline",
    "text": "Coingestion of <drug>acetaminophen</drug> with <drug>theophylline</drug>, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. ",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "phenobarbital",
    "entity2": "acetaminophen",
    "text": "Coingestion of acetaminophen with theophylline, <drug>phenobarbital</drug> with <drug>acetaminophen</drug>, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. ",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "valproic acid",
    "entity2": "phenobarbital",
    "text": "Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and <drug>valproic acid</drug> with <drug>phenobarbital</drug> at high to toxic concentrations decreases the binding of the target drug. ",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "simvastatin",
    "entity2": "clarithromycin",
    "text": "Rhabdomyolysis secondary to a drug interaction between <drug>simvastatin</drug> and <drug>clarithromycin</drug>.\r\n",
    "source": "MedLine"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Clarithromycin",
    "entity2": "simvastatin",
    "text": "DISCUSSION: <drug>Clarithromycin</drug> is a potent inhibitor of CYP3A4, the major enzyme responsible for <drug>simvastatin</drug> metabolism. ",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Cypermethrin",
    "entity2": "vitamin E",
    "text": "<drug>Cypermethrin</drug>-induced oxidative stress in rat brain and liver is prevented by <drug>vitamin E</drug> or allopurinol.\r\n",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Cypermethrin",
    "entity2": "allopurinol",
    "text": "<drug>Cypermethrin</drug>-induced oxidative stress in rat brain and liver is prevented by vitamin E or <drug>allopurinol</drug>.\r\n",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "allopurinol",
    "entity2": "cypermethrin",
    "text": "Pretreatment of rats with <drug>allopurinol</drug> (100 mg/kg, ip) or Vitamin E (100 mg/kg per day, ig, for 3 days and a dose of 40 mg/kg on the 4th day) provided significant protection against the elevation of TBARS levels in cerebral and hepatic tissues, induced by single high dose of oral <drug>cypermethrin</drug> administration within 4 h. ",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Vitamin E",
    "entity2": "cypermethrin",
    "text": "Pretreatment of rats with allopurinol (100 mg/kg, ip) or <drug>Vitamin E</drug> (100 mg/kg per day, ig, for 3 days and a dose of 40 mg/kg on the 4th day) provided significant protection against the elevation of TBARS levels in cerebral and hepatic tissues, induced by single high dose of oral <drug>cypermethrin</drug> administration within 4 h. ",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "cypermethrin",
    "entity2": "allopurinol",
    "text": "Thus, the results suggest that <drug>cypermethrin</drug> exposure of rats results in free radical-mediated tissue damage, as indicated by elevated cerebral and hepatic lipid peroxidation, which was prevented by <drug>allopurinol</drug> and Vitamin E.",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "cypermethrin",
    "entity2": "Vitamin E",
    "text": "Thus, the results suggest that <drug>cypermethrin</drug> exposure of rats results in free radical-mediated tissue damage, as indicated by elevated cerebral and hepatic lipid peroxidation, which was prevented by allopurinol and <drug>Vitamin E</drug>.",
    "source": "MedLine"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "cimetidine",
    "entity2": "verografine",
    "text": "[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of <drug>cimetidine</drug> in a dose of 20 mg/kg enhanced <drug>verografine</drug> and iodamide excretion in chronic canine experiments. ",
    "source": "MedLine"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "cimetidine",
    "entity2": "iodamide",
    "text": "[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of <drug>cimetidine</drug> in a dose of 20 mg/kg enhanced verografine and <drug>iodamide</drug> excretion in chronic canine experiments. ",
    "source": "MedLine"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "prostaglandin F2alpha",
    "entity2": "oxytocin",
    "text": "In vitro interaction of <drug>prostaglandin F2alpha</drug> and <drug>oxytocin</drug> in placental vessels.\n",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "PGF2alpha",
    "entity2": "oxytocin",
    "text": "<drug>PGF2alpha</drug> produced significantly increased vasoconstriction after a single administration of <drug>oxytocin</drug>. ",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "PGF2alpha",
    "entity2": "oxytocin",
    "text": "There is thus an enhancement effect of <drug>PGF2alpha</drug> upon the reaction of placental vessels to <drug>oxytocin</drug> in vitro.",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "glycine",
    "entity2": "glutamate",
    "text": "Interaction between <drug>glycine</drug> and <drug>glutamate</drug> in the development of spontaneous motility in chick embryos.\n",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "glycine",
    "entity2": "glutamate",
    "text": "The successive application of <drug>glycine</drug> (5 or 10 mg/kg egg weight (e.w.) and <drug>glutamate</drug> (15 mg/kg e.w.) in a 10 min interval significantly increased the activation of spontaneous motility of 17-day-old chick embryos in comparison with the effect of glutamate alone. ",
    "source": "MedLine"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "clindamycin",
    "entity2": "gentamicin",
    "text": "Interaction of <drug>clindamycin</drug> and <drug>gentamicin</drug> in vitro.\n",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "clindamycin",
    "entity2": "gentamicin",
    "text": "Combinations of <drug>clindamycin</drug> and <drug>gentamicin</drug> were indifferent for 29 strains and synergistic for 33 strains. ",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "clindamycin",
    "entity2": "gentamicin",
    "text": "Combinations of <drug>clindamycin</drug> and <drug>gentamicin</drug> were indifferent for 16 and synergistic for 11 of the resistant strains. ",
    "source": "MedLine"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Azithromycin",
    "entity2": "zidovudine",
    "text": "<drug>Azithromycin</drug> had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the <drug>zidovudine</drug> tmax by 44% and increased the intracellular exposure to phosphorylated zidovudine by 110%. ",
    "source": "MedLine"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Azithromycin",
    "entity2": "zidovudine",
    "text": "<drug>Azithromycin</drug> had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the zidovudine tmax by 44% and increased the intracellular exposure to phosphorylated <drug>zidovudine</drug> by 110%. ",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Diazepam",
    "entity2": "morphine",
    "text": "<drug>Diazepam</drug> at doses of 0.25 mg/kg and 2.5 mg/kg injected with <drug>morphine</drug> was found to decrease the antinociceptive effect of morphine. ",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "diazepam",
    "entity2": "metamizol",
    "text": "Similarly, <drug>diazepam</drug> decreased the antinociceptive effect of <drug>metamizol</drug> (only in the tail-flick test) and indomethacin. ",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "diazepam",
    "entity2": "indomethacin",
    "text": "Similarly, <drug>diazepam</drug> decreased the antinociceptive effect of metamizol (only in the tail-flick test) and <drug>indomethacin</drug>. ",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Midazolam",
    "entity2": "morphine",
    "text": "<drug>Midazolam</drug> used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of <drug>morphine</drug>, metamizol (only in the tail-flick test) and indomethacin.",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Midazolam",
    "entity2": "metamizol",
    "text": "<drug>Midazolam</drug> used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, <drug>metamizol</drug> (only in the tail-flick test) and indomethacin.",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Midazolam",
    "entity2": "indomethacin",
    "text": "<drug>Midazolam</drug> used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, metamizol (only in the tail-flick test) and <drug>indomethacin</drug>.",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "ethanol",
    "entity2": "disulfiram",
    "text": "Core temperature was decreased in rats in a dose-dependent manner when <drug>ethanol</drug> was administered to rats treated with <drug>disulfiram</drug> 8 hours before the ethanol challenge. ",
    "source": "MedLine"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "ketamine",
    "entity2": "halothane",
    "text": "Interaction of <drug>ketamine</drug> and <drug>halothane</drug> in rats.\n",
    "source": "MedLine"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "halothane",
    "entity2": "ketamine",
    "text": "However, <drug>halothane</drug> anesthetic requirement (i.e., MAC) was depressed in a dose-dependent fashion as much as 56% 1-2 hours and as much as 14% 5-6 hours after injection of <drug>ketamine</drug>, 50 mg/kg, im. ",
    "source": "MedLine"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "ketamine",
    "entity2": "halothane",
    "text": "The half-life of <drug>ketamine</drug> in plasma and brain was longer in the presence of <drug>halothane</drug> than when ketamine was given alone. ",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "ketamine",
    "entity2": "halothane",
    "text": "It is concluded that <drug>ketamine</drug> is not a short-acting drug and that concomitant use with <drug>halothane</drug> would be expected to prolong further the duration of its action on the central nervous system.",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Dexamethasone",
    "entity2": "insulin",
    "text": "<drug>Dexamethasone</drug> and retinyl acetate similarly inhibit and stimulate EGF- or <drug>insulin</drug>-induced proliferation of prostatic epithelium.",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "retinyl acetate",
    "entity2": "insulin",
    "text": "Dexamethasone and <drug>retinyl acetate</drug> similarly inhibit and stimulate EGF- or <drug>insulin</drug>-induced proliferation of prostatic epithelium.",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "dexamethasone",
    "entity2": "insulin",
    "text": "Although neither <drug>dexamethasone</drug> nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and <drug>insulin</drug>. ",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "retinyl acetate",
    "entity2": "insulin",
    "text": "Although neither dexamethasone nor <drug>retinyl acetate</drug> affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and <drug>insulin</drug>. ",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "retinyl acetate",
    "entity2": "insulin",
    "text": "However, <drug>retinyl acetate</drug> stimulated, but did not significantly inhibit, proliferation in the presence of <drug>insulin</drug>. ",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "dexamethasone",
    "entity2": "insulin",
    "text": "These results suggest that both <drug>dexamethasone</drug> and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of <drug>insulin</drug> and EGF.",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "retinyl acetate",
    "entity2": "insulin",
    "text": "These results suggest that both dexamethasone and <drug>retinyl acetate</drug>, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of <drug>insulin</drug> and EGF.",
    "source": "MedLine"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Amiodarone",
    "entity2": "digoxin",
    "text": "<drug>Amiodarone</drug> is known to raise serum <drug>digoxin</drug> levels. ",
    "source": "MedLine"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "amiodarone",
    "entity2": "digoxin",
    "text": "During <drug>amiodarone</drug> administration, systemic clearance of <drug>digoxin</drug> was reduced from 234 +/- 72 ml/min (mean +/- standard deviation) to 172 +/- 33 ml/min (p less than 0.01). ",
    "source": "MedLine"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "digoxin",
    "entity2": "amiodarone",
    "text": "These alterations in <drug>digoxin</drug> pharmacokinetics produced by <drug>amiodarone</drug> explain the increase in serum digoxin level that has been observed when this drug combination has been used clinically.",
    "source": "MedLine"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "theophylline",
    "entity2": "phenytoin",
    "text": "Enhanced <drug>theophylline</drug> clearance secondary to <drug>phenytoin</drug> therapy.\r\n",
    "source": "MedLine"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "theophylline",
    "entity2": "phenytoin",
    "text": "This report describes two cases in which <drug>theophylline</drug> clearance accelerated markedly with concomitant <drug>phenytoin</drug> administration. ",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "phenytoin",
    "entity2": "theophylline",
    "text": "With combined use, clinicians should be aware, when <drug>phenytoin</drug> is added, of the potential for reexacerbation of pulmonary symptomatology due to lowered serum <drug>theophylline</drug> concentrations.",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Etofibrate",
    "entity2": "heparin",
    "text": "<drug>Etofibrate</drug> elicited 62% enhancement of post-<drug>heparin</drug> lipolytic activity and 100% increase of 3H-triglyceride fractional clearance rate compared with placebo treatment. ",
    "source": "MedLine"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "gentamycin",
    "entity2": "atracurium",
    "text": "Interaction of <drug>gentamycin</drug> and <drug>atracurium</drug> in anaesthetised horses.\r\n",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "atracurium",
    "entity2": "gentamycin",
    "text": "Recovery of hoof twitch from 50% to 75% took 7.7 +/- 0.7 min for atracurium alone and 11.5 +/- 2.7 min for <drug>atracurium</drug> plus <drug>gentamycin</drug> (P = 0.03). ",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "atracurium",
    "entity2": "gentamycin",
    "text": "Recovery from 50% twitch to 75% fade recovery took 13.8 +/- 0.8 min for atracurium alone and 13.7 +/- 1.2 min for <drug>atracurium</drug> plus <drug>gentamycin</drug>. ",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "atracurium",
    "entity2": "gentamycin",
    "text": "At 75% recovery of fade, hoof twitch was 87 +/- 3% for atracurium alone and 82 +/- 4% for <drug>atracurium</drug> plus <drug>gentamycin</drug>. ",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "gentamycin",
    "entity2": "atracurium",
    "text": "It was concluded that, although <drug>gentamycin</drug> did augment the neuromuscular blockade of <drug>atracurium</drug>, the effect was minimal.",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "naloxone",
    "entity2": "morphine",
    "text": "the doses of <drug>naloxone</drug> required to antagonize the effects of (-)-NANM were more than 100 times higher than those required to antagonize the effects of <drug>morphine</drug>. ",
    "source": "MedLine"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "fluoxetine",
    "entity2": "cisapride",
    "text": "Coadministration of <drug>fluoxetine</drug> significantly decreased <drug>cisapride</drug> plasma concentrations. ",
    "source": "MedLine"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "cephaloridine",
    "entity2": "probenecid",
    "text": "(1968, 1970), the higher serum concentrations of penicillins and <drug>cephaloridine</drug> reached after administration of <drug>probenecid</drug> are due not only to slower renal elimination but also to an altered distribution in the body. ",
    "source": "MedLine"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "probenecid",
    "entity2": "cloxacillin",
    "text": "This might be explained by a blockade by <drug>probenecid</drug> of the elimination of <drug>cloxacillin</drug> by the liver.",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "MPTP",
    "entity2": "amphetamine",
    "text": "The <drug>MPTP</drug>-induced neuronal damage produced a tolerance to the disruptive effects of <drug>amphetamine</drug> and a supersensitivity to the disruptive effects of apomorphine in rats responding in a schedule controlled paradigm. ",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "MPTP",
    "entity2": "apomorphine",
    "text": "The <drug>MPTP</drug>-induced neuronal damage produced a tolerance to the disruptive effects of amphetamine and a supersensitivity to the disruptive effects of <drug>apomorphine</drug> in rats responding in a schedule controlled paradigm. ",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Methamphetamine",
    "entity2": "pargyline",
    "text": "<drug>Methamphetamine</drug>, like MPTP, produced depletions of striatal dopamine but these actions were potentiated by <drug>pargyline</drug> pretreatment. ",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "99mTc-methylene diphosphonate",
    "entity2": "gentamicin",
    "text": "Therapeutic drug monitoring can avoid iatrogenic alterations caused by <drug>99mTc-methylene diphosphonate</drug> (MDP)-<drug>gentamicin</drug> interaction.\r\n",
    "source": "MedLine"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "gentamicin",
    "entity2": "99mTc-MDP",
    "text": "Due to its nephrotoxicity, <drug>gentamicin</drug> may cause abnormal renal uptake to be seen on <drug>99mTc-MDP</drug> bone scintigraphy. ",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "ketamine",
    "entity2": "ouabain",
    "text": "In a comparison of digitalis tolerance in dogs anesthetized with <drug>ketamine</drug>, Innovar Vet, or pentobarbital, the dosage of <drug>ouabain</drug> needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. ",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "pentobarbital",
    "entity2": "ouabain",
    "text": "In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or <drug>pentobarbital</drug>, the dosage of <drug>ouabain</drug> needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. ",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "ouabain",
    "entity2": "ketamine",
    "text": "Ventricular tachycardia induced by <drug>ouabain</drug> was generally converted to sinus rhythm following administration of Innovar, <drug>ketamine</drug>, or droperidol but not after administration of fentayl alone or after pentobarbital.",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "ouabain",
    "entity2": "droperidol",
    "text": "Ventricular tachycardia induced by <drug>ouabain</drug> was generally converted to sinus rhythm following administration of Innovar, ketamine, or <drug>droperidol</drug> but not after administration of fentayl alone or after pentobarbital.",
    "source": "MedLine"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "phenytoin",
    "entity2": "quetiapine",
    "text": "This study demonstrated that the potent cytochrome P450 enzyme-inducer <drug>phenytoin</drug> did indeed have a marked effect on the metabolism of <drug>quetiapine</drug>, resulting in a 5-fold increase in clearance when administered concomitantly to patients with DSM-IV-diagnosed schizophrenia, schizoaffective disorder, or bipolar disorder. ",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "ADL 8-2698",
    "entity2": "morphine",
    "text": "<drug>ADL 8-2698</drug>, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous <drug>morphine</drug> without affecting analgesia.\r\n",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Morphine",
    "entity2": "ADL 8-2698",
    "text": "<drug>Morphine</drug> prolonged gastrointestinal transit time from 69 to 103 minutes (P = .005); this was prevented by <drug>ADL 8-2698</drug> (P = .004). ",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "ADL 8-2698",
    "entity2": "morphine",
    "text": "We conclude that <drug>ADL 8-2698</drug> prevents <drug>morphine</drug>-induced increases in gastrointestinal transit time by means of selective peripheral opioid anitagonism without affecting central opioid analgesia.",
    "source": "MedLine"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "Rifampin",
    "entity2": "warfarin",
    "text": "<drug>Rifampin</drug> and <drug>warfarin</drug>: a drug interaction.\r\n",
    "source": "MedLine"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "warfarin",
    "entity2": "rifampin",
    "text": "The drug interaction between <drug>warfarin</drug> and <drug>rifampin</drug> is not well known. ",
    "source": "MedLine"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Rifampin",
    "entity2": "warfarin",
    "text": "<drug>Rifampin</drug> has been reported to increase the <drug>warfarin</drug> requirements in human subjects ingesting these agents simultaneously. ",
    "source": "MedLine"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "rifampin",
    "entity2": "warfarin",
    "text": "The concomitant administration of <drug>rifampin</drug> and <drug>warfarin</drug> resulted in the need for an unusually high maintenance dose of warfarin (20 mg per day) in order to produce a therapeutic effect. ",
    "source": "MedLine"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "rifampin",
    "entity2": "warfarin",
    "text": "Withdrawal of <drug>rifampin</drug> decreased the <drug>warfarin</drug> requirement by 50%. ",
    "source": "MedLine"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "rifampin",
    "entity2": "warfarin",
    "text": "This effect may be mediated by the ability of <drug>rifampin</drug> to induce microsomal enzymes and, thus, the catabolism of <drug>warfarin</drug>. ",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "rifampin",
    "entity2": "warfarin",
    "text": "The effect of <drug>rifampin</drug> on the <drug>warfarin</drug> requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal. ",
    "source": "MedLine"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Fluvoxamine",
    "entity2": "tolbutamide",
    "text": "<drug>Fluvoxamine</drug> inhibits the CYP2C9 catalyzed biotransformation of <drug>tolbutamide</drug>.\n",
    "source": "MedLine"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "fluvoxamine",
    "entity2": "tolbutamide",
    "text": "RESULTS: During treatment with <drug>fluvoxamine</drug>, there was a statistically significant decrease in the median of the total clearance of <drug>tolbutamide</drug>, from 845 mL/h to 688 mL/h, among the volunteers who received 75 mg/d. ",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "naloxone",
    "entity2": "morphine",
    "text": "On the other hand, intrathecal <drug>naloxone</drug> (12-120 micrograms) had only a very weak effect on the tail-flick inhibition induced by intraventricular <drug>morphine</drug> (40 micrograms). ",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "naloxone",
    "entity2": "morphine",
    "text": "Intraventricular injection of <drug>naloxone</drug> at doses of 1.2 to 12 micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular beta-endorphin and <drug>morphine</drug>. ",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Physostigmine",
    "entity2": "alcohol",
    "text": "<drug>Physostigmine</drug> pretreatment augmented the depressant effect of <drug>alcohol</drug> on the early components P1 and N1, while attenuating alcohol's influence on components P2 and P3. ",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Physostigmine",
    "entity2": "alcohol",
    "text": "<drug>Physostigmine</drug> pretreatment augmented the depressant effect of alcohol on the early components P1 and N1, while attenuating <drug>alcohol</drug>'s influence on components P2 and P3. ",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "ouabain",
    "entity2": "phentolamine",
    "text": "When <drug>ouabain</drug> was applied to the muscle in the presence of <drug>phentolamine</drug>, both first and second contractile responses to PTX were abolished. ",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "acetaminophen",
    "entity2": "caffeine",
    "text": "Increased hepatotoxicity of <drug>acetaminophen</drug> by concomitant administration of <drug>caffeine</drug> in the rat.",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "acetaminophen",
    "entity2": "caffeine",
    "text": "Careful observations on hepatotoxicity are suggested when <drug>acetaminophen</drug> is prescribed with <drug>caffeine</drug>.",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "cocaine",
    "entity2": "norepinephrine",
    "text": "The uptake inhibitors <drug>cocaine</drug> and desipramine (3 mumol/liter) potentiated the positive inotropic effects of <drug>norepinephrine</drug> in nonfailing myocardium (p < 0.05) but not in functional class IV myocardium. ",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "desipramine",
    "entity2": "norepinephrine",
    "text": "The uptake inhibitors cocaine and <drug>desipramine</drug> (3 mumol/liter) potentiated the positive inotropic effects of <drug>norepinephrine</drug> in nonfailing myocardium (p < 0.05) but not in functional class IV myocardium. ",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "rifampicin",
    "entity2": "ofloxacin",
    "text": "When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of <drug>rifampicin</drug> (or rifabutin) and <drug>ofloxacin</drug>. ",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "rifabutin",
    "entity2": "ofloxacin",
    "text": "When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or <drug>rifabutin</drug>) and <drug>ofloxacin</drug>. ",
    "source": "MedLine"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Amprenavir",
    "entity2": "rifabutin",
    "text": "<drug>Amprenavir</drug> significantly increased the area under the curve at steady state (AUC(ss)) of <drug>rifabutin</drug> by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold. ",
    "source": "MedLine"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Rifampin",
    "entity2": "amprenavir",
    "text": "<drug>Rifampin</drug> significantly decreased the AUC(ss) of <drug>amprenavir</drug> by 82%, but amprenavir had no effect on rifampin pharmacokinetics. ",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Amprenavir",
    "entity2": "rifabutin",
    "text": "<drug>Amprenavir</drug> plus <drug>rifabutin</drug> was poorly tolerated, and 5 of 11 subjects discontinued therapy. ",
    "source": "MedLine"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Rifampin",
    "entity2": "amprenavir",
    "text": "<drug>Rifampin</drug> markedly increases the metabolic clearance of <drug>amprenavir</drug>, and coadministration is contraindicated. ",
    "source": "MedLine"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Amprenavir",
    "entity2": "rifabutin",
    "text": "<drug>Amprenavir</drug> significantly decreases clearance of <drug>rifabutin</drug> and 25-O-desacetylrifabutin, and the combination is poorly tolerated. ",
    "source": "MedLine"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "temazepam",
    "entity2": "ethanol",
    "text": "Acid-catalyzed ethanolysis of <drug>temazepam</drug> in anhydrous and aqueous <drug>ethanol</drug> solutions.",
    "source": "MedLine"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "temazepam",
    "entity2": "ethanol",
    "text": "In addition to this pharmacological interaction, this report describes a novel chemical reaction between <drug>temazepam</drug> (a benzodiazepine) and <drug>ethanol</drug> under acidic conditions similar to those found in vivo, resulting in a 3-ethoxylated product. ",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "thiabendazole",
    "entity2": "melarsoprol",
    "text": "Among the risk factors studied, two appear to increase the risk of ARE: the prescription of <drug>thiabendazole</drug> to treat strongyloidiasis during the <drug>melarsoprol</drug> cure and the bad general clinical conditions of patients. ",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "estradiol",
    "entity2": "noradrenaline",
    "text": "Aortic rings with intact endothelium from the high-dose (4 mg/kg/day) <drug>estradiol</drug> group were supersensitive to <drug>noradrenaline</drug> compared to the vehicle or low-dose (10 microg/kg/day) estradiol groups (pD2 values = 7.86+/-0.09, 7.30+/-0.11 and 7.35+/-0.04, respectively). ",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "estradiol",
    "entity2": "noradrenaline",
    "text": "Endothelium-intact aortic rings from high-<drug>estradiol</drug> rats were supersensitive to <drug>noradrenaline</drug> when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). ",
    "source": "MedLine"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "levamisole hydrochloride",
    "entity2": "alcohol",
    "text": "ERGAMISOL  (<drug>levamisole hydrochloride</drug>) has been reported to produce ANTABUSE-like side effects when given concomitantly with <drug>alcohol</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "levamisole",
    "entity2": "warfarin sodium",
    "text": "Because of reports of prolongation of the prothrombin time beyond the therapeutic range in patients taking concurrent <drug>levamisole</drug> and <drug>warfarin sodium</drug>, it is suggested that the prothrombin time be monitored carefully, and the dose of warfarin sodium or other coumarin-like drugs should be adjusted accordingly, in patients taking both drugs.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "rifampicin",
    "entity2": "exemestane",
    "text": "Co-medications that induce CYP 3A4 (e.g., <drug>rifampicin</drug>, phenytoin, carbamazepine, phenobarbital, or St. John s wort) may significantly decrease exposure to <drug>exemestane</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "phenytoin",
    "entity2": "exemestane",
    "text": "Co-medications that induce CYP 3A4 (e.g., rifampicin, <drug>phenytoin</drug>, carbamazepine, phenobarbital, or St. John s wort) may significantly decrease exposure to <drug>exemestane</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "carbamazepine",
    "entity2": "exemestane",
    "text": "Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, <drug>carbamazepine</drug>, phenobarbital, or St. John s wort) may significantly decrease exposure to <drug>exemestane</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "phenobarbital",
    "entity2": "exemestane",
    "text": "Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, <drug>phenobarbital</drug>, or St. John s wort) may significantly decrease exposure to <drug>exemestane</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "acetaminophen",
    "entity2": "Isoniazid",
    "text": "Acetaminophen: A report of severe <drug>acetaminophen</drug> toxicity was reported in a patient receiving <drug>Isoniazid</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "isoniazid",
    "entity2": "acetaminophen",
    "text": "It is believed that the toxicity may have resulted from a previously unrecognized interaction between <drug>isoniazid</drug> and <drug>acetaminophen</drug> and a molecular basis for this interaction has been proposed.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "isoniazid",
    "entity2": "acetaminophen",
    "text": "Furthermore it has been proposed that <drug>isoniazid</drug> resulted In induction of P-450IIE1 in the patients liver which, in turn, resulted in a greater proportion of the ingested <drug>acetaminophen</drug> being converted to the toxic metabolites.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Isoniazid",
    "entity2": "carbamazepine",
    "text": "Carbamazepine: <drug>Isoniazid</drug> is known to slow the metabolism of <drug>carbamazepine</drug> and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "Carbamazepine",
    "entity2": "isoniazid",
    "text": "Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels <drug>Carbamazepine</drug> levels should be determined prior to concurrent administration with <drug>isoniazid</drug>, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "Ketoconazole",
    "entity2": "Isoniazid",
    "text": "Ketoconazole: Potential interaction of <drug>Ketoconazole</drug> and <drug>Isoniazid</drug> may exist.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Isoniazid",
    "entity2": "phenytoin",
    "text": "Phenytoin: <drug>Isoniazid</drug> may increase serum levels of <drug>phenytoin</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "isoniazid",
    "entity2": "theophylline",
    "text": "Therophylline: A recent study has shown that concomitan administration of <drug>isoniazid</drug> and <drug>theophylline</drug> may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of isoniazid.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "valproate",
    "entity2": "isoniazid",
    "text": "Valproate: A recent case study has shown a possible increase in the plasma level of <drug>valproate</drug> when co administered with <drug>isoniazid</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "isoniazid",
    "entity2": "valproate",
    "text": "Plasma valproate concentration should be monitored when <drug>isoniazid</drug> and <drug>valproate</drug> are co administered, and appropriate dosage adjustments of valproate should be made.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Lamivudine",
    "entity2": "zalcitabine",
    "text": "<drug>Lamivudine</drug> and <drug>zalcitabine</drug> may inhibit the intracellular phosphorylation of one another.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "lamivudine",
    "entity2": "zalcitabine",
    "text": "Therefore, use of <drug>lamivudine</drug> in combination with <drug>zalcitabine</drug> is not recommended",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "nalidixic acid",
    "entity2": "warfarin",
    "text": "Quinolones, including <drug>nalidixic acid</drug>, may enhance the effects of the oral anticoagulant <drug>warfarin</drug> or its derivatives.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Nitrofurantoin",
    "entity2": "nalidixic acid",
    "text": "<drug>Nitrofurantoin</drug> interferes with the therapeutic action of <drug>nalidixic acid</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Tiagabine",
    "entity2": "valproate",
    "text": "Valproate: <drug>Tiagabine</drug> causes a slight decrease (about 10%) in steady-state <drug>valproate</drug> concentrations.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "tiagabine",
    "entity2": "carbamazepine",
    "text": "Effects of other Antiepilepsy Drugs (AEDs) on GABITRIL : Carbamazepine: Population pharmacokinetic analyses indicate that <drug>tiagabine</drug> clearance is 60% greater in patients taking <drug>carbamazepine</drug> with or without other enzyme- inducing AEDs.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "tiagabine",
    "entity2": "phenytoin",
    "text": "Phenytoin: Population pharmacokinetic analyses indicate that <drug>tiagabine</drug> clearance is 60% greater in patients taking <drug>phenytoin</drug> with or without other enzyme- inducing AEDs.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "tiagabine",
    "entity2": "phenobarbital",
    "text": "Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that <drug>tiagabine</drug> clearance is 60% greater in patients taking <drug>phenobarbital</drug> (primidone) with or without other enzyme-inducing AEDs.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "tiagabine",
    "entity2": "primidone",
    "text": "Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that <drug>tiagabine</drug> clearance is 60% greater in patients taking phenobarbital (<drug>primidone</drug>) with or without other enzyme-inducing AEDs.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "valproate",
    "entity2": "tiagabine",
    "text": "Valproate: The addition of tiagabine to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but <drug>valproate</drug> significantly decreased <drug>tiagabine</drug> binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "ethanol",
    "entity2": "tiagabine",
    "text": "Because of the possible additive effects of drugs that may depress the nervous system, <drug>ethanol</drug> or triazolam should be used cautiously in combination with <drug>tiagabine</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "triazolam",
    "entity2": "tiagabine",
    "text": "Because of the possible additive effects of drugs that may depress the nervous system, ethanol or <drug>triazolam</drug> should be used cautiously in combination with <drug>tiagabine</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Amantadine",
    "entity2": "clidinium",
    "text": "<drug>Amantadine</drug>, tricyclic antidepressants, and MAOIs may increase anticholinergic effect of <drug>clidinium</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Clidinium",
    "entity2": "levodopa",
    "text": "<drug>Clidinium</drug> may decrease the effect of phenothiazines, <drug>levodopa</drug>, and ketoconazole.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Clidinium",
    "entity2": "ketoconazole",
    "text": "<drug>Clidinium</drug> may decrease the effect of phenothiazines, levodopa, and <drug>ketoconazole</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Doxylamine",
    "entity2": "epinephrine",
    "text": "<drug>Doxylamine</drug> may enhance the effects of <drug>epinephrine</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "fluvoxamine",
    "entity2": "anagrelide",
    "text": "It is known that CYP1A2 is inhibited by several medicinal products, including <drug>fluvoxamine</drug>, and such medicinal products could theoretically adversely influence the clearance of <drug>anagrelide</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Anagrelide",
    "entity2": "theophylline",
    "text": "<drug>Anagrelide</drug> demonstrates some limited inhibitory activity towards CYP1A2 which may present a theoretical potential for interaction with other coadministered medicinal products sharing that clearance mechanism e.g. <drug>theophylline</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "milrinone",
    "entity2": "anagrelide",
    "text": "The effects of medicinal products with similar properties such as inotropes <drug>milrinone</drug>, enoximone, amrinone, olprinone and cilostazol may be exacerbated by <drug>anagrelide</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "enoximone",
    "entity2": "anagrelide",
    "text": "The effects of medicinal products with similar properties such as inotropes milrinone, <drug>enoximone</drug>, amrinone, olprinone and cilostazol may be exacerbated by <drug>anagrelide</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "amrinone",
    "entity2": "anagrelide",
    "text": "The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, <drug>amrinone</drug>, olprinone and cilostazol may be exacerbated by <drug>anagrelide</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "cilostazol",
    "entity2": "anagrelide",
    "text": "The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and <drug>cilostazol</drug> may be exacerbated by <drug>anagrelide</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "sucralfate",
    "entity2": "anagrelide",
    "text": "There is a single case report, which suggests that <drug>sucralfate</drug> may interfere with <drug>anagrelide</drug> absorption.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Phospholine Iodide",
    "entity2": "succinylcholine",
    "text": "<drug>Phospholine Iodide</drug> potentiates other cholinesterase inhibitors such as <drug>succinylcholine</drug> or organophosphate and carbamate insecticides.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "cholestyramine",
    "entity2": "leflunomide",
    "text": "Cholestyramine and Charcoal Administration of <drug>cholestyramine</drug> or activated charcoal in patients (n=13) and volunteers (n=96) resulted in a rapid and significant decrease in plasma M1 (the active metabolite of <drug>leflunomide</drug>) concentration .",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "activated charcoal",
    "entity2": "leflunomide",
    "text": "Cholestyramine and Charcoal Administration of cholestyramine or <drug>activated charcoal</drug> in patients (n=13) and volunteers (n=96) resulted in a rapid and significant decrease in plasma M1 (the active metabolite of <drug>leflunomide</drug>) concentration .",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "dapsone",
    "entity2": "clofazimine",
    "text": "If leprosy-associated inflammatory reactions develop in patients being treated with <drug>dapsone</drug> and <drug>clofazimine</drug>, it is still advisable to continue treatment with both drugs.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "EPA",
    "entity2": "ginkgo",
    "text": "Interactions may occur between <drug>EPA</drug> supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and <drug>ginkgo</drug> (Ginkgo biloba).",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "EPA",
    "entity2": "Ginkgo biloba",
    "text": "Interactions may occur between <drug>EPA</drug> supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (<drug>Ginkgo biloba</drug>).",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "baclofen",
    "entity2": "morphine",
    "text": "Interactions attributed to the combined use of <drug>baclofen</drug> injection and epidural <drug>morphine</drug> include hypotension and dyspnea.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "ranitidine",
    "entity2": "ceftibuten",
    "text": "however, 150 mg of <drug>ranitidine</drug> q12h for 3 days increased the <drug>ceftibuten</drug> C max by 23% and ceftibuten AUC by 16%.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "ranitidine",
    "entity2": "ceftibuten",
    "text": "however, 150 mg of <drug>ranitidine</drug> q12h for 3 days increased the ceftibuten C max by 23% and <drug>ceftibuten</drug> AUC by 16%.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "nitroglycerin",
    "entity2": "captopril",
    "text": "therefore, <drug>nitroglycerin</drug> or other nitrates (as used for management of angina) or other drugs having vasodilator activity should, if possible, be discontinued before starting <drug>captopril</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "indomethacin",
    "entity2": "captopril",
    "text": "Inhibitors Of Endogenous Prostaglandin Synthesis It has been reported that <drug>indomethacin</drug> may reduce the antihypertensive effect of <drug>captopril</drug>, especially in cases of low renin hypertension.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "DISULFIRAM",
    "entity2": "PHENYTOIN",
    "text": "<drug>DISULFIRAM</drug> SHOULD BE USED WITH CAUTION IN THOSE PATIENTS REVEIVING <drug>PHENYTOIN</drug> AND ITS CONGENERS.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "DISULFIRAM",
    "entity2": "PHENYTOIN",
    "text": "SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION, PRIOR TO ADMINISTERING <drug>DISULFIRAM</drug> TO A PATIENT ON <drug>PHENYTOIN</drug> THERAPY, A BASELINE PHENYTOIN SERUM LEVEL SHOULD BE OBTAINED.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "isoniazid",
    "entity2": "disulfiram",
    "text": "Patients taking <drug>isoniazid</drug> when <drug>disulfiram</drug> is given should be observed for the appearance of unsteady gait or marked changes in mental status;",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "disulfiram",
    "entity2": "nitrite",
    "text": "In rats, simultaneous ingestion of <drug>disulfiram</drug> and <drug>nitrite</drug> in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that disulfiram may react with nitrites in the rat stomach to form a nitrosamine, which is tumorigenic.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "levothyroxine sodium",
    "entity2": "aluminum hydoxide",
    "text": "Levothyroxine Sodium Absorption: The following agents may bind and decrease absorption of <drug>levothyroxine sodium</drug> from the gastrointestinal tract: <drug>aluminum hydoxide</drug>, cholestyramine resin, colestipol hydrochloride, ferrous sulfate, sodium polystyrene sulfonate, soybean flour (e.g., infant formula), sucralfate.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "levothyroxine sodium",
    "entity2": "cholestyramine",
    "text": "Levothyroxine Sodium Absorption: The following agents may bind and decrease absorption of <drug>levothyroxine sodium</drug> from the gastrointestinal tract: aluminum hydoxide, <drug>cholestyramine</drug> resin, colestipol hydrochloride, ferrous sulfate, sodium polystyrene sulfonate, soybean flour (e.g., infant formula), sucralfate.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "levothyroxine sodium",
    "entity2": "colestipol hydrochloride",
    "text": "Levothyroxine Sodium Absorption: The following agents may bind and decrease absorption of <drug>levothyroxine sodium</drug> from the gastrointestinal tract: aluminum hydoxide, cholestyramine resin, <drug>colestipol hydrochloride</drug>, ferrous sulfate, sodium polystyrene sulfonate, soybean flour (e.g., infant formula), sucralfate.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "levothyroxine sodium",
    "entity2": "ferrous sulfate",
    "text": "Levothyroxine Sodium Absorption: The following agents may bind and decrease absorption of <drug>levothyroxine sodium</drug> from the gastrointestinal tract: aluminum hydoxide, cholestyramine resin, colestipol hydrochloride, <drug>ferrous sulfate</drug>, sodium polystyrene sulfonate, soybean flour (e.g., infant formula), sucralfate.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "levothyroxine sodium",
    "entity2": "sodium polystyrene sulfonate",
    "text": "Levothyroxine Sodium Absorption: The following agents may bind and decrease absorption of <drug>levothyroxine sodium</drug> from the gastrointestinal tract: aluminum hydoxide, cholestyramine resin, colestipol hydrochloride, ferrous sulfate, <drug>sodium polystyrene sulfonate</drug>, soybean flour (e.g., infant formula), sucralfate.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "levothyroxine sodium",
    "entity2": "sucralfate",
    "text": "Levothyroxine Sodium Absorption: The following agents may bind and decrease absorption of <drug>levothyroxine sodium</drug> from the gastrointestinal tract: aluminum hydoxide, cholestyramine resin, colestipol hydrochloride, ferrous sulfate, sodium polystyrene sulfonate, soybean flour (e.g., infant formula), <drug>sucralfate</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "levothyroxine sodium",
    "entity2": "asparaginase",
    "text": "Binding to Serum Proteins: The following agents may either inhibit <drug>levothyroxine sodium</drug> binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, <drug>asparaginase</drug>, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "levothyroxine sodium",
    "entity2": "clofibrate",
    "text": "Binding to Serum Proteins: The following agents may either inhibit <drug>levothyroxine sodium</drug> binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, <drug>clofibrate</drug>, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "levothyroxine sodium",
    "entity2": "5-fluorouracil",
    "text": "Binding to Serum Proteins: The following agents may either inhibit <drug>levothyroxine sodium</drug> binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, <drug>5-fluorouracil</drug>, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "levothyroxine sodium",
    "entity2": "furosemide",
    "text": "Binding to Serum Proteins: The following agents may either inhibit <drug>levothyroxine sodium</drug> binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, <drug>furosemide</drug>, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "levothyroxine sodium",
    "entity2": "meclofenamic acid",
    "text": "Binding to Serum Proteins: The following agents may either inhibit <drug>levothyroxine sodium</drug> binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, <drug>meclofenamic acid</drug>, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "levothyroxine sodium",
    "entity2": "mefenamic acid",
    "text": "Binding to Serum Proteins: The following agents may either inhibit <drug>levothyroxine sodium</drug> binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, <drug>mefenamic acid</drug>, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "levothyroxine sodium",
    "entity2": "methadone",
    "text": "Binding to Serum Proteins: The following agents may either inhibit <drug>levothyroxine sodium</drug> binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, <drug>methadone</drug>, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "levothyroxine sodium",
    "entity2": "perphenazine",
    "text": "Binding to Serum Proteins: The following agents may either inhibit <drug>levothyroxine sodium</drug> binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, <drug>perphenazine</drug>, phenylbutazone, phenytoin, salicylates, tamoxifen.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "levothyroxine sodium",
    "entity2": "phenylbutazone",
    "text": "Binding to Serum Proteins: The following agents may either inhibit <drug>levothyroxine sodium</drug> binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, <drug>phenylbutazone</drug>, phenytoin, salicylates, tamoxifen.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "levothyroxine sodium",
    "entity2": "phenytoin",
    "text": "Binding to Serum Proteins: The following agents may either inhibit <drug>levothyroxine sodium</drug> binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, <drug>phenytoin</drug>, salicylates, tamoxifen.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "levothyroxine sodium",
    "entity2": "tamoxifen",
    "text": "Binding to Serum Proteins: The following agents may either inhibit <drug>levothyroxine sodium</drug> binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, <drug>tamoxifen</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "levothyroxine sodium",
    "entity2": "ketamine",
    "text": "Ketamine: Marked hypertension and tachycardia have been reported in association with concomitant administration of <drug>levothyroxine sodium</drug> and <drug>ketamine</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "cholestyramine",
    "entity2": "hydrochlorothiazide",
    "text": "Single doses of either <drug>cholestyramine</drug> or colestipol resins bind the <drug>hydrochlorothiazide</drug> and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "colestipol",
    "entity2": "hydrochlorothiazide",
    "text": "Single doses of either cholestyramine or <drug>colestipol</drug> resins bind the <drug>hydrochlorothiazide</drug> and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "lithium",
    "entity2": "Hydrochlorothiazide",
    "text": "Refer to the package insert for <drug>lithium</drug> preparations before use of such preparations with <drug>Hydrochlorothiazide</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "paroxetine",
    "entity2": "atomoxetine",
    "text": "In EM individuals treated with <drug>paroxetine</drug> or fluoxetine, the AUC of <drug>atomoxetine</drug> is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "fluoxetine",
    "entity2": "atomoxetine",
    "text": "In EM individuals treated with paroxetine or <drug>fluoxetine</drug>, the AUC of <drug>atomoxetine</drug> is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "acitretin",
    "entity2": "ethanol",
    "text": "Ethanol:Clinical evidence has shown that etretinate can be formed with concurrent ingestion of <drug>acitretin</drug> and <drug>ethanol</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "acitretin",
    "entity2": "glibenclamide",
    "text": "Glibenclamide: In a study of 7 healthy male volunteers, <drug>acitretin</drug> treatment potentiated the blood glucose lowering effect of <drug>glibenclamide</drug> (a sulfonylurea similar to chlorpropamide) in 3 of the 7 subjects.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "acitretin",
    "entity2": "progestin",
    "text": "However, it has been established that <drug>acitretin</drug> interferes with the contraceptive effect of microdosed <drug>progestin</drug> minipill preparations.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "progestin",
    "entity2": "Soriatane",
    "text": "Microdosed minipill <drug>progestin</drug> preparations are not recommended for use with <drug>Soriatane</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "methotrexate",
    "entity2": "etretinate",
    "text": "Methotrexate: An increased risk of hepatitis has been reported to result from combined use of <drug>methotrexate</drug> and <drug>etretinate</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "methotrexate",
    "entity2": "acitretin",
    "text": "Consequently, the combination of <drug>methotrexate</drug> with <drug>acitretin</drug> is also contraindicated.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "acitretin",
    "entity2": "phenytoin",
    "text": "Phenytoin: If <drug>acitretin</drug> is given concurrently with <drug>phenytoin</drug>, the protein binding of phenytoin may be reduced.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "adenosine",
    "entity2": "caffeine",
    "text": "The effects of <drug>adenosine</drug> are antagonized by methylxanthines such as <drug>caffeine</drug> and theophylline.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "adenosine",
    "entity2": "theophylline",
    "text": "The effects of <drug>adenosine</drug> are antagonized by methylxanthines such as caffeine and <drug>theophylline</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Adenosine",
    "entity2": "dipyridamole",
    "text": "<drug>Adenosine</drug> effects are potentiated by <drug>dipyridamole</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "adenosine",
    "entity2": "dipyridamole",
    "text": "Thus, smaller doses of <drug>adenosine</drug> may be effective in the presence of <drug>dipyridamole</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "adenosine",
    "entity2": "carbamazepine",
    "text": "As the primary effect of <drug>adenosine</drug> is to decrease conduction through the A-V node, higher degrees of heart block may be produced in the presence of <drug>carbamazepine</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Clonidine hydrochloride",
    "entity2": "alcohol",
    "text": "<drug>Clonidine hydrochloride</drug> may enhance the CNS-depressive effects of <drug>alcohol</drug>, barbiturates or other sedatives.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Amitriptyline",
    "entity2": "clonidine",
    "text": "<drug>Amitriptyline</drug> in combination with <drug>clonidine</drug> enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol, barbiturates or other sedating drugs.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Clonidine",
    "entity2": "alcohol",
    "text": "Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection <drug>Clonidine</drug> may potentiate the CNS-depressive effect of <drug>alcohol</drug>, barbiturates or other sedating drugs.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "fluphenazine",
    "entity2": "clonidine",
    "text": "There is one reported case of a patient with acute delirium associated with the simultaneous use of <drug>fluphenazine</drug> and oral <drug>clonidine</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Ethopropazine",
    "entity2": "alcohol",
    "text": "<drug>Ethopropazine</drug> may interact with <drug>alcohol</drug> or other CNS depressants, causing increased sedative effects.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Ethopropazine",
    "entity2": "chlorpromazine",
    "text": "<drug>Ethopropazine</drug> can interact with <drug>chlorpromazine</drug>, increasing the metabolism of chlorpromazine.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Fenfluramine",
    "entity2": "guanethidine",
    "text": "<drug>Fenfluramine</drug> may increase slightly the effect of antihypertensive drugs, e.g., <drug>guanethidine</drug>, methyldopa, reserpine.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Fenfluramine",
    "entity2": "methyldopa",
    "text": "<drug>Fenfluramine</drug> may increase slightly the effect of antihypertensive drugs, e.g., guanethidine, <drug>methyldopa</drug>, reserpine.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Fenfluramine",
    "entity2": "reserpine",
    "text": "<drug>Fenfluramine</drug> may increase slightly the effect of antihypertensive drugs, e.g., guanethidine, methyldopa, <drug>reserpine</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "pseudoephedrine",
    "entity2": "kaolin",
    "text": "Antacids increase the rate of absorption of <drug>pseudoephedrine</drug>, while <drug>kaolin</drug> decreases it.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "ethosuximide",
    "entity2": "phenytoin",
    "text": "Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, <drug>ethosuximide</drug> may elevate <drug>phenytoin</drug> serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "valproic acid",
    "entity2": "ethosuximide",
    "text": "Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and <drug>valproic acid</drug> has been reported to both increase and decrease <drug>ethosuximide</drug> levels).",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "nelfinavir",
    "entity2": "azithromycin",
    "text": "Co-administration of <drug>nelfinavir</drug> at steady-state with a single dose of <drug>azithromycin</drug> (2 x 600 mg tablets) results in increased azithromycin serum concentrations.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "azithromycin",
    "entity2": "nelfinavir",
    "text": "Although a dose adjustment of <drug>azithromycin</drug> is not recommended when administered in combination with <drug>nelfinavir</drug>, close monitoring for known side effects of azithromycin, such as liver enzyme abnormalities and hearing impairment, is warranted.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "azithromycin",
    "entity2": "warfarin",
    "text": "However, prudent medical practice dictates careful monitoring of prothrombin time in all patients treated with <drug>azithromycin</drug> and <drug>warfarin</drug> concomitantly.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "azithromycin",
    "entity2": "atorvastatin",
    "text": "When used in therapeutic doses, <drug>azithromycin</drug> had a modest effect on the pharmacokinetics of <drug>atorvastatin</drug>, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "azithromycin",
    "entity2": "carbamazepine",
    "text": "When used in therapeutic doses, <drug>azithromycin</drug> had a modest effect on the pharmacokinetics of atorvastatin, <drug>carbamazepine</drug>, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "azithromycin",
    "entity2": "cetirizine",
    "text": "When used in therapeutic doses, <drug>azithromycin</drug> had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, <drug>cetirizine</drug>, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "azithromycin",
    "entity2": "didanosine",
    "text": "When used in therapeutic doses, <drug>azithromycin</drug> had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, <drug>didanosine</drug>, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "azithromycin",
    "entity2": "efavirenz",
    "text": "When used in therapeutic doses, <drug>azithromycin</drug> had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, <drug>efavirenz</drug>, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "azithromycin",
    "entity2": "fluconazole",
    "text": "When used in therapeutic doses, <drug>azithromycin</drug> had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, <drug>fluconazole</drug>, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "azithromycin",
    "entity2": "indinavir",
    "text": "When used in therapeutic doses, <drug>azithromycin</drug> had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, <drug>indinavir</drug>, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "azithromycin",
    "entity2": "midazolam",
    "text": "When used in therapeutic doses, <drug>azithromycin</drug> had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, <drug>midazolam</drug>, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "azithromycin",
    "entity2": "rifabutin",
    "text": "When used in therapeutic doses, <drug>azithromycin</drug> had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, <drug>rifabutin</drug>, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "azithromycin",
    "entity2": "sildenafil",
    "text": "When used in therapeutic doses, <drug>azithromycin</drug> had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, <drug>sildenafil</drug>, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "azithromycin",
    "entity2": "theophylline",
    "text": "When used in therapeutic doses, <drug>azithromycin</drug> had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, <drug>theophylline</drug> (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "azithromycin",
    "entity2": "triazolam",
    "text": "When used in therapeutic doses, <drug>azithromycin</drug> had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), <drug>triazolam</drug>, trimethoprim/sulfamethoxazole or zidovudine.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "azithromycin",
    "entity2": "trimethoprim",
    "text": "When used in therapeutic doses, <drug>azithromycin</drug> had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, <drug>trimethoprim</drug>/sulfamethoxazole or zidovudine.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "azithromycin",
    "entity2": "sulfamethoxazole",
    "text": "When used in therapeutic doses, <drug>azithromycin</drug> had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/<drug>sulfamethoxazole</drug> or zidovudine.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "azithromycin",
    "entity2": "zidovudine",
    "text": "When used in therapeutic doses, <drug>azithromycin</drug> had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or <drug>zidovudine</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "efavirenz",
    "entity2": "azithromycin",
    "text": "Co-administration with <drug>efavirenz</drug> or fluconazole had a modest effect on the pharmacokinetics of <drug>azithromycin</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "fluconazole",
    "entity2": "azithromycin",
    "text": "Co-administration with efavirenz or <drug>fluconazole</drug> had a modest effect on the pharmacokinetics of <drug>azithromycin</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "lithium",
    "entity2": "chlorothiazide",
    "text": "Refer to the package insert for <drug>lithium</drug> preparations before use of such preparations with <drug>chlorothiazide</drug>",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "ammonium chloride",
    "entity2": "amphetamine",
    "text": "Urinary acidifying agents (<drug>ammonium chloride</drug>, sodium acid phosphate, etc.) increase the concentration of the ionized species of the <drug>amphetamine</drug> molecule, thereby increasing urinary excretion.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "sodium acid phosphate",
    "entity2": "amphetamine",
    "text": "Urinary acidifying agents (ammonium chloride, <drug>sodium acid phosphate</drug>, etc.) increase the concentration of the ionized species of the <drug>amphetamine</drug> molecule, thereby increasing urinary excretion.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "sodium bicarbonate",
    "entity2": "amphetamines",
    "text": "Alkalinizing agents: Gastrointestinal alkalinizing agents (<drug>sodium bicarbonate</drug>, etc.) increase absorption of <drug>amphetamines</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "acetazolamide",
    "entity2": "amphetamine",
    "text": "Urinary alkalinizing agents (<drug>acetazolamide</drug>, some thiazides) increase the concentration of the non-ionized species of the <drug>amphetamine</drug> molecule, thereby decreasing urinary excretion.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "d-amphetamine",
    "entity2": "desipramine",
    "text": "<drug>d-amphetamine</drug> with <drug>desipramine</drug> or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "d-amphetamine",
    "entity2": "protriptyline",
    "text": "<drug>d-amphetamine</drug> with desipramine or <drug>protriptyline</drug> and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Chloramphenicol",
    "entity2": "ceftazidime",
    "text": "<drug>Chloramphenicol</drug> has been shown to be antagonistic to beta-lactam antibiotics, including <drug>ceftazidime</drug>, based on in vitro studies and time kill curves with enteric gram-negative bacilli.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "felbamate",
    "entity2": "phenytoin",
    "text": "Increasing the <drug>felbamate</drug> dose to 1800 mg/day in six of these subjects increased the steady-state <drug>phenytoin</drug> Cmin to 25 7 micrograms/mL.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "felbamate",
    "entity2": "phenytoin",
    "text": "In order to maintain phenytoin levels, limit adverse experiences, and achieve the <drug>felbamate</drug> dose of 3600 mg/day, a <drug>phenytoin</drug> dose reduction of approximately 40% was necessary for eight of these 10 subjects.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "carbamazepine",
    "entity2": "felbamate",
    "text": "The <drug>carbamazepine</drug> steady-state Cmin decreased 31% to 5 1 micrograms/mL when <drug>felbamate</drug> (3000 mg/day, divided into three doses) was coadministered.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "felbamate",
    "entity2": "valproate",
    "text": "Increasing the <drug>felbamate</drug> dose to 2400 mg/day increased the steadystate <drug>valproate</drug> Cmin to 96 25 micrograms/mL.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "felbamate",
    "entity2": "phenobarbital",
    "text": "Phenobarbital: Coadministration of <drug>felbamate</drug> with <drug>phenobarbital</drug> causes an increase in phenobarbital plasma concentrations, In 12 otherwise healthy male volunteers ingesting phenobarbital, the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Phenytoin",
    "entity2": "felbamate",
    "text": "Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: <drug>Phenytoin</drug> causes an approximate doubling of the clearance of Felbatol  (<drug>felbamate</drug>) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "phenobarbital",
    "entity2": "felbamate",
    "text": "Phenobarbital: It appears that <drug>phenobarbital</drug> may reduce plasma <drug>felbamate</drug> concentrations.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Felbamate",
    "entity2": "gestodene",
    "text": "<drug>Felbamate</drug> treatment resulted in a 42% decrease in the <drug>gestodene</drug> AUC 0-24, but no clinically relevant effect was observed on the pharmacokinetic parameters of ethinyl estradiol.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "theophylline",
    "entity2": "cetirizine",
    "text": "In a multiple dose study of <drug>theophylline</drug> (400 mg once daily for 3 days) and <drug>cetirizine</drug> (20 mg once daily for 3 days), a 16% decrease in the clearance of cetirizine was observed.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "cetirizine",
    "entity2": "theophylline",
    "text": "There was a small decrease in the clearance of <drug>cetirizine</drug> caused by a 400-mg dose of <drug>theophylline</drug>;",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "duloxetine",
    "entity2": "fluvoxamine",
    "text": "Inhibitors of CYP1A2: Concomitant use of <drug>duloxetine</drug> with <drug>fluvoxamine</drug>, an inhibitor of CYP1A2, results in approximately a 6-fold increase in AUC and about a 2.5-fold increase in Cmax of duloxetine.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Paroxetine",
    "entity2": "duloxetine",
    "text": "<drug>Paroxetine</drug> (20 mg QD) increased the concentration of <drug>duloxetine</drug> (40 mg QD) by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "duloxetine",
    "entity2": "desipramine",
    "text": "When <drug>duloxetine</drug> was administered (at a dose of 60 mg BID) in conjunction with a single 50-mg dose of <drug>desipramine</drug>, a CYP2D6 substrate, the AUC of desipramine increased 3-fold.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "Duloxetine",
    "entity2": "nortriptyline",
    "text": "Therefore, co-administration of <drug>Duloxetine</drug> with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as <drug>nortriptyline</drug>, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "Duloxetine",
    "entity2": "amitriptyline",
    "text": "Therefore, co-administration of <drug>Duloxetine</drug> with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, <drug>amitriptyline</drug>, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "Duloxetine",
    "entity2": "imipramine",
    "text": "Therefore, co-administration of <drug>Duloxetine</drug> with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and <drug>imipramine</drug>), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "Duloxetine",
    "entity2": "propafenone",
    "text": "Therefore, co-administration of <drug>Duloxetine</drug> with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., <drug>propafenone</drug>, flecainide), should be approached with caution.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "Duloxetine",
    "entity2": "flecainide",
    "text": "Therefore, co-administration of <drug>Duloxetine</drug> with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, <drug>flecainide</drug>), should be approached with caution.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "Duloxetine",
    "entity2": "thioridazine",
    "text": "Because of the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of thioridazine, <drug>Duloxetine</drug> and <drug>thioridazine</drug> should not be co-administered.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "zaleplon",
    "entity2": "promethazine",
    "text": "Promethazine: Coadministration of a single dose of <drug>zaleplon</drug> and <drug>promethazine</drug> (10 and 25 mg, respectively) resulted in a 15% decrease in maximal plasma concentrations of zaleplon, but no change in the area under the plasma concentration-time curve.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "rifampin",
    "entity2": "zaleplon",
    "text": "Multiple-dose administration of the potent CYP3A4 inducer <drug>rifampin</drug> (600 mg every 24 hours, q24h, for 14 days), however, reduced <drug>zaleplon</drug> Cmax and AUC by approximately 80%.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "zaleplon",
    "entity2": "erythromycin",
    "text": "Coadministration of single, oral doses of <drug>zaleplon</drug> with <drug>erythromycin</drug> (10 mg and 800 mg, respectively), a strong, selective CYP3A4 inhibitor produced a 34% increase in zaleplons maximal plasma concentrations and a 20% increase in the area under the plasma concentration-time curve.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "ketoconazole",
    "entity2": "zaleplon",
    "text": "Other strong selective CYP3A4 inhibitors such as <drug>ketoconazole</drug> can also be expected to increase the exposure of <drug>zaleplon</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Cimetidine",
    "entity2": "zaleplon",
    "text": "Drugs That Inhibit Both Aldehyde Oxidase and CYP3A4 Cimetidine: <drug>Cimetidine</drug> inhibits both aldehyde oxidase (in vitro) and CYP3A4 (in vitro and in vivo), the primary and secondary enzymes, respectively, responsible for <drug>zaleplon</drug> metabolism.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "vitamin B12",
    "entity2": "folic acid",
    "text": "Medications can interfere with folate utilization, including: anticonvulsant medications (such as phenytoin, and primidone) metformin (sometimes prescribed to control blood sugar in type 2 diabetes) sulfasalazine (used to control inflammation associated with Crohns disease and ulcerative colitis) triamterene (a diuretic) Methotrexate There has been concern about the interaction between <drug>vitamin B12</drug> and <drug>folic acid</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "chlorpromazine",
    "entity2": "trihexyphenidyl",
    "text": "The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, <drug>chlorpromazine</drug>), an antiparkinsonian drug (eg, <drug>trihexyphenidyl</drug>), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "chlorpromazine",
    "entity2": "amitriptyline",
    "text": "The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, <drug>chlorpromazine</drug>), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, <drug>amitriptyline</drug>)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "trihexyphenidyl",
    "entity2": "amitriptyline",
    "text": "The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, <drug>trihexyphenidyl</drug>), and/or a tricyclic antidepressant (eg, <drug>amitriptyline</drug>)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Acetazolamide",
    "entity2": "amphetamine",
    "text": "<drug>Acetazolamide</drug> decreases urinary excretion of <drug>amphetamine</drug> and may enhance the magnitude and duration of their effect.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Acetazolamide",
    "entity2": "quinidine",
    "text": "<drug>Acetazolamide</drug> reduces urinary excretion of <drug>quinidine</drug> and may enhance its effect.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Acetazolamide",
    "entity2": "methenamine",
    "text": "<drug>Acetazolamide</drug> may prevent the urinary antiseptic effect of <drug>methenamine</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Acetazolamide",
    "entity2": "lithium",
    "text": "<drug>Acetazolamide</drug> increases <drug>lithium</drug> excretion and the lithium may be decreased.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Acetazolamide",
    "entity2": "sodium bicarbonate",
    "text": "<drug>Acetazolamide</drug> and <drug>sodium bicarbonate</drug> used concurrently increases the risk of renal calculus formation.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Acetazolamide",
    "entity2": "cyclosporine",
    "text": "<drug>Acetazolamide</drug> may elevate <drug>cyclosporine</drug> levels.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "Etonogestrel",
    "entity2": "acetaminophen",
    "text": "<drug>Etonogestrel</drug> may interact with the following medications: <drug>acetaminophen</drug> (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "Etonogestrel",
    "entity2": "ampicillin",
    "text": "<drug>Etonogestrel</drug> may interact with the following medications: acetaminophen (Tylenol), antibiotics such as <drug>ampicillin</drug> and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "Etonogestrel",
    "entity2": "tetracycline",
    "text": "<drug>Etonogestrel</drug> may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and <drug>tetracycline</drug>, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "Etonogestrel",
    "entity2": "Phenobarbital",
    "text": "<drug>Etonogestrel</drug> may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, <drug>Phenobarbital</drug>, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "Etonogestrel",
    "entity2": "atorvastatin",
    "text": "<drug>Etonogestrel</drug> may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), <drug>atorvastatin</drug> (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "Etonogestrel",
    "entity2": "clofibrate",
    "text": "<drug>Etonogestrel</drug> may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), <drug>clofibrate</drug> (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "Etonogestrel",
    "entity2": "cyclosporine",
    "text": "<drug>Etonogestrel</drug> may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), <drug>cyclosporine</drug> (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "Etonogestrel",
    "entity2": "morphine",
    "text": "<drug>Etonogestrel</drug> may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), <drug>morphine</drug> (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "Etonogestrel",
    "entity2": "phenylbutazone",
    "text": "<drug>Etonogestrel</drug> may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), <drug>phenylbutazone</drug>, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "Etonogestrel",
    "entity2": "prednisolone",
    "text": "<drug>Etonogestrel</drug> may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, <drug>prednisolone</drug> (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "Etonogestrel",
    "entity2": "rifampin",
    "text": "<drug>Etonogestrel</drug> may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (<drug>rifampin</drug>), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "Etonogestrel",
    "entity2": "temazepam",
    "text": "<drug>Etonogestrel</drug> may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, <drug>temazepam</drug>, theophylline (Theo-Dur), and vitamin C.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "Etonogestrel",
    "entity2": "theophylline",
    "text": "<drug>Etonogestrel</drug> may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, <drug>theophylline</drug> (Theo-Dur), and vitamin C.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "Etonogestrel",
    "entity2": "vitamin C",
    "text": "<drug>Etonogestrel</drug> may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and <drug>vitamin C</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "ethionamide",
    "entity2": "cycloserine",
    "text": "In particular, convulsions have been reported when <drug>ethionamide</drug> is administered with <drug>cycloserine</drug> and special care should be taken when the treatment regimen includes both of these drugs.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "carbamazepine",
    "entity2": "aripiprazole",
    "text": "Agents that induce CYP3A4 (eg, <drug>carbamazepine</drug>) could cause an increase in <drug>aripiprazole</drug> clearance and lower blood levels.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "ketoconazole",
    "entity2": "aripiprazole",
    "text": "Inhibitors of CYP3A4 (eg, <drug>ketoconazole</drug>) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit <drug>aripiprazole</drug> elimination and cause increased blood levels.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "quinidine",
    "entity2": "aripiprazole",
    "text": "Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, <drug>quinidine</drug>, fluoxetine, or paroxetine) can inhibit <drug>aripiprazole</drug> elimination and cause increased blood levels.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "fluoxetine",
    "entity2": "aripiprazole",
    "text": "Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, <drug>fluoxetine</drug>, or paroxetine) can inhibit <drug>aripiprazole</drug> elimination and cause increased blood levels.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "paroxetine",
    "entity2": "aripiprazole",
    "text": "Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or <drug>paroxetine</drug>) can inhibit <drug>aripiprazole</drug> elimination and cause increased blood levels.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "ketoconazole",
    "entity2": "aripiprazole",
    "text": "Ketoconazole: Coadministration of <drug>ketoconazole</drug> (200 mg/day for 14 days) with a 15-mg single dose of <drug>aripiprazole</drug> increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "ketoconazole",
    "entity2": "aripiprazole",
    "text": "When concomitant administration of <drug>ketoconazole</drug> with <drug>aripiprazole</drug> occurs, aripiprazole dose should be reduced to one-half of its normal dose.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "aripiprazole",
    "entity2": "quinidine",
    "text": "Quinidine: Coadministration of a 10-mg single dose of <drug>aripiprazole</drug> with <drug>quinidine</drug> (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of aripiprazole by 112% but decreased the AUC of its active metabolite, dehydroaripiprazole, by 35%.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "quinidine",
    "entity2": "aripiprazole",
    "text": "Aripiprazole dose should be reduced to one-half of its normal dose when concomitant administration of <drug>quinidine</drug> with <drug>aripiprazole</drug> occurs.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "carbamazepine",
    "entity2": "aripiprazole",
    "text": "Carbamazepine: Coadministration of <drug>carbamazepine</drug> (200 mg BID), a potent CYP3A4 inducer, with <drug>aripiprazole</drug> (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "carbamazepine",
    "entity2": "aripiprazole",
    "text": "When <drug>carbamazepine</drug> is added to <drug>aripiprazole</drug> therapy, aripiprazole dose should be doubled.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "carbamazepine",
    "entity2": "aripiprazole",
    "text": "When <drug>carbamazepine</drug> is withdrawn from the combination therapy, <drug>aripiprazole</drug> dose should then be reduced.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "dyphylline",
    "entity2": "probenecid",
    "text": "Concurrent administration of <drug>dyphylline</drug> and <drug>probenecid</drug>, which competes for tubular secretion, has been shown to increase the plasma half-life of dyphylline .",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "Nabilone",
    "entity2": "alcohol",
    "text": "<drug>Nabilone</drug> should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including <drug>alcohol</drug>, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Nabilone",
    "entity2": "diazepam",
    "text": "<drug>Nabilone</drug> has been shown to have an additive CNS depressant effect when given with either <drug>diazepam</drug>, secobarbitone sodium, alcohol or codeine.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Nabilone",
    "entity2": "alcohol",
    "text": "<drug>Nabilone</drug> has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, <drug>alcohol</drug> or codeine.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Nabilone",
    "entity2": "codeine",
    "text": "<drug>Nabilone</drug> has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or <drug>codeine</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "warfarin",
    "entity2": "ketorolac tromethamine",
    "text": "Warfarin, Digoxin, Salicylate, and Heparin The in vitro binding of <drug>warfarin</drug> to plasma proteins is only slightly reduced by <drug>ketorolac tromethamine</drug> (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "cimetidine",
    "entity2": "rofecoxib",
    "text": "Cimetidine: Co-administration with high doses of <drug>cimetidine</drug> [800 mg twice daily] increased the Cmax of <drug>rofecoxib</drug> by 21%, the AUC0-120hr by 23% and the t1/2 by 15%.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "methotrexate",
    "entity2": "rofecoxib",
    "text": "At 24 hours postdose, a similar proportion of patients treated with methotrexate alone (94%) and subsequently treated with <drug>methotrexate</drug> co-administered with 75 mg of <drug>rofecoxib</drug> (88%) had methotrexate plasma concentrations below the measurable limit (5 ng/mL).",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "warfarin",
    "entity2": "rofecoxib",
    "text": "In single and multiple dose studies in healthy subjects receiving both <drug>warfarin</drug> and <drug>rofecoxib</drug>, prothrombin time (measured as INR) was increased by approximately 8% to 11%.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Iodine",
    "entity2": "Carbimazole",
    "text": "<drug>Iodine</drug> or iodine excess may decrease the effect of <drug>Carbimazole</drug>, and an iodine deficiency can increase the effect of Carbimazole.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "iodine",
    "entity2": "Carbimazole",
    "text": "Iodine or iodine excess may decrease the effect of Carbimazole, and an <drug>iodine</drug> deficiency can increase the effect of <drug>Carbimazole</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Sucralfate",
    "entity2": "lomefloxacin",
    "text": "Antacids and sucralfate: <drug>Sucralfate</drug> and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with <drug>lomefloxacin</drug> and interfere with its bioavailability.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "magnesium",
    "entity2": "lomefloxacin",
    "text": "Antacids and sucralfate: Sucralfate and antacids containing <drug>magnesium</drug> or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with <drug>lomefloxacin</drug> and interfere with its bioavailability.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "aluminum",
    "entity2": "lomefloxacin",
    "text": "Antacids and sucralfate: Sucralfate and antacids containing magnesium or <drug>aluminum</drug>, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with <drug>lomefloxacin</drug> and interfere with its bioavailability.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "didanosine",
    "entity2": "lomefloxacin",
    "text": "Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (<drug>didanosine</drug>), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with <drug>lomefloxacin</drug> and interfere with its bioavailability.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Sucralfate",
    "entity2": "lomefloxacin",
    "text": "<drug>Sucralfate</drug> administered 2 hours before <drug>lomefloxacin</drug> resulted in a slower absorption (mean C max decreased by 30% and mean T max increased by 1 hour) and a lesser extent of absorption (mean AUC decreased by approximately 25%).",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Magnesium",
    "entity2": "lomefloxacin",
    "text": "<drug>Magnesium</drug>- and aluminum-containing antacids, administered concomitantly with <drug>lomefloxacin</drug>, significantly decreased the bioavailability (48%) of lomefloxacin.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "aluminum",
    "entity2": "lomefloxacin",
    "text": "Magnesium- and <drug>aluminum</drug>-containing antacids, administered concomitantly with <drug>lomefloxacin</drug>, significantly decreased the bioavailability (48%) of lomefloxacin.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "amyl nitrite",
    "entity2": "alcohol",
    "text": "Taking <drug>amyl nitrite</drug> after drinking <drug>alcohol</drug> may worsen side effects and may cause severe hypotension and cardiovascular collapse.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "warfarin",
    "entity2": "flutamide",
    "text": "Increases in prothrombin time have been noted in patients receiving long- term <drug>warfarin</drug> therapy after <drug>flutamide</drug> was initiated.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "Benzthiazide",
    "entity2": "alcohol",
    "text": "<drug>Benzthiazide</drug> may interact with <drug>alcohol</drug>, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "Benzthiazide",
    "entity2": "lithium",
    "text": "<drug>Benzthiazide</drug> may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, <drug>lithium</drug>, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "Benzthiazide",
    "entity2": "norepinephrine",
    "text": "<drug>Benzthiazide</drug> may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, <drug>norepinephrine</drug>, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "Benzthiazide",
    "entity2": "Ibuprofen",
    "text": "<drug>Benzthiazide</drug> may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or <drug>Ibuprofen</drug>, and high blood pressure medications.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "loracarbef",
    "entity2": "probenecid",
    "text": "Probenecid: As with other b-lactam antibiotics, renal excretion of <drug>loracarbef</drug> is inhibited by <drug>probenecid</drug> and resulted in an approximate 80% increase in the AUC for loracarbef.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "doxazosin",
    "entity2": "cimetidine",
    "text": "In a placebo-controlled trial in normal volunteers, the administration of a single 1 mg dose of <drug>doxazosin</drug> on day 1 of a four-day regimen of oral <drug>cimetidine</drug> (400 mg twice daily) resulted in a 10% increase in mean AUC of doxazosin (p=0.006), and a slight but not statistically significant increase in mean Cmax and mean half-life of doxazosin.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "docetaxel",
    "entity2": "cyclosporine",
    "text": "In vitro studies have shown that the metabolism of <drug>docetaxel</drug> may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as <drug>cyclosporine</drug>, terfenadine, ketoconazole, erythromycin, and troleandomycin.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "docetaxel",
    "entity2": "terfenadine",
    "text": "In vitro studies have shown that the metabolism of <drug>docetaxel</drug> may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, <drug>terfenadine</drug>, ketoconazole, erythromycin, and troleandomycin.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "docetaxel",
    "entity2": "ketoconazole",
    "text": "In vitro studies have shown that the metabolism of <drug>docetaxel</drug> may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, <drug>ketoconazole</drug>, erythromycin, and troleandomycin.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "docetaxel",
    "entity2": "erythromycin",
    "text": "In vitro studies have shown that the metabolism of <drug>docetaxel</drug> may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, ketoconazole, <drug>erythromycin</drug>, and troleandomycin.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "docetaxel",
    "entity2": "troleandomycin",
    "text": "In vitro studies have shown that the metabolism of <drug>docetaxel</drug> may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, ketoconazole, erythromycin, and <drug>troleandomycin</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "Lithium",
    "entity2": "bumetanide",
    "text": "- Lithium: <drug>Lithium</drug> should generally not be given with diuretics (such as <drug>bumetanide</drug>) because they reduce its renal clearance and add a high risk of lithium toxicity.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "probenecid",
    "entity2": "bumetanide",
    "text": "- Probenecid: Pretreatment with <drug>probenecid</drug> reduces both the natriuresis and hyperreninemia produced by <drug>bumetanide</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "probenecid",
    "entity2": "bumetanide",
    "text": "This antagonistic effect of <drug>probenecid</drug> on <drug>bumetanide</drug> natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of bumetanide.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "probenecid",
    "entity2": "bumetanide",
    "text": "Thus, <drug>probenecid</drug> should not be administered concurrently with <drug>bumetanide</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Indomethacin",
    "entity2": "bumetanide",
    "text": "- Indomethacin: <drug>Indomethacin</drug> blunts the increases in urine volume and sodium excretion seen during <drug>bumetanide</drug> treatment and inhibits the bumetanide-induced increase in plasma renin activity.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Indomethacin",
    "entity2": "bumetanide",
    "text": "- Indomethacin: <drug>Indomethacin</drug> blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the <drug>bumetanide</drug>-induced increase in plasma renin activity.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Probenecid",
    "entity2": "ampicillin",
    "text": "<drug>Probenecid</drug>: May decrease renal tubular secretion of <drug>ampicillin</drug> resulting in increased blood levels and/or ampicillin toxicity.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "diclofenac",
    "entity2": "warfarin",
    "text": "Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs, including <drug>diclofenac</drug>, and <drug>warfarin</drug> requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "diclofenac",
    "entity2": "digoxin",
    "text": "Ingestion of <drug>diclofenac</drug> may increase serum concentrations of <drug>digoxin</drug> and methotrexate and increase cyclosporine s nephrotoxicity.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "diclofenac",
    "entity2": "methotrexate",
    "text": "Ingestion of <drug>diclofenac</drug> may increase serum concentrations of digoxin and <drug>methotrexate</drug> and increase cyclosporine s nephrotoxicity.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "diclofenac",
    "entity2": "cyclosporine",
    "text": "Ingestion of <drug>diclofenac</drug> may increase serum concentrations of digoxin and methotrexate and increase <drug>cyclosporine</drug> s nephrotoxicity.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "diclofenac",
    "entity2": "digoxin",
    "text": "Patients who begin taking <drug>diclofenac</drug> or who increase their diclofenac dose or any other NSAID while taking <drug>digoxin</drug>, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "diclofenac",
    "entity2": "methotrexate",
    "text": "Patients who begin taking <drug>diclofenac</drug> or who increase their diclofenac dose or any other NSAID while taking digoxin, <drug>methotrexate</drug>, or cyclosporine may develop toxicity characteristics for these drugs.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "diclofenac",
    "entity2": "cyclosporine",
    "text": "Patients who begin taking <drug>diclofenac</drug> or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or <drug>cyclosporine</drug> may develop toxicity characteristics for these drugs.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Diclofenac",
    "entity2": "lithium",
    "text": "Lithium: <drug>Diclofenac</drug> decreases <drug>lithium</drug> renal clearance and increases lithium plasma levels.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Diclofenac",
    "entity2": "lithium",
    "text": "Lithium: <drug>Diclofenac</drug> decreases lithium renal clearance and increases <drug>lithium</drug> plasma levels.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "diclofenac",
    "entity2": "lithium",
    "text": "In patients taking <drug>diclofenac</drug> and <drug>lithium</drug> concomitantly, lithium toxicity may develop.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "insulin",
    "entity2": "diclofenac",
    "text": "There are rare reports, however, from marketing experiences, of changes in effects of <drug>insulin</drug> or oral hypoglycemic agents in the presence of <drug>diclofenac</drug> that necessitated changes in the doses of such agents.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "diclofenac",
    "entity2": "insulin",
    "text": "A direct causal relationship has not been established, but physicians should consider the possibility that <drug>diclofenac</drug> may alter a diabetic patient s response to <drug>insulin</drug> or oral hypoglycemic agents.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "phenobarbital",
    "entity2": "diclofenac",
    "text": "Phenobarbital toxicity has been reported to have occurred in a patient on chronic <drug>phenobarbital</drug> treatment following the initiation of <drug>diclofenac</drug> therapy.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "diclofenac",
    "entity2": "salicylic acid",
    "text": "Protein Binding In vitro, <drug>diclofenac</drug> interferes minimally or not at all with the protein binding of <drug>salicylic acid</drug> (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "diclofenac",
    "entity2": "tolbutamide",
    "text": "Protein Binding In vitro, <drug>diclofenac</drug> interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), <drug>tolbutamide</drug>, prednisolone (10% decrease in binding), or warfarin.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "diclofenac",
    "entity2": "prednisolone",
    "text": "Protein Binding In vitro, <drug>diclofenac</drug> interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, <drug>prednisolone</drug> (10% decrease in binding), or warfarin.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "diclofenac",
    "entity2": "warfarin",
    "text": "Protein Binding In vitro, <drug>diclofenac</drug> interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or <drug>warfarin</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "famotidine",
    "entity2": "dasatinib",
    "text": "H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, <drug>famotidine</drug> and omeprazole) is likely to reduce <drug>dasatinib</drug> exposure.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "omeprazole",
    "entity2": "dasatinib",
    "text": "H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and <drug>omeprazole</drug>) is likely to reduce <drug>dasatinib</drug> exposure.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "cromolyn sodium",
    "entity2": "isoproterenol",
    "text": "The addition of 540 mg/kg/day of <drug>cromolyn sodium</drug> (approximately 340 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) to 2.7 mg/kg/day of <drug>isoproterenol</drug> (approximately 7 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) appears to have increased the incidence of both resorptions and malformations.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "disopyramide phosphate",
    "entity2": "erythromycin",
    "text": "Patients taking <drug>disopyramide phosphate</drug> and <drug>erythromycin</drug> concomitantly may develop increased serum concentrations of disopyramide resulting in excessive widening of the QRS complex and/or prolongation of the Q-T interval.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "disopyramide",
    "entity2": "verapamil",
    "text": "Until data on possible interactions between verapamil and disopyramide phosphate are obtained, <drug>disopyramide</drug> should not be administered within 48 hours before or 24 hours after <drug>verapamil</drug> administration.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Ribavirin",
    "entity2": "stavudine",
    "text": "Stavudine and Zidovudine <drug>Ribavirin</drug> can antagonize the in vitro antiviral activity of <drug>stavudine</drug> and zidovudine against HIV.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Ribavirin",
    "entity2": "zidovudine",
    "text": "Stavudine and Zidovudine <drug>Ribavirin</drug> can antagonize the in vitro antiviral activity of stavudine and <drug>zidovudine</drug> against HIV.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Hydrochlorothiazide",
    "entity2": "ketoprofen",
    "text": "Diuretic: <drug>Hydrochlorothiazide</drug>, given concomitantly with <drug>ketoprofen</drug>, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "ketoprofen",
    "entity2": "warfarin",
    "text": "Because prostaglandina play an important role in hemostasis and ketoprofen has an effect on platelet function as well, concurent therapy with <drug>ketoprofen</drug> and <drug>warfarin</drug> requires close monitoring of patients on both drugs.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Probenecid",
    "entity2": "ketoprofen",
    "text": "Probenecid: <drug>Probenecid</drug> increases both free and bound <drug>ketoprofen</drug> by reducing the plasma clearance of ketoprofen to about one-third, as well as decreasing its protein binding.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "ketoprofen",
    "entity2": "probenecid",
    "text": "Therefore, the combination of <drug>ketoprofen</drug> and <drug>probenecid</drug> is not recommended.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Ketoprofen",
    "entity2": "methotrexate",
    "text": "Methotrexate: <drug>Ketoprofen</drug>, like other NSAIDs, may cause changes in the elimination of <drug>methotrexate</drug> leading to elevated serum levels of the drug and increased toxicity.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "ketoprofen",
    "entity2": "lithium",
    "text": "It is recommended that plasma lithium levels be monitored when <drug>ketoprofen</drug> is coadministered with <drug>lithium</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "quinidine",
    "entity2": "carvedilol",
    "text": "poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as <drug>quinidine</drug>, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of <drug>carvedilol</drug> .",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "fluoxetine",
    "entity2": "carvedilol",
    "text": "poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, <drug>fluoxetine</drug>, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of <drug>carvedilol</drug> .",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "paroxetine",
    "entity2": "carvedilol",
    "text": "poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, <drug>paroxetine</drug>, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of <drug>carvedilol</drug> .",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "propafenone",
    "entity2": "carvedilol",
    "text": "poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and <drug>propafenone</drug>) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of <drug>carvedilol</drug> .",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "cyclosporine",
    "entity2": "carvedilol",
    "text": "Cyclosporine: Modest increases in mean trough <drug>cyclosporine</drug> concentrations were observed following initiation of <drug>carvedilol</drug> treatment in 21 renal transplant patients suffering from chronic vascular rejection.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "cyclosporine",
    "entity2": "carvedilol",
    "text": "Due to wide interindividual variability in the dose adjustment required, it is recommended that <drug>cyclosporine</drug> concentrations be monitored closely after initiation of <drug>carvedilol</drug> therapy and that the dose of cyclosporine be adjusted as appropriate.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "carvedilol",
    "entity2": "cyclosporine",
    "text": "Due to wide interindividual variability in the dose adjustment required, it is recommended that cyclosporine concentrations be monitored closely after initiation of <drug>carvedilol</drug> therapy and that the dose of <drug>cyclosporine</drug> be adjusted as appropriate.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "digoxin",
    "entity2": "carvedilol",
    "text": "Digoxin: Digoxin concentrations are increased by about 15% when <drug>digoxin</drug> and <drug>carvedilol</drug> are administered concomitantly.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Rifampin",
    "entity2": "carvedilol",
    "text": "Inducers and Inhibitors of Hepatic Metabolism: <drug>Rifampin</drug> reduced plasma concentrations of <drug>carvedilol</drug> by about 70%.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "L-histidine",
    "entity2": "medroxyprogesterone acetate",
    "text": "Medroxyprogesterone Acetate - <drug>L-histidine</drug> was observed to enhance (in tissue culture) the effect of <drug>medroxyprogesterone acetate</drug> in reducing the number of human breast cancer cells that were in the S phase.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "Azlocillin",
    "entity2": "amikacin",
    "text": "<drug>Azlocillin</drug> should not be administered concomitantly with <drug>amikacin</drug>, ciprofloxacin, gentamicin, netilmicin, or tobramycin.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "Azlocillin",
    "entity2": "ciprofloxacin",
    "text": "<drug>Azlocillin</drug> should not be administered concomitantly with amikacin, <drug>ciprofloxacin</drug>, gentamicin, netilmicin, or tobramycin.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "Azlocillin",
    "entity2": "gentamicin",
    "text": "<drug>Azlocillin</drug> should not be administered concomitantly with amikacin, ciprofloxacin, <drug>gentamicin</drug>, netilmicin, or tobramycin.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "Azlocillin",
    "entity2": "netilmicin",
    "text": "<drug>Azlocillin</drug> should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, <drug>netilmicin</drug>, or tobramycin.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "Azlocillin",
    "entity2": "tobramycin",
    "text": "<drug>Azlocillin</drug> should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or <drug>tobramycin</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "diuretics",
    "entity2": "enalapril",
    "text": "Hypotension: Patients on Diuretic Therapy: Patients on <drug>diuretics</drug> and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with <drug>enalapril</drug> or enalaprilat.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "diuretics",
    "entity2": "enalaprilat",
    "text": "Hypotension: Patients on Diuretic Therapy: Patients on <drug>diuretics</drug> and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with enalapril or <drug>enalaprilat</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "enalapril",
    "entity2": "diuretic",
    "text": "The possibility of hypotensive effects with <drug>enalapril</drug> or enalaprilat can be minimized by either discontinuing the <drug>diuretic</drug> or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "enalaprilat",
    "entity2": "diuretic",
    "text": "The possibility of hypotensive effects with enalapril or <drug>enalaprilat</drug> can be minimized by either discontinuing the <drug>diuretic</drug> or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "enalapril",
    "entity2": "lithium",
    "text": "It is recommended that serum lithium levels be monitored frequently if <drug>enalapril</drug> is administered concomitantly with <drug>lithium</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "fentanyl",
    "entity2": "ritonavir",
    "text": "The concomitant use of transdermal <drug>fentanyl</drug> with <drug>ritonavir</drug> or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "fentanyl",
    "entity2": "ketoconazole",
    "text": "The concomitant use of transdermal <drug>fentanyl</drug> with ritonavir or other potent 3A4 inhibitors such as <drug>ketoconazole</drug>, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "fentanyl",
    "entity2": "itraconazole",
    "text": "The concomitant use of transdermal <drug>fentanyl</drug> with ritonavir or other potent 3A4 inhibitors such as ketoconazole, <drug>itraconazole</drug>, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "fentanyl",
    "entity2": "troleandomycin",
    "text": "The concomitant use of transdermal <drug>fentanyl</drug> with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, <drug>troleandomycin</drug>, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "fentanyl",
    "entity2": "clarithromycin",
    "text": "The concomitant use of transdermal <drug>fentanyl</drug> with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, <drug>clarithromycin</drug>, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "fentanyl",
    "entity2": "nelfinavir",
    "text": "The concomitant use of transdermal <drug>fentanyl</drug> with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, <drug>nelfinavir</drug>, and nefazadone may result in an increase in fentanyl plasma concentrations.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "diltiazem",
    "entity2": "fentanyl",
    "text": "The concomitant use of other CYP3A4 inhibitors such as <drug>diltiazem</drug> and erythromycin with transdermal <drug>fentanyl</drug> may also result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "erythromycin",
    "entity2": "fentanyl",
    "text": "The concomitant use of other CYP3A4 inhibitors such as diltiazem and <drug>erythromycin</drug> with transdermal <drug>fentanyl</drug> may also result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "alcohol",
    "entity2": "fentanyl",
    "text": "Central Nervous System Depressants: The concomitant use of DURAGESIC  (<drug>fentanyl</drug> transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and <drug>alcohol</drug>, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Corticotropin",
    "entity2": "amphotericin B",
    "text": "Corticosteroids and <drug>Corticotropin</drug> (ACTH): may potentiate <drug>amphotericin B</drug>- induced hypokalemia which may predispose the patient to cardiac dysfunction.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "amphotericin B",
    "entity2": "flucytosine",
    "text": "Flucytosine: while a synergistic relationship with <drug>amphotericin B</drug> has been reported, concomitant use may increase the toxicity of <drug>flucytosine</drug> by possibly increasing its cellular uptake and/or impairing its renal excretion.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "amphotericin B",
    "entity2": "tubocurarine",
    "text": "Skeletal muscle relaxants: <drug>amphotericin B</drug>-induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants (e.g., <drug>tubocurarine</drug>).",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "guanfacine",
    "entity2": "phenobarbital",
    "text": "The administration of <drug>guanfacine</drug> concomitantly with known microsomal enzyme inducer (<drug>phenobarbital</drug> or phenytoin) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "guanfacine",
    "entity2": "phenytoin",
    "text": "The administration of <drug>guanfacine</drug> concomitantly with known microsomal enzyme inducer (phenobarbital or <drug>phenytoin</drug>) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "nadolol",
    "entity2": "guanfacine",
    "text": "Noncardioselective beta-blockers (<drug>nadolol</drug>,porpranolol,timolol) may exacerbate rebound hypertension when <drug>guanfacine</drug> is withdrawn.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "timolol",
    "entity2": "guanfacine",
    "text": "Noncardioselective beta-blockers (nadolol,porpranolol,<drug>timolol</drug>) may exacerbate rebound hypertension when <drug>guanfacine</drug> is withdrawn.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "nortriptyline",
    "entity2": "fluoxetine hydrochloride",
    "text": "There have been greater than 2-fold increases in previously stable plasma levels of other antidepressants, including <drug>nortriptyline</drug>, when <drug>fluoxetine hydrochloride</drug> has been administered in combination with these agents.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "alcohol",
    "entity2": "hydrocodone",
    "text": "Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including <drug>alcohol</drug>) concomitantly with <drug>hydrocodone</drug> and acetaminophen tablets may exhibit an additive CNS depression.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "CMI",
    "entity2": "haloperidol",
    "text": "The plasma concentration of <drug>CMI</drug> has been reported to be increased by the concomitant administration of <drug>haloperidol</drug>;",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "methylphenidate",
    "entity2": "CMI",
    "text": "plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of <drug>methylphenidate</drug> or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with <drug>CMI</drug> as well.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "cimetidine",
    "entity2": "CMI",
    "text": "plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., <drug>cimetidine</drug>, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with <drug>CMI</drug> as well.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "fluoxetine",
    "entity2": "CMI",
    "text": "plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, <drug>fluoxetine</drug>) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with <drug>CMI</drug> as well.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "phenytoin",
    "entity2": "CMI",
    "text": "plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, <drug>phenytoin</drug>), and such an effect may be anticipated with <drug>CMI</drug> as well.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "CMI",
    "entity2": "phenobarbital",
    "text": "Administration of <drug>CMI</drug> has been reported to increase the plasma levels of <drug>phenobarbital</drug>, if given concomitantly.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "danazol",
    "entity2": "lovastatin",
    "text": "Danazol: The risk of myopathy/rhabdomyolysis is increased by concomitant administration of <drug>danazol</drug> particularly with higher doses of <drug>lovastatin</drug> (see WARNINGS, Myopathy/Rhabdomyolysis).",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "cephalexin",
    "entity2": "metformin",
    "text": "Metformin: In healthy subjects given single 500 mg doses of <drug>cephalexin</drug> and <drug>metformin</drug>, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "cephalexin",
    "entity2": "metformin",
    "text": "Although not observed in this study, adverse effects could potentially arise from co-administration of <drug>cephalexin</drug> and <drug>metformin</drug> by inhibition of tubular secretion via organic cationic transporter systems.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "cephalexin",
    "entity2": "metformin",
    "text": "Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking <drug>cephalexin</drug> and <drug>metformin</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "cephalexin",
    "entity2": "probenecid",
    "text": "Probenecid: As with other b-lactams, the renal excretion of <drug>cephalexin</drug> is inhibited by <drug>probenecid</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "lymecycline",
    "entity2": "iron",
    "text": "The absorption of <drug>lymecycline</drug> may be affected by the simultaneous administration of indigestion remedies, <drug>iron</drug> or zinc supplements.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "lymecycline",
    "entity2": "zinc",
    "text": "The absorption of <drug>lymecycline</drug> may be affected by the simultaneous administration of indigestion remedies, iron or <drug>zinc</drug> supplements.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Warfarin",
    "entity2": "Meclofenamate sodium",
    "text": "<drug>Warfarin</drug>: <drug>Meclofenamate sodium</drug> enhances the effect of warfarin.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "meclofenamate sodium",
    "entity2": "warfarin",
    "text": "Therefore, when <drug>meclofenamate sodium</drug> is given to a patient receiving <drug>warfarin</drug>, the dosage of warfarin should be reduced to prevent excessive prolongation of the prothrombin time.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "levobupivacaine",
    "entity2": "phenytoin",
    "text": "Although no clinical studies have been conducted, it is likely that the metabolism of <drug>levobupivacaine</drug> may be affected by the known CYP3A4 inducers (such as <drug>phenytoin</drug>, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "levobupivacaine",
    "entity2": "phenobarbital",
    "text": "Although no clinical studies have been conducted, it is likely that the metabolism of <drug>levobupivacaine</drug> may be affected by the known CYP3A4 inducers (such as phenytoin, <drug>phenobarbital</drug>, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "levobupivacaine",
    "entity2": "rifampin",
    "text": "Although no clinical studies have been conducted, it is likely that the metabolism of <drug>levobupivacaine</drug> may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, <drug>rifampin</drug>), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "levobupivacaine",
    "entity2": "ketoconazole",
    "text": "Although no clinical studies have been conducted, it is likely that the metabolism of <drug>levobupivacaine</drug> may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., <drug>ketoconazole</drug>;",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "cimetidine",
    "entity2": "isradipine",
    "text": "Cimetidine: In a study in healthy volunteers, a one-week course of <drug>cimetidine</drug> at 400 mg b.i.d. with a single 5 mg dose of <drug>isradipine</drug> on the sixth day showed an increase in isradipine mean peak plasma concentrations (36%) and significant increase in area under the curve (50%).",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "isradipine",
    "entity2": "cimetidine",
    "text": "If <drug>isradipine</drug> therapy is initiated in a patient currently receiving <drug>cimetidine</drug> careful monitoring for adverse reactions is advised and downward dose adjustment may be required.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "rifampicin",
    "entity2": "isradipine",
    "text": "Rifampicin: In a study in healthy volunteers, a six-day course of <drug>rifampicin</drug> at 600 mg/day followed by a single 5 mg dose of <drug>isradipine</drug> resulted in a reduction in isradipine levels to below detectable limits.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "rifampicin",
    "entity2": "isradipine",
    "text": "If <drug>rifampicin</drug> therapy is required, <drug>isradipine</drug> concentrations and therapeutic effects are likely to be markedly reduced or abolished as a consequence of increased metabolism and higher clearance of isradipine.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "ammonium chloride",
    "entity2": "amphetamine",
    "text": "Urinary acidifying agents These agents (<drug>ammonium chloride</drug>, sodium acid phosphate, etc.) increase the concentration of the ionized species of the <drug>amphetamine</drug> molecule, thereby increasing urinary excretion.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "sodium acid phosphate",
    "entity2": "amphetamine",
    "text": "Urinary acidifying agents These agents (ammonium chloride, <drug>sodium acid phosphate</drug>, etc.) increase the concentration of the ionized species of the <drug>amphetamine</drug> molecule, thereby increasing urinary excretion.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "d-amphetamine",
    "entity2": "desipramine",
    "text": "<drug>d-amphetamine</drug> with <drug>desipramine</drug> or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "d-amphetamine",
    "entity2": "protriptyline",
    "text": "<drug>d-amphetamine</drug> with desipramine or <drug>protriptyline</drug> and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "furazolidone",
    "entity2": "amphetamine",
    "text": "MAO inhibitors MAOI antidepressants, as well as a metabolite of <drug>furazolidone</drug>, slow <drug>amphetamine</drug> metabolism.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "propoxyphene",
    "entity2": "amphetamine",
    "text": "Propoxyphene: In cases of <drug>propoxyphene</drug> overdosage, <drug>amphetamine</drug> CNS stimulation is potentiated and fatal convulsions can occur.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Cimetidine",
    "entity2": "labetalol HCl",
    "text": "<drug>Cimetidine</drug> has been shown to increase the bioavailability of <drug>labetalol HCl</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "halothane",
    "entity2": "labetalol HCl",
    "text": "Synergism has been shown between <drug>halothane</drug> anesthesia and intravenously administered <drug>labetalol HCl</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "labetalol HCl",
    "entity2": "halothane",
    "text": "During controlled hypotensive anesthesia using <drug>labetalol HCl</drug> in association with <drug>halothane</drug>, high concentrations (3% or above) of halothane should not be used because the degree of hypotension will be increased and because of the possibility of a large reduction in cardiac output and an increase in central venous pressure.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Labetalol HCl",
    "entity2": "nitroglycerin",
    "text": "<drug>Labetalol HCl</drug> blunts the reflex tachycardia produced by <drug>nitroglycerin</drug> without preventing its hypotensive effect.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "labetalol HCl",
    "entity2": "nitroglycerin",
    "text": "If <drug>labetalol HCl</drug> is used with <drug>nitroglycerin</drug> in patients with angina pectoris, additional antihypertensive effects may occur.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Sumatriptan",
    "entity2": "dihydroergotamine mesylate",
    "text": "Sumatriptan: <drug>Sumatriptan</drug> has been reported to cause coronary artery vasospasm, and its effect could be additive with D.H.E. 45  (<drug>dihydroergotamine mesylate</drug>) Injection, USP.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "Sumatriptan",
    "entity2": "dihydroergotamine mesylate",
    "text": "<drug>Sumatriptan</drug> and D.H.E. 45  (<drug>dihydroergotamine mesylate</drug>) Injection, USP should not be taken within 24 hours of each other..",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "propranolol",
    "entity2": "ergotamine",
    "text": "Beta Blockers: Although the results of a clinical study did not indicate a safe problem associated with the administration of D.H.E. 45  (dihydroergotamine mesylate) Injection, USP to subjects already receiving propranolol, there have been reports that <drug>propranolol</drug> may potentiate the vasoconstrictive action of <drug>ergotamine</drug> by blocking the vasodilating property of epinephrine.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Nicotine",
    "entity2": "ergot",
    "text": "Nicotine: <drug>Nicotine</drug> may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to <drug>ergot</drug> therapy.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "L-phenylalanine",
    "entity2": "selegiline",
    "text": "Selegiline - <drug>L-phenylalanine</drug> and the selective MAO inhibitor <drug>selegiline</drug> may have synergistic antidepressant activity if used concomitantly.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Flupenthixol",
    "entity2": "Ethanol",
    "text": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: <drug>Flupenthixol</drug> and <drug>Ethanol</drug> cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "Netilmicin",
    "entity2": "furosemide",
    "text": "<drug>Netilmicin</drug> should not be administered concomitantly with potent loop diuretics such as <drug>furosemide</drug> and ethacrynic acid as the potential for ototoxicity is enhanced by the combination.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "Netilmicin",
    "entity2": "ethacrynic acid",
    "text": "<drug>Netilmicin</drug> should not be administered concomitantly with potent loop diuretics such as furosemide and <drug>ethacrynic acid</drug> as the potential for ototoxicity is enhanced by the combination.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "allopurinol",
    "entity2": "ampicillin",
    "text": "The concurrent administration of <drug>allopurinol</drug> and <drug>ampicillin</drug> increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "ampicillin",
    "entity2": "allopurinol",
    "text": "It is not known whether this potentiation of <drug>ampicillin</drug> rashes is due to <drug>allopurinol</drug> or the hyperuricemia present in these patients.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "fexofenadine hydrochloride",
    "entity2": "ketoconazole",
    "text": "However, co  administration of <drug>fexofenadine hydrochloride</drug> with either <drug>ketoconazole</drug> or erythromycin led to increased plasma concentrations of fexofenadine.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "fexofenadine hydrochloride",
    "entity2": "erythromycin",
    "text": "However, co  administration of <drug>fexofenadine hydrochloride</drug> with either ketoconazole or <drug>erythromycin</drug> led to increased plasma concentrations of fexofenadine.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "ketoconazole",
    "entity2": "fexofenadine",
    "text": "These studies indicate that <drug>ketoconazole</drug> or erythromycin co-administration enhances <drug>fexofenadine</drug> gastrointestinal absorption.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "erythromycin",
    "entity2": "fexofenadine",
    "text": "These studies indicate that ketoconazole or <drug>erythromycin</drug> co-administration enhances <drug>fexofenadine</drug> gastrointestinal absorption.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "ketoconazole",
    "entity2": "fexofenadine",
    "text": "This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein. in vivo animal studies also suggest that in addition to enhancing absorption, <drug>ketoconazole</drug> decreases <drug>fexofenadine</drug> gastrointestinal secretion, while erythromycin may also decrease biliary excretion.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "fexofenadine hydrochloride",
    "entity2": "aluminum",
    "text": "Drug Interactions with Antacids Administration of 120 mg of <drug>fexofenadine hydrochloride</drug> (2 x 60 mg capsule) within 15 minutes of an <drug>aluminum</drug> and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "fexofenadine hydrochloride",
    "entity2": "magnesium",
    "text": "Drug Interactions with Antacids Administration of 120 mg of <drug>fexofenadine hydrochloride</drug> (2 x 60 mg capsule) within 15 minutes of an aluminum and <drug>magnesium</drug> containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Naproxen",
    "entity2": "propranolol",
    "text": "<drug>Naproxen</drug> and other NSAIDs can reduce the antihypertensive effect of <drug>propranolol</drug> and other beta-blockers.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Probenecid",
    "entity2": "naproxen",
    "text": "<drug>Probenecid</drug> given concurrently increases <drug>naproxen</drug> anion plasma levels and extends its plasma half-life significantly.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "naproxen",
    "entity2": "methotrexate",
    "text": "Caution should be used if <drug>naproxen</drug> is administered concomitantly with <drug>methotrexate</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Naproxen",
    "entity2": "methotrexate",
    "text": "<drug>Naproxen</drug>, naproxen sodium and other NSAIDs have been reported to reduce the tubular secretion of <drug>methotrexate</drug> in an animal model, possibly increasing the toxicity of methotrexate.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "naproxen sodium",
    "entity2": "methotrexate",
    "text": "Naproxen, <drug>naproxen sodium</drug> and other NSAIDs have been reported to reduce the tubular secretion of <drug>methotrexate</drug> in an animal model, possibly increasing the toxicity of methotrexate.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "phenytoin",
    "entity2": "fludrocortisone acetate",
    "text": "Barbiturates, <drug>phenytoin</drug>, or rifampin increased metabolic clearance of <drug>fludrocortisone acetate</drug> because of the induction of hepatic enzymes.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "rifampin",
    "entity2": "fludrocortisone acetate",
    "text": "Barbiturates, phenytoin, or <drug>rifampin</drug> increased metabolic clearance of <drug>fludrocortisone acetate</drug> because of the induction of hepatic enzymes.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Ethoxzolamide",
    "entity2": "procainamide",
    "text": "<drug>Ethoxzolamide</drug> may increase the action of tricyclics, amphetamines, <drug>procainamide</drug>, and quinidine.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Ethoxzolamide",
    "entity2": "quinidine",
    "text": "<drug>Ethoxzolamide</drug> may increase the action of tricyclics, amphetamines, procainamide, and <drug>quinidine</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "ethoxzolamide",
    "entity2": "amphotericin B",
    "text": "Coadministration of <drug>ethoxzolamide</drug> with other diuretics, <drug>amphotericin B</drug>, and corticosteroids may cause hypokalemia.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "Dexbrompheniramine",
    "entity2": "alcohol",
    "text": "<drug>Dexbrompheniramine</drug> can interact with <drug>alcohol</drug> or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "Furosemide",
    "entity2": "ethacrynic acid",
    "text": "<drug>Furosemide</drug> should not be used concomitantly with <drug>ethacrynic acid</drug> because of the possibility of ototoxicity.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Furosemide",
    "entity2": "tubocurarine",
    "text": "<drug>Furosemide</drug> has a tendency to antagonize the skeletal muscle relaxing effect of <drug>tubocurarine</drug> and may potentiate the action of succinylcholine.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Furosemide",
    "entity2": "succinylcholine",
    "text": "<drug>Furosemide</drug> has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of <drug>succinylcholine</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Furosemide",
    "entity2": "norepinephrine",
    "text": "<drug>Furosemide</drug> may decrease arterial responsiveness to <drug>norepinephrine</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "sucralfate",
    "entity2": "furosemide",
    "text": "Tablets Simultaneous administration of <drug>sucralfate</drug> and <drug>furosemide</drug> tablets may reduce the natriuretic and antihypertensive effects of furosemide.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "furosemide",
    "entity2": "sucralfate",
    "text": "The intake of <drug>furosemide</drug> and <drug>sucralfate</drug> should be separated by at least two hours.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "furosemide",
    "entity2": "acetylsalicylic acid",
    "text": "Tablets, Injection, and Oral Solution One study in six subjects demonstrated that the combination of <drug>furosemide</drug> and <drug>acetylsalicylic acid</drug> temporarily reduced creatinine clearance in patients with chronic renal insufficiency.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "indomethacin",
    "entity2": "furosemide",
    "text": "Literature reports indicate that coadministration of <drug>indomethacin</drug> may reduce the natriuretic and antihypertensive effects of <drug>furosemide</drug> in some patients by inhibiting prostaglandin synthesis.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "indomethacin",
    "entity2": "furosemide",
    "text": "Patients receiving both <drug>indomethacin</drug> and <drug>furosemide</drug> should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "omeprazole",
    "entity2": "cilostazol",
    "text": "Pharmacokinetic studies have demonstrated that <drug>omeprazole</drug> and erythromycin significantly increased the systemic exposure of <drug>cilostazol</drug> and/or its major metabolites.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "erythromycin",
    "entity2": "cilostazol",
    "text": "Pharmacokinetic studies have demonstrated that omeprazole and <drug>erythromycin</drug> significantly increased the systemic exposure of <drug>cilostazol</drug> and/or its major metabolites.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "cilostazol",
    "entity2": "diltiazem",
    "text": "Population pharmacokinetic studies showed higher concentrations of <drug>cilostazol</drug> among patients concurrently treated with <drug>diltiazem</drug>, an inhibitor of C.P.A..",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "ranitidine",
    "entity2": "alendronate",
    "text": "Intravenous <drug>ranitidine</drug> was shown to double the bioavailability of oral <drug>alendronate</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "calcium",
    "entity2": "alendronate",
    "text": "Products containing <drug>calcium</drug> and other multivalent cations likely will interfere with absorption of <drug>alendronate</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "multivalent cations",
    "entity2": "alendronate",
    "text": "Products containing calcium and other <drug>multivalent cations</drug> likely will interfere with absorption of <drug>alendronate</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "calcium",
    "entity2": "Ibandronate",
    "text": "Products containing <drug>calcium</drug> and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of <drug>Ibandronate</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "aluminum",
    "entity2": "Ibandronate",
    "text": "Products containing calcium and other multivalent cations (such as <drug>aluminum</drug>, magnesium, iron) are likely to interfere with absorption of <drug>Ibandronate</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "magnesium",
    "entity2": "Ibandronate",
    "text": "Products containing calcium and other multivalent cations (such as aluminum, <drug>magnesium</drug>, iron) are likely to interfere with absorption of <drug>Ibandronate</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "iron",
    "entity2": "Ibandronate",
    "text": "Products containing calcium and other multivalent cations (such as aluminum, magnesium, <drug>iron</drug>) are likely to interfere with absorption of <drug>Ibandronate</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "probenecid",
    "entity2": "acyclovir",
    "text": "Co-administration of <drug>probenecid</drug> with <drug>acyclovir</drug> has been shown to increase the mean half-life and the area under the concentration-time curve.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "clonidine",
    "entity2": "insulin",
    "text": "Beta-blockers, <drug>clonidine</drug>, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of <drug>insulin</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "lithium",
    "entity2": "insulin",
    "text": "Beta-blockers, clonidine, <drug>lithium</drug> salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of <drug>insulin</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "alcohol",
    "entity2": "insulin",
    "text": "Beta-blockers, clonidine, lithium salts, and <drug>alcohol</drug> may either potentiate or weaken the blood-glucose-lowering effect of <drug>insulin</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Chlorprothixene",
    "entity2": "lithium",
    "text": "<drug>Chlorprothixene</drug> may increase the plasma-level of concomitantly given <drug>lithium</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "chlorprothixene",
    "entity2": "tramadol",
    "text": "Avoid the concomitant use of <drug>chlorprothixene</drug> and <drug>tramadol</drug> (Ultram).",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "capecitabine",
    "entity2": "phenprocoumon",
    "text": "Coumarin Anticoagulants Altered coagulation parameters and/or bleeding have been reported in patients taking <drug>capecitabine</drug> concomitantly with coumarin-derivative anticoagulants such as warfarin and <drug>phenprocoumon</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "5-fluorouracil",
    "entity2": "leucovorin",
    "text": "Leucovorin: The concentration of <drug>5-fluorouracil</drug> is increased and its toxicity may be enhanced by <drug>leucovorin</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "leucovorin",
    "entity2": "fluorouracil",
    "text": "Deaths from severe enterocolitis, diarrhea, and dehydration have been reported in elderly patients receiving weekly <drug>leucovorin</drug> and <drug>fluorouracil</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Cholestyramine",
    "entity2": "T4",
    "text": "Cholestyramine: <drug>Cholestyramine</drug> binds both <drug>T4</drug> and T3 in the intestine, thus impairing absorption of these thyroid hormones.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Cholestyramine",
    "entity2": "T3",
    "text": "Cholestyramine: <drug>Cholestyramine</drug> binds both T4 and <drug>T3</drug> in the intestine, thus impairing absorption of these thyroid hormones.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Thyroxine",
    "entity2": "epinephrine",
    "text": "Vasopressors: <drug>Thyroxine</drug> increases the adrenergic effect of catecholamines such as <drug>epinephrine</drug> and norepinephrine.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Thyroxine",
    "entity2": "norepinephrine",
    "text": "Vasopressors: <drug>Thyroxine</drug> increases the adrenergic effect of catecholamines such as epinephrine and <drug>norepinephrine</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "dexamethasone",
    "entity2": "albendazole",
    "text": "Dexamethasone: Steady-state trough concentrations of albendazole sulfoxide were about 56% higher when 8 mg <drug>dexamethasone</drug> was coadministered with each dose of <drug>albendazole</drug> (15 mg/kg/day) in eight neurocysticercosis patients.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "praziquantel",
    "entity2": "albendazole sulfoxide",
    "text": "Praziquantel: In the fed state, <drug>praziquantel</drug> (40 mg/kg) increased mean maximum plasma concentration and area under the curve of <drug>albendazole sulfoxide</drug> by about 50% in healthy subjects (n=10) compared with a separate group of subjects (n=6) given albendazole alone.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Albendazole sulfoxide",
    "entity2": "cimetidine",
    "text": "Cimetidine: <drug>Albendazole sulfoxide</drug> concentrations in bile and cystic fluid were increased (about 2-fold) in hydatid cyst patients treated with <drug>cimetidine</drug> (10 mg/kg/day) (n=7) compared with albendazole (20 mg/kg/day) alone (n=12).",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "trazodone hydrochloride",
    "entity2": "buspirone HCl",
    "text": "There is one report suggesting that the concomitant use of <drug>trazodone hydrochloride</drug> (Desyrel) and <drug>buspirone HCl</drug> may have caused 3- to 6-fold elevations on SGPT (ALT) in a few patients.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "buspirone HCl",
    "entity2": "haloperidol",
    "text": "In a study in normal volunteers, concomitant administration of <drug>buspirone HCl</drug> and <drug>haloperidol</drug> resulted in increased serum haloperidol concentrations.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "buspirone",
    "entity2": "warfarin",
    "text": "However, there has been one report of prolonged prothrombin time when <drug>buspirone</drug> was added to the regimen of a patient treated with <drug>warfarin</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "buspirone",
    "entity2": "digoxin",
    "text": "In vitro, <drug>buspirone</drug> may displace less firmly bound drugs like <drug>digoxin</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "idoxuridine",
    "entity2": "boric acid",
    "text": "When you are using <drug>idoxuridine</drug>, it is especially important that your health care professional know if you are using the following: Eye product containing <drug>boric acid</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Boric acid",
    "entity2": "idoxuridine",
    "text": "<drug>Boric acid</drug> may interact with the <drug>idoxuridine</drug> preparation causing a gritty substance to form or may interact with the preservative in the idoxuridine preparation causing a toxic effect in the eye.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "diltiazem hydrochloride",
    "entity2": "propranolol",
    "text": "Administration of <drug>diltiazem hydrochloride</drug> concomitantly with <drug>propranolol</drug> in five normal volunteers resulted in increased propranolol levels in all subjects and bioavailability of propranolol was increased approximately 50%.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "propranolol",
    "entity2": "diltiazem",
    "text": "In vitro, <drug>propranolol</drug> appears to be displaced from its binding sites by <drug>diltiazem</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "cimetidine",
    "entity2": "diltiazem",
    "text": "A study in six healthy volunteers has shown a significant increase in peak diltiazem plasma levels (58%) and AUC (53%) after a 1-week course of <drug>cimetidine</drug> 1200 mg/day and a single dose of <drug>diltiazem</drug> 60mg.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "cimetidine",
    "entity2": "diltiazem",
    "text": "The effect may be mediated by <drug>cimetidine</drug>s known inhibition of hepatic cytochrome P-450, the enzyme system responsible for the first-pass metabolism of <drug>diltiazem</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "diltiazem",
    "entity2": "cimetidine",
    "text": "Patients currently receiving <drug>diltiazem</drug> therapy should be carefully monitored for a change in pharmacological effect when initiating and discontinuing therapy with <drug>cimetidine</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "diltiazem hydrochloride",
    "entity2": "digoxin",
    "text": "Administration of <drug>diltiazem hydrochloride</drug> with <drug>digoxin</drug> in 24 healthy male subjects increased plasma digoxin concentrations approximately 20%.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "digoxin",
    "entity2": "diltiazem hydrochloride",
    "text": "Since there have been conflicting results regarding the effect of digoxin levels, it is recommended that <drug>digoxin</drug> levels be monitored when initiating, adjusting, and discontinuing <drug>diltiazem hydrochloride</drug> therapy to avoid possible over- or under-digitalization.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "diltiazem",
    "entity2": "cyclosporine",
    "text": "A pharmacokinetic interaction between <drug>diltiazem</drug> and <drug>cyclosporine</drug> has been observed during studies involving renal and cardiac transplant patients.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "cyclosporine",
    "entity2": "diltiazem",
    "text": "In renal and cardiac transplant recipients, a reduction of <drug>cyclosporine</drug> dose ranging from 15% to 48% was necessary to maintain cyclosporine trough concentrations similar to those seen prior to the addition of <drug>diltiazem</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "cyclosporine",
    "entity2": "diltiazem",
    "text": "If these agents are to be administered concurrently, <drug>cyclosporine</drug> concentrations should be monitored, especially when <drug>diltiazem</drug> therapy is initiated, adjusted, or discontinued.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "diltiazem",
    "entity2": "carbamazepine",
    "text": "Concomitant administration of <drug>diltiazem</drug> with <drug>carbamazepine</drug> has been reported to result in elevated serum levels of carbamazepine (40% to 72% increase), resulting in toxicity in some cases.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "diltiazem",
    "entity2": "midazolam",
    "text": "Studies showed that <drug>diltiazem</drug> increased the AUC of <drug>midazolam</drug> and triazolam by 3-4 fold and the Cmax by 2-fold, compared to placebo.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "diltiazem",
    "entity2": "triazolam",
    "text": "Studies showed that <drug>diltiazem</drug> increased the AUC of midazolam and <drug>triazolam</drug> by 3-4 fold and the Cmax by 2-fold, compared to placebo.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "midazolam",
    "entity2": "diltiazem",
    "text": "The elimination half life of <drug>midazolam</drug> and triazolam also increased (1.5-2.5 fold) during coadministration with <drug>diltiazem</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "triazolam",
    "entity2": "diltiazem",
    "text": "The elimination half life of midazolam and <drug>triazolam</drug> also increased (1.5-2.5 fold) during coadministration with <drug>diltiazem</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "diltiazem",
    "entity2": "midazolam",
    "text": "These pharmacokinetic effects seen during <drug>diltiazem</drug> coadministration can result in increased clinical effects (e.g., prolonged sodation)of both <drug>midazolam</drug> and triazolam.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "diltiazem",
    "entity2": "triazolam",
    "text": "These pharmacokinetic effects seen during <drug>diltiazem</drug> coadministration can result in increased clinical effects (e.g., prolonged sodation)of both midazolam and <drug>triazolam</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "diltiazem",
    "entity2": "lovastatin",
    "text": "In a ten-subject study, coadministration of <drug>diltiazem</drug> (120 mg bid) with <drug>lovastatin</drug> resulted in a 3-4 times increase in mean lovastatin AUC and Cmax vs. lovastatin alone;",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "rifampin",
    "entity2": "diltiazem",
    "text": "Coadministration of <drug>rifampin</drug> with <drug>diltiazem</drug> lowered the diltiazem plasma concentrations to undetectable levels.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "diltiazem",
    "entity2": "rifampin",
    "text": "Coadministration of <drug>diltiazem</drug> with <drug>rifampin</drug> or any known CYP3A4 inducer should be avoided when possible, and alternative therapy considered.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Cytosine arabinoside",
    "entity2": "flucytosine",
    "text": "<drug>Cytosine arabinoside</drug>, a cytostatic agent, has been reported to inactivate the antifungal activity of <drug>flucytosine</drug> by competitive inhibition.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "phenytoin",
    "entity2": "calcitriol",
    "text": "Phenytoin/Phenobarbital: The coadministration of <drug>phenytoin</drug> or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of <drug>calcitriol</drug>/ergocalcitriol by accelerating metabolism.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "phenobarbital",
    "entity2": "calcitriol",
    "text": "Phenytoin/Phenobarbital: The coadministration of phenytoin or <drug>phenobarbital</drug> will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of <drug>calcitriol</drug>/ergocalcitriol by accelerating metabolism.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "apomorphine",
    "entity2": "ondansetron",
    "text": "5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when <drug>apomorphine</drug> was administered with <drug>ondansetron</drug>, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "apomorphine",
    "entity2": "ondansetron",
    "text": "5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of <drug>apomorphine</drug> with drugs of the 5HT3 antagonist class (including, for example, <drug>ondansetron</drug>, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "apomorphine",
    "entity2": "granisetron",
    "text": "5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of <drug>apomorphine</drug> with drugs of the 5HT3 antagonist class (including, for example, ondansetron, <drug>granisetron</drug>, dolasetron, palonosetron, and alosetron) is contraindicated .",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "apomorphine",
    "entity2": "dolasetron",
    "text": "5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of <drug>apomorphine</drug> with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, <drug>dolasetron</drug>, palonosetron, and alosetron) is contraindicated .",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "apomorphine",
    "entity2": "palonosetron",
    "text": "5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of <drug>apomorphine</drug> with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, <drug>palonosetron</drug>, and alosetron) is contraindicated .",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "apomorphine",
    "entity2": "alosetron",
    "text": "5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of <drug>apomorphine</drug> with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and <drug>alosetron</drug>) is contraindicated .",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "famotidine",
    "entity2": "cefditoren pivoxil",
    "text": "H2-Receptor Antagonists: Co-administration of a single dose of intravenously administered <drug>famotidine</drug> (20 mg) reduced the oral absorption of a single 400 mg dose of <drug>cefditoren pivoxil</drug> administered following a meal, as evidenced by a 27% decrease in mean Cmax and a 22% decrease in mean AUC.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "probenecid",
    "entity2": "cefditoren pivoxil",
    "text": "Probenecid: As with other b-lactam antibiotics, co-administration of <drug>probenecid</drug> with <drug>cefditoren pivoxil</drug> resulted in an increase in the plasma exposure of cefditoren, with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "bepridil hydrochloride",
    "entity2": "digoxin",
    "text": "Digoxin: In controlled studies in healthy volunteers, <drug>bepridil hydrochloride</drug> either had no effect (one study) or was associated with modest increases, about 30% (two studies) in steady-state serum <drug>digoxin</drug> concentrations.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "cerivastatin sodium",
    "entity2": "cholestyramine",
    "text": "In the first study, concomitant administration of 0.2 mg <drug>cerivastatin sodium</drug> and 12 g <drug>cholestyramine</drug> resulted in decreases of more than 22% for AUC and 40% for Cmax when compared to dosing cerivastatin sodium alone.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "cholestyramine",
    "entity2": "cerivastatin sodium",
    "text": "However, in the second study, administration of 12 g <drug>cholestyramine</drug> 1 hour before the evening meal and 0.3 mg <drug>cerivastatin sodium</drug> approximately 4 hours after the same evening meal resulted in a decrease in the cerivastatin AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing cerivastatin sodium alone.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "cerivastatin",
    "entity2": "erythromycin",
    "text": "ERYTHROMYCIN: In hypercholesterolemic patients, steady-state <drug>cerivastatin</drug> AUC and Cmax increased approximately 50% and 24% respectively after 10 days with co-administration of <drug>erythromycin</drug>, a known inhibitor of cytochrome P450 3A4.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Fluvoxamine",
    "entity2": "alosetron",
    "text": "<drug>Fluvoxamine</drug> increased mean <drug>alosetron</drug> plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "alosetron",
    "entity2": "fluvoxamine",
    "text": "Concomitant administration of <drug>alosetron</drug> and <drug>fluvoxamine</drug> is contraindicated.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "alosetron",
    "entity2": "cimetidine",
    "text": "Concomitant administration of <drug>alosetron</drug> and moderate CYP1A2 inhibitors, including quinolone antibiotics and <drug>cimetidine</drug>, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Ketoconazole",
    "entity2": "alosetron",
    "text": "<drug>Ketoconazole</drug> increased mean <drug>alosetron</drug> plasma concentrations (AUC) by 29%.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "alosetron",
    "entity2": "ketoconazole",
    "text": "Caution should be used when <drug>alosetron</drug> and <drug>ketoconazole</drug> are administered concomitantly.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "alosetron",
    "entity2": "clarithromycin",
    "text": "Coadministration of <drug>alosetron</drug> and strong CYP3A4 inhibitors, such as <drug>clarithromycin</drug>, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "alosetron",
    "entity2": "telithromycin",
    "text": "Coadministration of <drug>alosetron</drug> and strong CYP3A4 inhibitors, such as clarithromycin, <drug>telithromycin</drug>, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "alosetron",
    "entity2": "voriconazole",
    "text": "Coadministration of <drug>alosetron</drug> and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, <drug>voriconazole</drug>, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "alosetron",
    "entity2": "itraconazole",
    "text": "Coadministration of <drug>alosetron</drug> and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and <drug>itraconazole</drug> has not been evaluated but should be undertaken with caution because of similar potential drug interactions.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "alosetron",
    "entity2": "isoniazid",
    "text": "Although not studied with <drug>alosetron</drug>, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as <drug>isoniazid</drug>, procainamide, and hydralazine.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "alosetron",
    "entity2": "procainamide",
    "text": "Although not studied with <drug>alosetron</drug>, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, <drug>procainamide</drug>, and hydralazine.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "alosetron",
    "entity2": "hydralazine",
    "text": "Although not studied with <drug>alosetron</drug>, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and <drug>hydralazine</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "diflunisal",
    "entity2": "warfarin",
    "text": "Oral Anticoagulants: In some normal volunteers, the concomitant administration of <drug>diflunisal</drug> and <drug>warfarin</drug>, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "diflunisal",
    "entity2": "acenocoumarol",
    "text": "Oral Anticoagulants: In some normal volunteers, the concomitant administration of <drug>diflunisal</drug> and warfarin, <drug>acenocoumarol</drug>, or phenprocoumon resulted in prolongation of prothrombin time.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "diflunisal",
    "entity2": "phenprocoumon",
    "text": "Oral Anticoagulants: In some normal volunteers, the concomitant administration of <drug>diflunisal</drug> and warfarin, acenocoumarol, or <drug>phenprocoumon</drug> resulted in prolongation of prothrombin time.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "diflunisal",
    "entity2": "hydrochlorothiazide",
    "text": "Hydrochlorothiazide: In normal volunteers, concomitant administration of <drug>diflunisal</drug> and <drug>hydrochlorothiazide</drug> resulted in significantly increased plasma levels of hydrochlorothiazide.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Diflunisal",
    "entity2": "hydrochlorothiazide",
    "text": "<drug>Diflunisal</drug> decreased the hyperuricemic effect of <drug>hydrochlorothiazide</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Diflunisal",
    "entity2": "furosemide",
    "text": "<drug>Diflunisal</drug> decreased the hyperuricemic effect of <drug>furosemide</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "diflunisal",
    "entity2": "acetaminophen",
    "text": "Acetaminophen: In normal volunteers, concomitant administration of <drug>diflunisal</drug> and <drug>acetaminophen</drug> resulted in an approximate 50% increase in plasma levels of acetaminophen.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "diflunisal",
    "entity2": "acetaminophen",
    "text": "Since acetaminophen in high doses has been associated with hepatotoxicity, concomitant administration of <drug>diflunisal</drug> and <drug>acetaminophen</drug> should be used cautiously, with careful monitoring of patients.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "diflunisal",
    "entity2": "acetaminophen",
    "text": "Concomitant administration of <drug>diflunisal</drug> and <drug>acetaminophen</drug> in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "diflunisal",
    "entity2": "methotrexate",
    "text": "Methotrexate: Caution should be used if <drug>diflunisal</drug> is administered concomitantly with <drug>methotrexate</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "diflunisal",
    "entity2": "indomethacin",
    "text": "Nonsteroidal Anti-Inflammatory Drugs: The administration of <drug>diflunisal</drug> to normal volunteers receiving <drug>indomethacin</drug> decreased the renal clearance and significantly increased the plasma levels of indomethacin.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "indomethacin",
    "entity2": "diflunisal",
    "text": "In some patients the combined use of <drug>indomethacin</drug> and <drug>diflunisal</drug> has been associated with fatal gastrointestinal hemorrhage.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "indomethacin",
    "entity2": "diflunisal",
    "text": "Therefore, <drug>indomethacin</drug> and <drug>diflunisal</drug> should not be used concomitantly.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "diflunisal",
    "entity2": "sulindac",
    "text": "Sulindac: The concomitant administration of <drug>diflunisal</drug> and <drug>sulindac</drug> in normal volunteers resulted in lowering of the plasma levels of the active sulindac sulfide metabolite by approximately one-third.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "diflunisal",
    "entity2": "naproxen",
    "text": "Naproxen: The concomitant administration of <drug>diflunisal</drug> and <drug>naproxen</drug> in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "imipramine",
    "entity2": "cimetidine",
    "text": "The plasma concentration of <drug>imipramine</drug> may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., <drug>cimetidine</drug>, fluoxetine) and decrease by concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "imipramine",
    "entity2": "fluoxetine",
    "text": "The plasma concentration of <drug>imipramine</drug> may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, <drug>fluoxetine</drug>) and decrease by concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "imipramine",
    "entity2": "phenytoin",
    "text": "The plasma concentration of <drug>imipramine</drug> may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration of hepatic enzyme inducers (e.g., barbiturates, <drug>phenytoin</drug>), and adjustment of the dosage of imipramine may therefore be necessary.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "nisoldipine",
    "entity2": "cimetidine 400 mg",
    "text": "A 30 to 45% increase in AUC and Cmax of <drug>nisoldipine</drug> was observed with concomitant administration of <drug>cimetidine 400 mg</drug> twice daily.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Propranolol",
    "entity2": "nisoldipine",
    "text": "<drug>Propranolol</drug> attenuated the heart rate increase following administration of immediate release <drug>nisoldipine</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Quinidine",
    "entity2": "nisoldipine",
    "text": "<drug>Quinidine</drug> at 648 mg bid decreased the bioavailability (AUC) of <drug>nisoldipine</drug> by 26%, but not the peak concentration.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "nisoldipine",
    "entity2": "quinidine",
    "text": "The immediate release, but not the coat-core formulation of <drug>nisoldipine</drug> increased plasma <drug>quinidine</drug> concentrations by about 20%.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "probenecid",
    "entity2": "ertapenem",
    "text": "When ertapenem is co-administered with probenecid (500 mg p.o. every 6 hours), <drug>probenecid</drug> competes for active tubular secretion and reduces the renal clearance of <drug>ertapenem</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "ertapenem",
    "entity2": "probenecid",
    "text": "Based on total <drug>ertapenem</drug> concentrations, <drug>probenecid</drug> increased the AUC by 25% and reduced the plasma and renal clearances by 20% and 35%, respectively.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "probenecid",
    "entity2": "ertapenem",
    "text": "Because of the small effect on half-life, the coadministration with <drug>probenecid</drug> to extend the half-life of <drug>ertapenem</drug> is not recommended.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "azathioprine",
    "entity2": "allopurinol",
    "text": "Use with Allopurinol: The principal pathway for detoxification of <drug>azathioprine</drug> is inhibited by <drug>allopurinol</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "azathioprine",
    "entity2": "allopurinol",
    "text": "Patients receiving <drug>azathioprine</drug> and <drug>allopurinol</drug> concomitantly should have a dose reduction of azathioprine, to approximately 1/3 to 1/4 the usual dose.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Codeine",
    "entity2": "alcohol",
    "text": "<drug>Codeine</drug> in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including <drug>alcohol</drug>) has additive depressant effects.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "Isocarboxazid",
    "entity2": "disulfiram",
    "text": "<drug>Isocarboxazid</drug> should be administered with caution to patients receiving Antabuse (<drug>disulfiram</drug>, Wyeth-Ayerst Laboratories).",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "diethylpropion",
    "entity2": "guanethidine",
    "text": "conversely, <drug>diethylpropion</drug> may interfere with antihypertensive drugs (i.e., <drug>guanethidine</drug>, a-methyldopa).",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "diethylpropion",
    "entity2": "a-methyldopa",
    "text": "conversely, <drug>diethylpropion</drug> may interfere with antihypertensive drugs (i.e., guanethidine, <drug>a-methyldopa</drug>).",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "colestipol",
    "entity2": "atorvastatin",
    "text": "Colestipol: Plasma concentrations of atorvastatin decreased approximately 25% when <drug>colestipol</drug> and <drug>atorvastatin</drug> were coadministered.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "atorvastatin",
    "entity2": "colestipol",
    "text": "However, LDL-C reduction was greater when <drug>atorvastatin</drug> and <drug>colestipol</drug> were coadministered than when either drug was given alone.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "atorvastatin",
    "entity2": "digoxin",
    "text": "Digoxin: When multiple doses of <drug>atorvastatin</drug> and <drug>digoxin</drug> were coadministered, steady-state plasma digoxin concentrations increased by approximately 20%.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "atorvastatin",
    "entity2": "erythromycin",
    "text": "Erythromycin: In healthy individuals, plasma concentrations of atorvastatin increased approximately 40% with coadministration of <drug>atorvastatin</drug> and <drug>erythromycin</drug>, a known inhibitor of cytochrome P450 3A4.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "atorvastatin",
    "entity2": "norethindrone",
    "text": "Oral Contraceptives: Coadministration of <drug>atorvastatin</drug> and an oral contraceptive increased AUC values for <drug>norethindrone</drug> and ethinyl estradiol by approximately 30% and 20%.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "atorvastatin",
    "entity2": "ethinyl estradiol",
    "text": "Oral Contraceptives: Coadministration of <drug>atorvastatin</drug> and an oral contraceptive increased AUC values for norethindrone and <drug>ethinyl estradiol</drug> by approximately 30% and 20%.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "loxapine",
    "entity2": "lorazepam",
    "text": "There have been rare reports of significant respiratory depression, stupor and/or hypotension with the concomitant use of <drug>loxapine</drug> and <drug>lorazepam</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Allopurinol",
    "entity2": "mercaptopurine",
    "text": "Mercaptopurine/Azathioprine: <drug>Allopurinol</drug> inhibits the enzymatic oxidation of <drug>mercaptopurine</drug> and azathioprine to 6-thiouric acid.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Allopurinol",
    "entity2": "azathioprine",
    "text": "Mercaptopurine/Azathioprine: <drug>Allopurinol</drug> inhibits the enzymatic oxidation of mercaptopurine and <drug>azathioprine</drug> to 6-thiouric acid.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "allopurinol",
    "entity2": "mercaptopurine",
    "text": "In patients receiving mercaptopurine (Purinethol) or azathioprine (Imuran), the concomitant administration of 300-600 mg of <drug>allopurinol</drug> per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of <drug>mercaptopurine</drug> or azathioprine.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "allopurinol",
    "entity2": "azathioprine",
    "text": "In patients receiving mercaptopurine (Purinethol) or azathioprine (Imuran), the concomitant administration of 300-600 mg of <drug>allopurinol</drug> per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or <drug>azathioprine</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "allopurinol",
    "entity2": "dicumarol",
    "text": "Dicumarol: It has been reported that <drug>allopurinol</drug> prolongs the half-life of the anticoagulant, <drug>dicumarol</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "ampicillin",
    "entity2": "allopurinol",
    "text": "Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving <drug>ampicillin</drug> or amoxicillin concurrently with <drug>allopurinol</drug> compared to patients who are not receiving both drugs.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "amoxicillin",
    "entity2": "allopurinol",
    "text": "Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving ampicillin or <drug>amoxicillin</drug> concurrently with <drug>allopurinol</drug> compared to patients who are not receiving both drugs.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "cyclophosphamide",
    "entity2": "allopurinol",
    "text": "Cytotoxic Agents: Enhanced bone marrow suppression by <drug>cyclophosphamide</drug> and other cytotoxic agents has been reported among patients with neoplastic disease, except leukemia, in the presence of <drug>allopurinol</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Chlorpropamide",
    "entity2": "allopurinol",
    "text": "Chlorpropamide: <drug>Chlorpropamide</drug>s plasma half-life may be prolonged by <drug>allopurinol</drug>, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "allopurinol",
    "entity2": "chlorpropamide",
    "text": "Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since <drug>allopurinol</drug> and <drug>chlorpropamide</drug> may compete for excretion in the renal tubule.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "allopurinol",
    "entity2": "chlorpropamide",
    "text": "The risk of hypoglycemia secondary to this mechanism may be increased if <drug>allopurinol</drug> and <drug>chlorpropamide</drug> are given concomitantly in the presence of renal insufficiency.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "cyclosporine",
    "entity2": "allopurinol sodium",
    "text": "Cyclosporin: Reports indicate that <drug>cyclosporine</drug> levels may be increased during concomitant treatment with <drug>allopurinol sodium</drug> for injection.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "haloperidol",
    "entity2": "rifampin",
    "text": "In a study of 12 schizophrenic patients coadministered oral <drug>haloperidol</drug> and <drug>rifampin</drug>, plasma haloperidol levels were decreased by a mean of 70% and mean scores on the Brief Psychiatric Rating Scale were increased from baseline.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "rifampin",
    "entity2": "haloperidol",
    "text": "In 5 other schizophrenic patients treated with oral haloperidol and rifampin, discontinuation of <drug>rifampin</drug> produced a mean 3.3-fold increase in <drug>haloperidol</drug> concentrations.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "rifampin",
    "entity2": "haloperidol",
    "text": "Thus, careful monitoring of clinical status is warranted when <drug>rifampin</drug> is administered or discontinued in <drug>haloperidol</drug>-treated patients.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "carbamazepine",
    "entity2": "lithium",
    "text": "Pharmacological/Pharmacodynamic Interactions with Carbamazepine Concomitant administration of <drug>carbamazepine</drug> and <drug>lithium</drug> may increase the risk of neurotoxic side effects.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "chloroquine",
    "entity2": "carbamazepine",
    "text": "Additionally, anti-malarial drugs, such as <drug>chloroquine</drug> and mefloquine, may antagonize the activity of <drug>carbamazepine</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "mefloquine",
    "entity2": "carbamazepine",
    "text": "Additionally, anti-malarial drugs, such as chloroquine and <drug>mefloquine</drug>, may antagonize the activity of <drug>carbamazepine</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "ciclesonide",
    "entity2": "ketoconazole",
    "text": "In another drug interaction study, co-administration of orally inhaled <drug>ciclesonide</drug> and oral <drug>ketoconazole</drug>, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of des-ciclesonide by approximately 3.6-fold at steady state, while levels of ciclesonide remained unchanged.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "ketoconazole",
    "entity2": "ciclesonide",
    "text": "Therefore, <drug>ketoconazole</drug> should be administered with caution with intranasal <drug>ciclesonide</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "phenytoin",
    "entity2": "alcohol",
    "text": "The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma <drug>phenytoin</drug> concentrations include: acute <drug>alcohol</drug> intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "phenytoin",
    "entity2": "amiodarone",
    "text": "The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma <drug>phenytoin</drug> concentrations include: acute alcohol intake, <drug>amiodarone</drug>, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "phenytoin",
    "entity2": "chlordiazepoxide",
    "text": "The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma <drug>phenytoin</drug> concentrations include: acute alcohol intake, amiodarone, chboramphenicol, <drug>chlordiazepoxide</drug>, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "phenytoin",
    "entity2": "cimetidine",
    "text": "The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma <drug>phenytoin</drug> concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, <drug>cimetidine</drug>, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "phenytoin",
    "entity2": "diazepam",
    "text": "The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma <drug>phenytoin</drug> concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, <drug>diazepam</drug>, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "phenytoin",
    "entity2": "dicumarol",
    "text": "The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma <drug>phenytoin</drug> concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, <drug>dicumarol</drug>, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "phenytoin",
    "entity2": "disulfiram",
    "text": "The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma <drug>phenytoin</drug> concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, <drug>disulfiram</drug>, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "phenytoin",
    "entity2": "ethosuximide",
    "text": "The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma <drug>phenytoin</drug> concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, <drug>ethosuximide</drug>, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "phenytoin",
    "entity2": "fluoxetine",
    "text": "The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma <drug>phenytoin</drug> concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, <drug>fluoxetine</drug>, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "phenytoin",
    "entity2": "halothane",
    "text": "The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma <drug>phenytoin</drug> concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, <drug>halothane</drug>, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "phenytoin",
    "entity2": "isoniazid",
    "text": "The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma <drug>phenytoin</drug> concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, <drug>isoniazid</drug>, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "phenytoin",
    "entity2": "methylphenidate",
    "text": "The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma <drug>phenytoin</drug> concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, <drug>methylphenidate</drug>, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "phenytoin",
    "entity2": "phenylbutazone",
    "text": "The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma <drug>phenytoin</drug> concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, <drug>phenylbutazone</drug>, salicylates, succinimides, sulfonamides, tolbutamide, trazodone",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "phenytoin",
    "entity2": "tolbutamide",
    "text": "The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma <drug>phenytoin</drug> concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, <drug>tolbutamide</drug>, trazodone",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "phenytoin",
    "entity2": "trazodone",
    "text": "The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma <drug>phenytoin</drug> concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, <drug>trazodone</drug>",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "phenytoin",
    "entity2": "carbamazepine",
    "text": "- Drugs that may decrease plasma <drug>phenytoin</drug> concentrations include: <drug>carbamazepine</drug>, chronic alcohol abuse, reserpine",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "phenytoin",
    "entity2": "alcohol",
    "text": "- Drugs that may decrease plasma <drug>phenytoin</drug> concentrations include: carbamazepine, chronic <drug>alcohol</drug> abuse, reserpine",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "phenytoin",
    "entity2": "reserpine",
    "text": "- Drugs that may decrease plasma <drug>phenytoin</drug> concentrations include: carbamazepine, chronic alcohol abuse, <drug>reserpine</drug>",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "phenytoin",
    "entity2": "phenobarbital",
    "text": "- Drugs that may either increase or decrease plasma <drug>phenytoin</drug> concentrations include: <drug>phenobarbital</drug>, vaiproic acid, and sodium valproate.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "phenytoin",
    "entity2": "sodium valproate",
    "text": "- Drugs that may either increase or decrease plasma <drug>phenytoin</drug> concentrations include: phenobarbital, vaiproic acid, and <drug>sodium valproate</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "phenytoin",
    "entity2": "phenobarbital",
    "text": "Similarly, the effects of <drug>phenytoin</drug> on <drug>phenobarbital</drug>, valproic acid and sodium plasma valproate concentrations are unpredictable",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "phenytoin",
    "entity2": "valproic acid",
    "text": "Similarly, the effects of <drug>phenytoin</drug> on phenobarbital, <drug>valproic acid</drug> and sodium plasma valproate concentrations are unpredictable",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "phenytoin",
    "entity2": "valproate",
    "text": "Similarly, the effects of <drug>phenytoin</drug> on phenobarbital, valproic acid and sodium plasma <drug>valproate</drug> concentrations are unpredictable",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "phenytoin",
    "entity2": "digitoxin",
    "text": "- Drugs whose efficacy is impaired by <drug>phenytoin</drug> include: anticoagulants, corticosteroids, coumarin, <drug>digitoxin</drug>, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "phenytoin",
    "entity2": "doxycycline",
    "text": "- Drugs whose efficacy is impaired by <drug>phenytoin</drug> include: anticoagulants, corticosteroids, coumarin, digitoxin, <drug>doxycycline</drug>, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "phenytoin",
    "entity2": "furosemide",
    "text": "- Drugs whose efficacy is impaired by <drug>phenytoin</drug> include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, <drug>furosemide</drug>, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "phenytoin",
    "entity2": "rifampin",
    "text": "- Drugs whose efficacy is impaired by <drug>phenytoin</drug> include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, <drug>rifampin</drug>, quinidine, theophylline, vitamin D.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "phenytoin",
    "entity2": "quinidine",
    "text": "- Drugs whose efficacy is impaired by <drug>phenytoin</drug> include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, <drug>quinidine</drug>, theophylline, vitamin D.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "phenytoin",
    "entity2": "theophylline",
    "text": "- Drugs whose efficacy is impaired by <drug>phenytoin</drug> include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, <drug>theophylline</drug>, vitamin D.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "clonazepam",
    "entity2": "propantheline",
    "text": "In a study in which the 2 mg <drug>clonazepam</drug> orally disintegrating tablet was administered with and without <drug>propantheline</drug> (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "clonazepam",
    "entity2": "propantheline",
    "text": "In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of <drug>clonazepam</drug> was 20% lower when the orally disintegrating tablet was given with <drug>propantheline</drug> compared to when it was given alone.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "phenytoin",
    "entity2": "clonazepam",
    "text": "Cytochrome P-450 inducers, such as <drug>phenytoin</drug>, carbamazepine and phenobarbital, induce <drug>clonazepam</drug> metabolism, causing an approximately 30% decrease in plasma clonazepam levels.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "carbamazepine",
    "entity2": "clonazepam",
    "text": "Cytochrome P-450 inducers, such as phenytoin, <drug>carbamazepine</drug> and phenobarbital, induce <drug>clonazepam</drug> metabolism, causing an approximately 30% decrease in plasma clonazepam levels.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "phenobarbital",
    "entity2": "clonazepam",
    "text": "Cytochrome P-450 inducers, such as phenytoin, carbamazepine and <drug>phenobarbital</drug>, induce <drug>clonazepam</drug> metabolism, causing an approximately 30% decrease in plasma clonazepam levels.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Ibuprofen",
    "entity2": "methotrexate",
    "text": "Methotrexate: <drug>Ibuprofen</drug>, as well as other nonsteroidal anti-inflammatory drugs, probably reduces the tubular secretion of <drug>methotrexate</drug> based on in vitro studies in rabbit kidney slices.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "ibuprofen",
    "entity2": "methotrexate",
    "text": "This may indicate that <drug>ibuprofen</drug> could enhance the toxicity of <drug>methotrexate</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "ibuprofen",
    "entity2": "methotrexate",
    "text": "Caution should be used if <drug>ibuprofen</drug> is administered concomitantly with <drug>methotrexate</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "ibuprofen",
    "entity2": "furosemide",
    "text": "Furosemide: Clinical studies, as well as random observations, have shown that <drug>ibuprofen</drug> can reduce the natriuretic effect of <drug>furosemide</drug> and thiazides in some patients.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Ibuprofen",
    "entity2": "lithium",
    "text": "Lithium: <drug>Ibuprofen</drug> produced an elevation of plasma <drug>lithium</drug> levels and a reduction in renal lithium clearance in a study of eleven normal volunteers.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "ibuprofen",
    "entity2": "lithium",
    "text": "Thus, when <drug>ibuprofen</drug> and <drug>lithium</drug> are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "L-methionine",
    "entity2": "acetaminophen",
    "text": "Acetaminophen and methotrexate - <drug>L-methionine</drug> may decrease hepatic toxicity in those with <drug>acetaminophen</drug> overdosage or in those taking methotrexate.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "L-methionine",
    "entity2": "methotrexate",
    "text": "Acetaminophen and methotrexate - <drug>L-methionine</drug> may decrease hepatic toxicity in those with acetaminophen overdosage or in those taking <drug>methotrexate</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Methionine",
    "entity2": "gentamicin",
    "text": "Gentamicin - <drug>Methionine</drug> may protect against the ototoxic effects of <drug>gentamicin</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "cyclophosphamide",
    "entity2": "phenobarbital",
    "text": "The rate of metabolism and the leukopenic activity of <drug>cyclophosphamide</drug> reportedly are increased by chronic administration of high doses of <drug>phenobarbital</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Cyclophosphamide",
    "entity2": "succinylcholine chloride",
    "text": "<drug>Cyclophosphamide</drug> treatment, which causes a marked and persistent inhibition of cholinesterase activity, potentiates the effect of <drug>succinylcholine chloride</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "felodipine",
    "entity2": "phenytoin",
    "text": "Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of <drug>felodipine</drug> were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, <drug>phenytoin</drug>, carbamazepine, or phenobarbital) than in healthy volunteers.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "felodipine",
    "entity2": "carbamazepine",
    "text": "Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of <drug>felodipine</drug> were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, <drug>carbamazepine</drug>, or phenobarbital) than in healthy volunteers.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "felodipine",
    "entity2": "phenobarbital",
    "text": "Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of <drug>felodipine</drug> were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or <drug>phenobarbital</drug>) than in healthy volunteers.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "L-arginine",
    "entity2": "cyclosporin",
    "text": "Cyclosporine - <drug>L-arginine</drug> may counteract the antinaturetic effect of <drug>cyclosporin</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "L-arginine",
    "entity2": "ibuprofen",
    "text": "Ibuprofen - <drug>L-arginine</drug> may increase the absorption of <drug>ibuprofen</drug> if taken concomitantly.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "L-arginine",
    "entity2": "nitrates",
    "text": "Organic nitrates - <drug>L-arginine</drug> supplements theoretically may potentiate the effects of organic <drug>nitrates</drug> if taken concomitantly.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "L-arginine",
    "entity2": "sildenafil citrate",
    "text": "Sildenafil citrate - Theoretically, <drug>L-arginine</drug> supplements taken concomitantly with <drug>sildenafil citrate</drug>, may potentiate the effects of the drug.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "desipramine",
    "entity2": "chlordiazepoxide",
    "text": "If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of <drug>desipramine</drug> and benzodiazepines (e.g., <drug>chlordiazepoxide</drug> or diazepam) are additive.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "desipramine",
    "entity2": "diazepam",
    "text": "If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of <drug>desipramine</drug> and benzodiazepines (e.g., chlordiazepoxide or <drug>diazepam</drug>) are additive.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "digoxin",
    "entity2": "nifedipine",
    "text": "Digitalis: Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between <drug>digoxin</drug> and <drug>nifedipine</drug>, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "digoxin",
    "entity2": "nifedipine",
    "text": "Digitalis: Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine, it is recommended that <drug>digoxin</drug> levels be monitored when initiating, adjusting, and discontinuing <drug>nifedipine</drug> to avoid possible over- or under-digitalization.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "digoxin",
    "entity2": "digoxin",
    "text": "Extended Release Tablets: Administration of nifedipine with <drug>digoxin</drug> increased <drug>digoxin</drug> levels in 9 of 12 normal volunteers.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "digoxin",
    "entity2": "nifedipine",
    "text": "Since there have been isolated reports of patients with elevated digoxin levels, it is recommended that <drug>digoxin</drug> levels be monitored when initiating, adjusting, and discontinuing <drug>nifedipine</drug> to avoid possible over- or under-digitalization.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "quinidine",
    "entity2": "nifedipine",
    "text": "Quinidine: Immediate Release Capsules: There have been rare reports of an interaction between <drug>quinidine</drug> and <drug>nifedipine</drug> (with a decreased plasma level of quinidine).",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "cimetidine",
    "entity2": "nifedipine",
    "text": "Cimetidine: A study in 6 healthy volunteers has shown a significant increase in peak nifedipine plasma levels (80%) and area-under-the-curve (74%) after a 1 week course of <drug>cimetidine</drug> at 1000 mg per day and <drug>nifedipine</drug> at 40 mg per day.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "nifedipine",
    "entity2": "cimetidine",
    "text": "If <drug>nifedipine</drug> therapy is initiated in a patient currently receiving <drug>cimetidine</drug>, cautious titration is advised.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "phenylbutazone",
    "entity2": "aspirin",
    "text": "Pyrazolone Derivatives (<drug>phenylbutazone</drug>, oxyphenbutazone, and possibly dipyrone): Concomitant administration with <drug>aspirin</drug> may increase the risk of gastrointestinal ulceration.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "oxyphenbutazone",
    "entity2": "aspirin",
    "text": "Pyrazolone Derivatives (phenylbutazone, <drug>oxyphenbutazone</drug>, and possibly dipyrone): Concomitant administration with <drug>aspirin</drug> may increase the risk of gastrointestinal ulceration.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "dipyrone",
    "entity2": "aspirin",
    "text": "Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly <drug>dipyrone</drug>): Concomitant administration with <drug>aspirin</drug> may increase the risk of gastrointestinal ulceration.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "Aspirin",
    "entity2": "nonsteroidal anti-inflammatory",
    "text": "Nonsteroidal Antiinflammatory Agents: <drug>Aspirin</drug> is contraindicated in patients who are hypersensitive to <drug>nonsteroidal anti-inflammatory</drug> agents.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Ketoconazole",
    "entity2": "terfenadine",
    "text": "The following drug interactions have been identified involving NIZORAL Tablets and other drugs metabolized by the cytochrome P450 3A4 enzyme system: <drug>Ketoconazole</drug> tablets inhibit the metabolism of <drug>terfenadine</drug>, resulting in an increased plasma concentration of terfenadine and a delay in the elimination of its acid metabolite.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "ketoconazole",
    "entity2": "astemizole",
    "text": "Pharmacokinetic data indicate that oral <drug>ketoconazole</drug> inhibits the metabolism of <drug>astemizole</drug>, resulting in elevated plasma levels of astemizole and its active metabolite desmethylastemizole which may prolong QT intervals.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "astemizole",
    "entity2": "ketoconazole",
    "text": "Coadministration of <drug>astemizole</drug> with <drug>ketoconazole</drug> tablets is therefore contraindicated.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "ketoconazole",
    "entity2": "cisapride",
    "text": "Human pharmacokinetics data indicate that oral <drug>ketoconazole</drug> potently inhibits the metabolism of <drug>cisapride</drug> resulting in a mean eight-fold increase in AUC of cisapride.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "ketoconazole",
    "entity2": "cisapride",
    "text": "Data suggest that coadministration of oral <drug>ketoconazole</drug> and <drug>cisapride</drug> can result in prolongation of the QT interval on the ECG.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "ketoconazole",
    "entity2": "cisapride",
    "text": "Therefore concomitant administration of <drug>ketoconazole</drug> tablets with <drug>cisapride</drug> is contraindicated.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Ketoconazole",
    "entity2": "cyclosporine",
    "text": "<drug>Ketoconazole</drug> tablets may alter the metabolism of <drug>cyclosporine</drug>, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Ketoconazole",
    "entity2": "tacrolimus",
    "text": "<drug>Ketoconazole</drug> tablets may alter the metabolism of cyclosporine, <drug>tacrolimus</drug>, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Ketoconazole",
    "entity2": "methylprednisolone",
    "text": "<drug>Ketoconazole</drug> tablets may alter the metabolism of cyclosporine, tacrolimus, and <drug>methylprednisolone</drug>, resulting in elevated plasma concentrations of the latter drugs.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "digoxin",
    "entity2": "ketoconazole",
    "text": "It is, therefore, advisable to monitor <drug>digoxin</drug> concentrations in patients receiving <drug>ketoconazole</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "ketoconazole",
    "entity2": "phenytoin",
    "text": "Concomitant administration of <drug>ketoconazole</drug> tablets with <drug>phenytoin</drug> may alter the metabolism of one or both of the drugs.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "ketoconazole",
    "entity2": "phenytoin",
    "text": "It is suggested to monitor both <drug>ketoconazole</drug> and <drug>phenytoin</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "rifampin",
    "entity2": "ketoconazole",
    "text": "Concomitant administration of <drug>rifampin</drug> with <drug>ketoconazole</drug> tablets reduces the blood levels of the latter.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "INH",
    "entity2": "ketoconazole",
    "text": "<drug>INH</drug> (Isoniazid) is also reported to affect <drug>ketoconazole</drug> concentrations adversely.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Isoniazid",
    "entity2": "ketoconazole",
    "text": "INH (<drug>Isoniazid</drug>) is also reported to affect <drug>ketoconazole</drug> concentrations adversely.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "ketoconazole",
    "entity2": "loratadine",
    "text": "After the coadministration of 200 mg oral <drug>ketoconazole</drug> twice daily and one 20 mg dose of <drug>loratadine</drug> to 11 subjects, the AUC and Cmax of loratadine averaged 302% (  142 S.D.) and 251% (  68 S.D.), respectively, of those obtained after co-treatment with placebo.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Aminoglutethimide",
    "entity2": "warfarin",
    "text": "<drug>Aminoglutethimide</drug> diminishes the effect of coumarin and <drug>warfarin</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Diphenhydramine hydrochloride",
    "entity2": "alcohol",
    "text": "<drug>Diphenhydramine hydrochloride</drug> has additive effects with <drug>alcohol</drug> and other CNS depressants (hypnotics, sedatives, tranquilizers, etc).",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "lansoprazole",
    "entity2": "theophylline",
    "text": "When <drug>lansoprazole</drug> was administered concomitantly with <drug>theophylline</drug> (CYP1A2, CYP3A), a minor increase (10%) in the clearance of theophylline was seen.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "theophylline",
    "entity2": "lansoprazole",
    "text": "Nonetheless, individual patients may require additional titration of their <drug>theophylline</drug> dosage when <drug>lansoprazole</drug> is started or stopped to ensure clinically effective blood levels.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "lansoprazole",
    "entity2": "ketoconazole",
    "text": "therefore, it is theoretically possible that <drug>lansoprazole</drug> may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. <drug>ketoconazole</drug>, ampicillin esters, iron salts, digoxin).",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "lansoprazole",
    "entity2": "ampicillin",
    "text": "therefore, it is theoretically possible that <drug>lansoprazole</drug> may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, <drug>ampicillin</drug> esters, iron salts, digoxin).",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "lansoprazole",
    "entity2": "iron",
    "text": "therefore, it is theoretically possible that <drug>lansoprazole</drug> may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, <drug>iron</drug> salts, digoxin).",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "lansoprazole",
    "entity2": "digoxin",
    "text": "therefore, it is theoretically possible that <drug>lansoprazole</drug> may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, <drug>digoxin</drug>).",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "cinoxacin",
    "entity2": "caffeine",
    "text": "Although this interaction has not been reported with cinoxacin, caution should be exercised when <drug>cinoxacin</drug> is given concomitantly with <drug>caffeine</drug>-containing products.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "cinoxacin",
    "entity2": "warfarin",
    "text": "Quinolones, including <drug>cinoxacin</drug>, may enhance the effects of oral anticoagulants, such as <drug>warfarin</drug> or its derivatives.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "quinidine",
    "entity2": "doxepin",
    "text": "Inhibitors or substrates of CYP2D6 (i.e., <drug>quinidine</drug>, selective serotonin reuptake inhibitors [SSRIs]) may increase the plasma concentration of <drug>doxepin</drug> when administered concomitantly.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "tolazamide",
    "entity2": "doxepin",
    "text": "Tolazamide: A case of severe hypoglycemia has been reported in a type II diabetic patient maintained on <drug>tolazamide</drug> (1 gm/day) 11 days after the addition of <drug>doxepin</drug> (75 mg/day).",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "codeine",
    "entity2": "alcohol",
    "text": "The use of <drug>codeine</drug> may result in additive CNS depressant effects when coadministered with <drug>alcohol</drug>, antihistamines, psychotropics or other drugs that produce CNS depression.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "dextromethorphan hydrobromide",
    "entity2": "alcohol",
    "text": "The use of <drug>dextromethorphan hydrobromide</drug> may result in additive CNS depressant effects when coadministered with <drug>alcohol</drug>, antihistamines, psychotropics or other drugs that produce CNS depression.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "paclitaxel",
    "entity2": "doxorubicin",
    "text": "Reports in the literature suggest that plasma levels of doxorubicin (and its active metabolite doxorubicinol) may be increased when <drug>paclitaxel</drug> and <drug>doxorubicin</drug> are used in combination.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "clindamycin",
    "entity2": "erythromycin",
    "text": "Antagonism has been demonstrated between <drug>clindamycin</drug> and <drug>erythromycin</drug> in vitro.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Terfenadine",
    "entity2": "ketoconazole",
    "text": "<drug>Terfenadine</drug>, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that <drug>ketoconazole</drug>, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "astemizole",
    "entity2": "ketoconazole",
    "text": "Terfenadine, <drug>astemizole</drug> and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that <drug>ketoconazole</drug>, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "cisapride",
    "entity2": "ketoconazole",
    "text": "Terfenadine, astemizole and <drug>cisapride</drug> are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that <drug>ketoconazole</drug>, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "fluvoxamine",
    "entity2": "alprazolam",
    "text": "Although it has not been definitively demonstrated that fluvoxamine is a potent IIIA4 inhibitor, it is likely to be, given the substantial interaction of <drug>fluvoxamine</drug> with <drug>alprazolam</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "fluvoxamine",
    "entity2": "terbinafine",
    "text": "Consequently, it is recommended that <drug>fluvoxamine</drug> not be used in combination with either <drug>terbinafine</drug>, astemizole, or cisapride.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "fluvoxamine",
    "entity2": "astemizole",
    "text": "Consequently, it is recommended that <drug>fluvoxamine</drug> not be used in combination with either terbinafine, <drug>astemizole</drug>, or cisapride.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "fluvoxamine",
    "entity2": "cisapride",
    "text": "Consequently, it is recommended that <drug>fluvoxamine</drug> not be used in combination with either terbinafine, astemizole, or <drug>cisapride</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "alprazolam",
    "entity2": "fluvoxamine",
    "text": "Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., <drug>alprazolam</drug>, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by <drug>fluvoxamine</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "midazolam",
    "entity2": "fluvoxamine",
    "text": "Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, <drug>midazolam</drug>, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by <drug>fluvoxamine</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "triazolam",
    "entity2": "fluvoxamine",
    "text": "Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, <drug>triazolam</drug> elc.) should be used with caution because the clearance of these drugs is likely to be reduced by <drug>fluvoxamine</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "fluvoxamine maleate",
    "entity2": "alprazolam",
    "text": "Alprazolam: When <drug>fluvoxamine maleate</drug> (100 mg qd) and <drug>alprazolam</drug> (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1/2,) of alprazolam were approximately twice those observed when alprazolam was administered alone;",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "alprazolam",
    "entity2": "Fluvoxamine",
    "text": "This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If <drug>alprazolam</drug> is co-administered with <drug>Fluvoxamine</drug> Tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "Fluvoxamine",
    "entity2": "diazepam",
    "text": "Diazepam: The co-administration of <drug>Fluvoxamine</drug> Tablets and <drug>diazepam</drug> is generally not advisable.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "fluvoxamine",
    "entity2": "diazepam",
    "text": "Because <drug>fluvoxamine</drug> reduces the clearance of both <drug>diazepam</drug> and its active metabolite, N-desmethyldiazepam, there is a strong likelihood of substantial accumulation of both species during chronic co-administration.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "fluvoxamine",
    "entity2": "diazepam",
    "text": "Evidence supporting the conclusion that it is inadvisable to co-administer <drug>fluvoxamine</drug> and <drug>diazepam</drug> is derived from a study in which healthy volunteers taking 150 mg/day of fluvoxamine were administered a single oral dose of 10 mg of diazepam.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "alprazolam",
    "entity2": "fluvoxamine",
    "text": "Moreover, as noted with <drug>alprazolam</drug>, the effect of <drug>fluvoxamine</drug> may even be more pronounced when it is administered at higher doses.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "diazepam",
    "entity2": "fluvoxamine",
    "text": "Accordingly, <drug>diazepam</drug> and <drug>fluvoxamine</drug> should not ordinarily be co-administered.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "theophylline",
    "entity2": "fluvoxamine maleate",
    "text": "Therefore, if <drug>theophylline</drug> is co-administered with <drug>fluvoxamine maleate</drug>, its dose should be reduced to one third of the usual daily maintenance dose and plasma concentrations of theophylline should to monitored.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "fluvoxamine maleate",
    "entity2": "warfarin",
    "text": "Warfarin: When <drug>fluvoxamine maleate</drug> (50 mg tid) was administered concomitantly with <drug>warfarin</drug> for two weeks, warfarin plasma concentrations increased by 98% and prothrombin times were prolonged.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Tetracycline",
    "entity2": "penicillin",
    "text": "<drug>Tetracycline</drug>, a bacteriostatic antibiotic, may antagonize the bactercidal effect of <drug>penicillin</drug> and concurrent use of these drugs should be avoided.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Phenylbutazone",
    "entity2": "etodolac",
    "text": "Phenylbutazone: <drug>Phenylbutazone</drug> causes increase (by about 80%) in the free fraction of <drug>etodolac</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "etodolac",
    "entity2": "phenylbutazone",
    "text": "Although in vivo studies have not been done to see if <drug>etodolac</drug> clearance is changed by coadministration of <drug>phenylbutazone</drug>, it is not recommended that they be coadministered.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "warfarin",
    "entity2": "etodolac",
    "text": "Short-term pharmacokinetic studies have demonstrated that concomitant administration of <drug>warfarin</drug> and Lodine  (<drug>etodolac</drug> capsules and tablets) results in reduced protein binding of warfarin, but there was no change in the clearance of free warfarin.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "etodolac",
    "entity2": "warfarin",
    "text": "However, caution should be exercised because there have been a few spontaneous reports of prolonged prothrombin times, with or without bleeding, in <drug>etodolac</drug>-treated patients receiving concomitant <drug>warfarin</drug> therapy.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "magnesium hydroxide",
    "entity2": "mefenamic acid",
    "text": "Antacids: In a single dose study (n=6), ingestion of an antacid containing 1.7-gram of <drug>magnesium hydroxide</drug> with 500-mg of <drug>mefenamic acid</drug> increased the Cmax and AUC of mefenamic acid by 125% and 36%, respectively.  A number of compounds are inhibitors of CYP2C9 including fluconazole, lovastatin and trimethoprim.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "ethacrynic acid",
    "entity2": "warfarin",
    "text": "A number of drugs, including <drug>ethacrynic acid</drug>, have been shown to displace <drug>warfarin</drug> from plasma protein;",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "lincomycin",
    "entity2": "erythromycin",
    "text": "Antagonism between <drug>lincomycin</drug> and <drug>erythromycin</drug> in vitro has been demonstrated.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "magnesium trisilicate",
    "entity2": "nitrofurantoin",
    "text": "Antacids containing <drug>magnesium trisilicate</drug>, when administered concomitantly with <drug>nitrofurantoin</drug>, reduce both the rate and extent of absorption.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "nitrofurantoin",
    "entity2": "magnesium trisilicate",
    "text": "The mechanism for this interaction probably is adsorption of <drug>nitrofurantoin</drug> onto the surface of <drug>magnesium trisilicate</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "probenecid",
    "entity2": "nitrofurantoin",
    "text": "Uricosuric drugs, such as <drug>probenecid</drug> and sulfinpyrazone, can inhibit renal tubular secretion of <drug>nitrofurantoin</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "sulfinpyrazone",
    "entity2": "nitrofurantoin",
    "text": "Uricosuric drugs, such as probenecid and <drug>sulfinpyrazone</drug>, can inhibit renal tubular secretion of <drug>nitrofurantoin</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Indinavir",
    "entity2": "amprenavir",
    "text": "<drug>Indinavir</drug> steady-state Cmax, A.C. and Cmin were decreased by 22%, 38%, and 27%, respectively, by concomitant <drug>amprenavir</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Saquinavir",
    "entity2": "amprenavir",
    "text": "<drug>Saquinavir</drug> steady-state Cmax, A.C. and Cmin were increased 21%, decreased 19%, and decreased 48%, respectively, by concomitant <drug>amprenavir</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Nelfinavir",
    "entity2": "amprenavir",
    "text": "<drug>Nelfinavir</drug> steady-state Cmax, A.C. and Cmin were increased by 12%, 15%, and 14%, respectively, by concomitant <drug>amprenavir</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "amprenavir",
    "entity2": "methadone",
    "text": "Methadone: Coadministration of <drug>amprenavir</drug> and <drug>methadone</drug> can decrease plasma levels of methadone.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "amprenavir",
    "entity2": "methadone",
    "text": "Coadministration of <drug>amprenavir</drug> and <drug>methadone</drug> as compared to a non-matched historicalcontrol group resulted in a 30%, 27%, and 25% decrease in serum amprenavir AUC, Cmax, andCmin, respectively.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Amprenavir",
    "entity2": "ritonavir",
    "text": "Laboratory Tests: The combination of <drug>Amprenavir</drug> and low-dose <drug>ritonavir</drug> has been associated with elevations of cholesterol and triglycerides, SGOT (AST), and SGPT (ALT) in some patients.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "Amprenavir",
    "entity2": "ritonavir",
    "text": "Appropriate laboratory testing should be considered prior to initiating combination therapy with <drug>Amprenavir</drug> and <drug>ritonavir</drug> and at periodic intervals or if any clinical signs or symptoms of hyperlipidemia or elevated liver function tests occur during therapy.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "Bentiromide",
    "entity2": "acetaminophen",
    "text": "<drug>Bentiromide</drug> may interact with <drug>acetaminophen</drug> (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "Bentiromide",
    "entity2": "chloramphenicol",
    "text": "<drug>Bentiromide</drug> may interact with acetaminophen (e.g., Tylenol), <drug>chloramphenicol</drug> (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "Bentiromide",
    "entity2": "benzocaine",
    "text": "<drug>Bentiromide</drug> may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., <drug>benzocaine</drug> and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "Bentiromide",
    "entity2": "lidocaine",
    "text": "<drug>Bentiromide</drug> may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and <drug>lidocaine</drug>), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "Bentiromide",
    "entity2": "procainamide",
    "text": "<drug>Bentiromide</drug> may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), <drug>procainamide</drug> (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "ergotamine",
    "entity2": "naratriptan",
    "text": "Because there is a theoretical basis that these effects may be additive, use of <drug>ergotamine</drug>-containing or ergot-type medications (like dihydroergotamine or methysergide) and <drug>naratriptan</drug> within 24 hours is contraindicated.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "dihydroergotamine",
    "entity2": "naratriptan",
    "text": "Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like <drug>dihydroergotamine</drug> or methysergide) and <drug>naratriptan</drug> within 24 hours is contraindicated.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "methysergide",
    "entity2": "naratriptan",
    "text": "Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or <drug>methysergide</drug>) and <drug>naratriptan</drug> within 24 hours is contraindicated.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Itraconazole",
    "entity2": "busulfan",
    "text": "<drug>Itraconazole</drug> decreases <drug>busulfan</drug> clearance by up to 25%, and may produce AUCs   1500  M min in some patients.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Phenytoin",
    "entity2": "busulfan",
    "text": "<drug>Phenytoin</drug> increases the clearance of <drug>busulfan</drug> by 15% or more, possibly due to the induction of glutathione-S-transferase.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "Sulfacetamide",
    "entity2": "silver",
    "text": "<drug>Sulfacetamide</drug> preparations are incompatible with <drug>silver</drug> preparations.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "aluminum hydroxide",
    "entity2": "fosinopril",
    "text": "Antacids: In a clinical pharmacology study, coadministration of an antacid (<drug>aluminum hydroxide</drug>, magnesium hydroxide, and simethicone) with <drug>fosinopril</drug> reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "magnesium hydroxide",
    "entity2": "fosinopril",
    "text": "Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, <drug>magnesium hydroxide</drug>, and simethicone) with <drug>fosinopril</drug> reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "simethicone",
    "entity2": "fosinopril",
    "text": "Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and <drug>simethicone</drug>) with <drug>fosinopril</drug> reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "alprazolam",
    "entity2": "ethanol",
    "text": "The benzodiazepines, including <drug>alprazolam</drug>, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, antihistaminics, <drug>ethanol</drug>, and other drugs which themselves produce CNS depression.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "imipramine",
    "entity2": "alprazolam",
    "text": "The steady state plasma concentrations of <drug>imipramine</drug> and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of <drug>alprazolam</drug> tablets in doses up to 4 mg/day.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "desipramine",
    "entity2": "alprazolam",
    "text": "The steady state plasma concentrations of imipramine and <drug>desipramine</drug> have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of <drug>alprazolam</drug> tablets in doses up to 4 mg/day.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "fluoxetine",
    "entity2": "alprazolam",
    "text": "Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with alprazolam): Coadministration of <drug>fluoxetine</drug> with <drug>alprazolam</drug> increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "propoxyphene",
    "entity2": "alprazolam",
    "text": "Coadministration of <drug>propoxyphene</drug> decreased the maximum plasma concentration of <drug>alprazolam</drug> by 6%, decreased clearance by 38%, and increased half-life by 58%.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "alprazolam",
    "entity2": "diltiazem",
    "text": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with <drug>alprazolam</drug> for the following: <drug>diltiazem</drug>, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "alprazolam",
    "entity2": "isoniazid",
    "text": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with <drug>alprazolam</drug> for the following: diltiazem, <drug>isoniazid</drug>, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "erythromycin",
    "entity2": "alprazolam",
    "text": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with <drug>alprazolam</drug> for the following: diltiazem, isoniazid, macrolide antibiotics such as <drug>erythromycin</drug> and clarithromycin, and grapefruit juice.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "clarithromycin",
    "entity2": "alprazolam",
    "text": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with <drug>alprazolam</drug> for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and <drug>clarithromycin</drug>, and grapefruit juice.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "alprazolam",
    "entity2": "sertraline",
    "text": "Data from in vitro studies of alprazolam suggest a possible drug interaction with <drug>alprazolam</drug> for the following: <drug>sertraline</drug> and paroxetine.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "alprazolam",
    "entity2": "paroxetine",
    "text": "Data from in vitro studies of alprazolam suggest a possible drug interaction with <drug>alprazolam</drug> for the following: sertraline and <drug>paroxetine</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "alprazolam",
    "entity2": "ergotamine",
    "text": "Data from in vitro studies of benzodiazepines other than <drug>alprazolam</drug> suggest a possible drug interaction for the following: <drug>ergotamine</drug>, cyclosporine, amiodarone, nicardipine, and nifedipine.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "alprazolam",
    "entity2": "cyclosporine",
    "text": "Data from in vitro studies of benzodiazepines other than <drug>alprazolam</drug> suggest a possible drug interaction for the following: ergotamine, <drug>cyclosporine</drug>, amiodarone, nicardipine, and nifedipine.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "alprazolam",
    "entity2": "amiodarone",
    "text": "Data from in vitro studies of benzodiazepines other than <drug>alprazolam</drug> suggest a possible drug interaction for the following: ergotamine, cyclosporine, <drug>amiodarone</drug>, nicardipine, and nifedipine.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "alprazolam",
    "entity2": "nicardipine",
    "text": "Data from in vitro studies of benzodiazepines other than <drug>alprazolam</drug> suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, <drug>nicardipine</drug>, and nifedipine.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "alprazolam",
    "entity2": "nifedipine",
    "text": "Data from in vitro studies of benzodiazepines other than <drug>alprazolam</drug> suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and <drug>nifedipine</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "cimetidine",
    "entity2": "nimodipine",
    "text": "A study in eight healthy volunteers has shown a 50% increase in mean peak nimodipine plasma concentrations and a 90% increase in mean area under the curve, after a one week course of <drug>cimetidine</drug> at 1,000 mg/day and <drug>nimodipine</drug> at 90 mg/day.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Chlorthalidone",
    "entity2": "tubocurarine",
    "text": "<drug>Chlorthalidone</drug> and related drugs may increase the responsiveness to <drug>tubocurarine</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Chlorthalidone",
    "entity2": "norepinephrine",
    "text": "<drug>Chlorthalidone</drug> and related drugs may decrease arterial responsiveness to <drug>norepinephrine</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "tamoxifen",
    "entity2": "anastrozole",
    "text": "Based on clinical and pharmacokinetic results from the ATAC trial, <drug>tamoxifen</drug> should not be administered with <drug>anastrozole</drug> (see CLINICAL PHARMACOLOGY   Drug Interactions and CLINICAL PHARMACOLOGY - Clinical Studies - Adjuvant Treatment of Breast Cancer in Postmenopausal Women subsections).",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "anastrozole",
    "entity2": "tamoxifen",
    "text": "Co-administration of <drug>anastrozole</drug> and <drug>tamoxifen</drug> resulted in a reduction of anastrozole plasma levels by 27% compared with those achieved with anastrozole alone.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "halofantrine",
    "entity2": "Mefloquine",
    "text": "Because of the danger of a potentially fatal prolongation of the QTc interval, <drug>halofantrine</drug> must not be given simultaneously with or subsequent to <drug>Mefloquine</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Mefloquine",
    "entity2": "quinine",
    "text": "Concomitant administration of <drug>Mefloquine</drug> and other related compounds (eg, <drug>quinine</drug>, quinidine and chloroquine) may produce electrocardiographic abnormalities and increase the risk of convulsions.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Mefloquine",
    "entity2": "quinidine",
    "text": "Concomitant administration of <drug>Mefloquine</drug> and other related compounds (eg, quinine, <drug>quinidine</drug> and chloroquine) may produce electrocardiographic abnormalities and increase the risk of convulsions.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Mefloquine",
    "entity2": "chloroquine",
    "text": "Concomitant administration of <drug>Mefloquine</drug> and other related compounds (eg, quinine, quinidine and <drug>chloroquine</drug>) may produce electrocardiographic abnormalities and increase the risk of convulsions.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Mefloquine",
    "entity2": "anti-arrhythmic",
    "text": "This appears to be the only clinically relevant interaction of this kind with <drug>Mefloquine</drug>, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, <drug>anti-arrhythmic</drug> or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "valproic acid",
    "entity2": "Mefloquine",
    "text": "In patients taking an anticonvulsant (eg, <drug>valproic acid</drug>, carbamazepine, phenobarbital or phenytoin), the concomitant use of <drug>Mefloquine</drug> may reduce seizure control by lowering the plasma levels of the anticonvulsant.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "carbamazepine",
    "entity2": "Mefloquine",
    "text": "In patients taking an anticonvulsant (eg, valproic acid, <drug>carbamazepine</drug>, phenobarbital or phenytoin), the concomitant use of <drug>Mefloquine</drug> may reduce seizure control by lowering the plasma levels of the anticonvulsant.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "phenobarbital",
    "entity2": "Mefloquine",
    "text": "In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, <drug>phenobarbital</drug> or phenytoin), the concomitant use of <drug>Mefloquine</drug> may reduce seizure control by lowering the plasma levels of the anticonvulsant.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "phenytoin",
    "entity2": "Mefloquine",
    "text": "In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or <drug>phenytoin</drug>), the concomitant use of <drug>Mefloquine</drug> may reduce seizure control by lowering the plasma levels of the anticonvulsant.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "Indinavir",
    "entity2": "didanosine",
    "text": "<drug>Indinavir</drug> and <drug>didanosine</drug> formulations containing buffer should be administered at least one hour apart on an empty stomach.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "indinavir",
    "entity2": "efavirenz",
    "text": "Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased <drug>indinavir</drug> metabolism due to <drug>efavirenz</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Indinavir",
    "entity2": "nevirapine",
    "text": "<drug>Indinavir</drug> concentrations may be decreased in the presence of <drug>nevirapine</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "indinavir",
    "entity2": "ritonavir",
    "text": "Preliminary clinical data suggest that the incidence of nephrolithiasis is higher in patients receiving <drug>indinavir</drug> in combination with <drug>ritonavir</drug> than those receiving CRIXIVAN 800 mg q8h.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "Sildenafil",
    "entity2": "indinavir",
    "text": "<drug>Sildenafil</drug> dose should not exceed a maximum of 25 mg in a 48- hour period in patients receiving concomitant <drug>indinavir</drug> therapy.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "Tadalafil",
    "entity2": "indinavir",
    "text": "<drug>Tadalafil</drug> dose should not exceed a maximum of 10 mg in a 72- hour period in patients receiving concomitant <drug>indinavir</drug> therapy.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "Vardenafil",
    "entity2": "indinavir",
    "text": "<drug>Vardenafil</drug> dose should not exceed a maximum of 2.5 mg in a 24-hour period in patients receiving concomitant <drug>indinavir</drug> therapy.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "kaolin",
    "entity2": "chloroquine",
    "text": "Antacids and kaolin: Antacids and <drug>kaolin</drug> can reduce absorption of <drug>chloroquine</drug>;",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Cimetidine",
    "entity2": "chloroquine",
    "text": "Cimetidine: <drug>Cimetidine</drug> can inhibit the metabolism of <drug>chloroquine</drug>, increasing its plasma level.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "chloroquine",
    "entity2": "ampicillin",
    "text": "Ampicillin: In a study of healthy volunteers, <drug>chloroquine</drug> significantly reduced the bioavailability of <drug>ampicillin</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "chloroquine",
    "entity2": "cyclosporin",
    "text": "Cyclosporin: After introduction of <drug>chloroquine</drug> (oral form), a sudden increase in serum <drug>cyclosporin</drug> level has been reported.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "dobutamine",
    "entity2": "nitroprusside",
    "text": "Preliminary studies indicate that the concomitant use of <drug>dobutamine</drug> and <drug>nitroprusside</drug> results in a higher cardiac output and, usually, a lower pulmonary wedge pressure than when either drug is used alone.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "nabumetone",
    "entity2": "warfarin",
    "text": "Caution should be exercised when administering <drug>nabumetone</drug> with <drug>warfarin</drug> since interactions have been seen with other NSAIDs.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "estazolam",
    "entity2": "carbamazepine",
    "text": "While no in vivo drug-drug interaction studies were conducted between <drug>estazolam</drug> and inducers of CYP3A, compounds that are potent CYP3A inducers (such as <drug>carbamazepine</drug>, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "estazolam",
    "entity2": "phenytoin",
    "text": "While no in vivo drug-drug interaction studies were conducted between <drug>estazolam</drug> and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, <drug>phenytoin</drug>, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "estazolam",
    "entity2": "rifampin",
    "text": "While no in vivo drug-drug interaction studies were conducted between <drug>estazolam</drug> and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, <drug>rifampin</drug>, and barbiturates) would be expected to decrease estazolam concentrations.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "estazolam",
    "entity2": "estazolam",
    "text": "While no in vivo drug-drug interaction studies were conducted between <drug>estazolam</drug> and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease <drug>estazolam</drug> concentrations.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "estazolam",
    "entity2": "ketoconazole",
    "text": "Consequently, <drug>estazolam</drug> should be avoided in patients receiving <drug>ketoconazole</drug> and itraconazole, which are very potent inhibitors of CYP3A.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "estazolam",
    "entity2": "itraconazole",
    "text": "Consequently, <drug>estazolam</drug> should be avoided in patients receiving ketoconazole and <drug>itraconazole</drug>, which are very potent inhibitors of CYP3A.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "phenytoin",
    "entity2": "flecainide",
    "text": "Limited data in patients receiving known enzyme inducers ( <drug>phenytoin</drug>, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of <drug>flecainide</drug> elimination.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "phenobarbital",
    "entity2": "flecainide",
    "text": "Limited data in patients receiving known enzyme inducers ( phenytoin, <drug>phenobarbital</drug>, carbamazepine ) indicate only a 30% increase in the rate of <drug>flecainide</drug> elimination.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "carbamazepine",
    "entity2": "flecainide",
    "text": "Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, <drug>carbamazepine</drug> ) indicate only a 30% increase in the rate of <drug>flecainide</drug> elimination.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "cimetidine",
    "entity2": "flecainide",
    "text": "In healthy subjects receiving <drug>cimetidine</drug> (1 gm daily) for one week, plasma <drug>flecainide</drug> levels increased by about 30% and half-life increased by about 10%.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "amiodarone",
    "entity2": "flecainide",
    "text": "When <drug>amiodarone</drug> is added to <drug>flecainide</drug> therapy, plasma flecainide levels may increase two-fold or more in some patients, if flecainide dosage is not reduced.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "quinidine",
    "entity2": "flecainide",
    "text": "Drugs that inhibit cytochrome P450IID6, such as <drug>quinidine</drug> , might increase the plasma concentrations of <drug>flecainide</drug> in patients that are on chronic flecainide therapy;",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "clonidine",
    "entity2": "insulin",
    "text": "Beta-blockers, <drug>clonidine</drug>, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of <drug>insulin</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "lithium",
    "entity2": "insulin",
    "text": "Beta-blockers, clonidine, <drug>lithium</drug> salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of <drug>insulin</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "alcohol",
    "entity2": "insulin",
    "text": "Beta-blockers, clonidine, lithium salts, and <drug>alcohol</drug> may either potentiate or weaken the blood-glucose-lowering effect of <drug>insulin</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "Isoproterenol hydrochloride",
    "entity2": "epinephrine",
    "text": "<drug>Isoproterenol hydrochloride</drug> injection and <drug>epinephrine</drug> should not be administered simultaneously because both drugs are direct cardiac stimulants and their combined effects may induce serious arrhythmias.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Erythromycin",
    "entity2": "vardenafil",
    "text": "<drug>Erythromycin</drug> (500 mg t.i.d) produced a 4-fold increase in <drug>vardenafil</drug> AUC and a 3-fold increase in Cmax when co-administered with Vardenafil 5 mg in healthy volunteers.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "Vardenafil",
    "entity2": "erythromycin",
    "text": "It is recommended not to exceed a single 5 mg dose of <drug>Vardenafil</drug> in a 24-hour period when used in combination with <drug>erythromycin</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Ketoconazole",
    "entity2": "vardenafil",
    "text": "<drug>Ketoconazole</drug> (200 mg once daily) produced a 10-fold increase in <drug>vardenafil</drug> AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "Vardenafil",
    "entity2": "ketoconazole",
    "text": "A 5-mg <drug>Vardenafil</drug> dose should not be exceeded when used in combination with 200 mg once daily <drug>ketoconazole</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "Vardenafil",
    "entity2": "ketoconazole",
    "text": "Since higher doses of ketoconazole (400 mg daily) may result in higher increases in Cmax and AUC, a single 2.5 mg dose of <drug>Vardenafil</drug> should not be exceeded in a 24-hour period when used in combination with <drug>ketoconazole</drug> 400 mg daily.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Indinavir",
    "entity2": "Vardenafil",
    "text": "HIV Protease Inhibitors: <drug>Indinavir</drug> (800 mg t.i.d.) co-administered with <drug>Vardenafil</drug> 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "Vardenafil",
    "entity2": "indinavir",
    "text": "It is recommended not to exceed a single 2.5 mg <drug>Vardenafil</drug> dose in a 24-hour period when used in combination with <drug>indinavir</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Ritonavir",
    "entity2": "Vardenafil",
    "text": "<drug>Ritonavir</drug> (600 mg b.i.d.) co-administered with <drug>Vardenafil</drug> 5 mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in vardenafil Cmax.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "vardenafil",
    "entity2": "ritonavir",
    "text": "The interaction is a consequence of blocking hepatic metabolism of <drug>vardenafil</drug> by <drug>ritonavir</drug>, a highly potent CYP3A4 inhibitor, which also inhibits CYP2C9.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Ritonavir",
    "entity2": "vardenafil",
    "text": "<drug>Ritonavir</drug> significantly prolonged the half-life of <drug>vardenafil</drug> to 26 hours.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "Vardenafil",
    "entity2": "ritonavir",
    "text": "Consequently, it is recommended not to exceed a single 2.5 mg <drug>Vardenafil</drug> dose in a 72-hour period when used in combination with <drug>ritonavir</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "nifedipine",
    "entity2": "Vardenafil",
    "text": "In these patients whose hypertension was controlled with <drug>nifedipine</drug>, <drug>Vardenafil</drug> 20 mg produced mean additional supine systolic/diastolic blood pressure reductions of 6/5 mm Hg compared to placebo.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Vardenafil",
    "entity2": "terazosin",
    "text": "Alpha-blockers: When <drug>Vardenafil</drug> 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of <drug>terazosin</drug>, significant hypotension developed in a substantial number of subjects.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Vardenafil",
    "entity2": "terazosin",
    "text": "With simultaneous dosing of <drug>Vardenafil</drug> 10 mg and <drug>terazosin</drug> 10 mg, 6 of 8 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Vardenafil",
    "entity2": "terazosin",
    "text": "With simultaneous dosing of <drug>Vardenafil</drug> 20 mg and <drug>terazosin</drug> 10 mg, 2 of 9 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Vardenafil",
    "entity2": "terazosin",
    "text": "When <drug>Vardenafil</drug> dosing was separated from <drug>terazosin</drug> 10 mg by 6 hours, 7 of 28 subjects who received 20 mg of Vardenafil experienced a decrease in standing systolic blood pressure below 85 mm Hg.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Vardenafil",
    "entity2": "tamsulosin",
    "text": "In a similar study with tamsulosin in healthy volunteers, 1 of 24 subjects dosed with <drug>Vardenafil</drug> 20 mg and <drug>tamsulosin</drug> 0.4 mg separated by 6 hours experienced a standing systolic blood pressure below 85 mm Hg.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Vardenafil",
    "entity2": "tamsulosin",
    "text": "Two of 16 subjects dosed simultaneously with <drug>Vardenafil</drug> 10 mg and <drug>tamsulosin</drug> 0.4 mg experienced a standing systolic blood pressure below 85 mm Hg.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Vardenafil",
    "entity2": "ritonavir",
    "text": "Ritonavir and indinavir: Upon concomitant administration of 5 mg of <drug>Vardenafil</drug> with 600 mg BID <drug>ritonavir</drug>, the Cmax and AUC of ritonavir were reduced by approximately 20%.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Vardenafil",
    "entity2": "indinavir",
    "text": "Upon administration of 10 mg of <drug>Vardenafil</drug> with 800 mg TID <drug>indinavir</drug>, the Cmax and AUC of indinavir were reduced by 40% and 30%, respectively.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "L-glutamine",
    "entity2": "human growth hormone",
    "text": "Human growth hormone - Concomitant use of <drug>L-glutamine</drug> and <drug>human growth hormone</drug> may enhance nutrient absorption in those with severe short bowel syndrome.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "L-glutamine",
    "entity2": "indomethacin",
    "text": "Indomethacin - Concomitant use of <drug>L-glutamine</drug> and <drug>indomethacin</drug> may ameliorate increased intestinal permeability caused by indomethacin.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "methotrexate",
    "entity2": "L-glutamine",
    "text": "Methotrexate - There is one report that <drug>methotrexate</drug> may decrease the possible effectiveness of supplemental <drug>L-glutamine</drug> for chemotherapy-induced mucositis.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "methotrexate",
    "entity2": "L-glutamine",
    "text": "In another report, nine patients with breast cancer were reported to have decreased symptoms of <drug>methotrexate</drug>-related toxicity when given supplemental <drug>L-glutamine</drug> at a dose of 0.5 gram/kilogram/day.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "L-glutamine",
    "entity2": "paclitaxel",
    "text": "Paclitaxel - In one report, <drug>L-glutamine</drug> at a dose of 10 grams three times daily, given 24 hours after receiving <drug>paclitaxel</drug>, appeared to prevent the development of myalgia and arthralgia, adverse reactions of paclitaxel.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "alcohol",
    "entity2": "ethchlorvynol",
    "text": "Other depressasnts such as <drug>alcohol</drug>, barbiturates, and MAOIs may enhance CNS depression when administered with <drug>ethchlorvynol</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "dopamine",
    "entity2": "Bretylium Tosylate",
    "text": "The pressor effects of catecholamines such as <drug>dopamine</drug> or norepinephrine are enhanced by <drug>Bretylium Tosylate</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "norepinephrine",
    "entity2": "Bretylium Tosylate",
    "text": "The pressor effects of catecholamines such as dopamine or <drug>norepinephrine</drug> are enhanced by <drug>Bretylium Tosylate</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "ketoconazole",
    "entity2": "bexarotene",
    "text": "On the basis of the metabolism of bexarotene by cytochrome P450 3A4, <drug>ketoconazole</drug>, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma <drug>bexarotene</drug> concentrations.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "itraconazole",
    "entity2": "bexarotene",
    "text": "On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, <drug>itraconazole</drug>, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma <drug>bexarotene</drug> concentrations.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "erythromycin",
    "entity2": "bexarotene",
    "text": "On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, <drug>erythromycin</drug>, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma <drug>bexarotene</drug> concentrations.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "gemfibrozil",
    "entity2": "bexarotene",
    "text": "On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, <drug>gemfibrozil</drug>, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma <drug>bexarotene</drug> concentrations.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "rifampin",
    "entity2": "bexarotene",
    "text": "Furthermore, <drug>rifampin</drug>, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma <drug>bexarotene</drug> concentrations.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "phenytoin",
    "entity2": "bexarotene",
    "text": "Furthermore, rifampin, <drug>phenytoin</drug>, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma <drug>bexarotene</drug> concentrations.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "phenobarbital",
    "entity2": "bexarotene",
    "text": "Furthermore, rifampin, phenytoin, <drug>phenobarbital</drug>, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma <drug>bexarotene</drug> concentrations.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "eplerenone",
    "entity2": "erythromycin",
    "text": "Administration of <drug>eplerenone</drug> with other CYP3A4 inhibitors (e.g., <drug>erythromycin</drug> 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "eplerenone",
    "entity2": "verapamil",
    "text": "Administration of <drug>eplerenone</drug> with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, <drug>verapamil</drug> 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "eplerenone",
    "entity2": "saquinavir",
    "text": "Administration of <drug>eplerenone</drug> with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, <drug>saquinavir</drug> 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "eplerenone",
    "entity2": "fluconazole",
    "text": "Administration of <drug>eplerenone</drug> with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, <drug>fluconazole</drug> 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Tetracycline",
    "entity2": "penicillin",
    "text": "<drug>Tetracycline</drug>, a bacteriostatic antibiotic, may antagonize the bactericidal effect of <drug>penicillin</drug> and concurrent use of these drugs should be avoided.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "diazoxide",
    "entity2": "hydralazine",
    "text": "Profound hypotensive episodes may occur when <drug>diazoxide</drug> infection and <drug>hydralazine</drug> are used concomitantly.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Propranolol",
    "entity2": "hydralazine",
    "text": "<drug>Propranolol</drug> increases <drug>hydralazine</drug>s serum concentrations.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "dapsone",
    "entity2": "saquinavir",
    "text": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, <drug>dapsone</drug>, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with <drug>saquinavir</drug>;",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "saquinavir",
    "entity2": "disopyramide",
    "text": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, <drug>disopyramide</drug>, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with <drug>saquinavir</drug>;",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "saquinavir",
    "entity2": "quinine",
    "text": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, <drug>quinine</drug>, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with <drug>saquinavir</drug>;",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "saquinavir",
    "entity2": "amiodarone",
    "text": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, <drug>amiodarone</drug>, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with <drug>saquinavir</drug>;",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "saquinavir",
    "entity2": "quinidine",
    "text": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, <drug>quinidine</drug>, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with <drug>saquinavir</drug>;",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "saquinavir",
    "entity2": "warfarin",
    "text": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, <drug>warfarin</drug>, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with <drug>saquinavir</drug>;",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "saquinavir",
    "entity2": "tacrolimus",
    "text": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, <drug>tacrolimus</drug>, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with <drug>saquinavir</drug>;",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "saquinavir",
    "entity2": "cyclosporine",
    "text": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, <drug>cyclosporine</drug>, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with <drug>saquinavir</drug>;",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "pimozide",
    "entity2": "saquinavir",
    "text": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, <drug>pimozide</drug>, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with <drug>saquinavir</drug>;",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "carbamazepine",
    "entity2": "saquinavir",
    "text": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, <drug>carbamazepine</drug>, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with <drug>saquinavir</drug>;",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "fentanyl",
    "entity2": "saquinavir",
    "text": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, <drug>fentanyl</drug>, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with <drug>saquinavir</drug>;",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "alfentanyl",
    "entity2": "saquinavir",
    "text": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, <drug>alfentanyl</drug>, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with <drug>saquinavir</drug>;",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "alprazolam",
    "entity2": "saquinavir",
    "text": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, <drug>alprazolam</drug>, and triazolam) may have elevated plasma concentrations when coadministered with <drug>saquinavir</drug>;",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "triazolam",
    "entity2": "saquinavir",
    "text": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and <drug>triazolam</drug>) may have elevated plasma concentrations when coadministered with <drug>saquinavir</drug>;",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "phenobarbital",
    "entity2": "saquinavir",
    "text": "Coadministration with compounds that are potent inducers of CYP3A4 (eg, <drug>phenobarbital</drug>, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of <drug>saquinavir</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "phenytoin",
    "entity2": "saquinavir",
    "text": "Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, <drug>phenytoin</drug>, dexamethasone, carbamazepine) may result in decreased plasma levels of <drug>saquinavir</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "dexamethasone",
    "entity2": "saquinavir",
    "text": "Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, <drug>dexamethasone</drug>, carbamazepine) may result in decreased plasma levels of <drug>saquinavir</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "carbamazepine",
    "entity2": "saquinavir",
    "text": "Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, <drug>carbamazepine</drug>) may result in decreased plasma levels of <drug>saquinavir</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "Chlorotrianisene",
    "entity2": "bromocriptine",
    "text": "<drug>Chlorotrianisene</drug> may interact with antidepressants, aspirin, barbiturates, <drug>bromocriptine</drug>, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "Chlorotrianisene",
    "entity2": "calcium",
    "text": "<drug>Chlorotrianisene</drug> may interact with antidepressants, aspirin, barbiturates, bromocriptine, <drug>calcium</drug> supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "Chlorotrianisene",
    "entity2": "corticotropin",
    "text": "<drug>Chlorotrianisene</drug> may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, <drug>corticotropin</drug>, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "Chlorotrianisene",
    "entity2": "cyclosporine",
    "text": "<drug>Chlorotrianisene</drug> may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, <drug>cyclosporine</drug>, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "Chlorotrianisene",
    "entity2": "dantrolene",
    "text": "<drug>Chlorotrianisene</drug> may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, <drug>dantrolene</drug>, nicotine, somatropin, tamoxifen, and warfarin.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "Chlorotrianisene",
    "entity2": "nicotine",
    "text": "<drug>Chlorotrianisene</drug> may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, <drug>nicotine</drug>, somatropin, tamoxifen, and warfarin.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "Chlorotrianisene",
    "entity2": "somatropin",
    "text": "<drug>Chlorotrianisene</drug> may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, <drug>somatropin</drug>, tamoxifen, and warfarin.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "Chlorotrianisene",
    "entity2": "tamoxifen",
    "text": "<drug>Chlorotrianisene</drug> may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, <drug>tamoxifen</drug>, and warfarin.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "Chlorotrianisene",
    "entity2": "warfarin",
    "text": "<drug>Chlorotrianisene</drug> may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and <drug>warfarin</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "cyclosporine",
    "entity2": "caspofungin",
    "text": "In two clinical studies, <drug>cyclosporine</drug> (one 4 mg/kg dose or two 3 mg/kg doses) increased the AUC of <drug>caspofungin</drug> by approximately 35%.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "rifampin",
    "entity2": "caspofungin",
    "text": "A drug-drug interaction study with <drug>rifampin</drug> in healthy volunteers has shown a 30% decrease in <drug>caspofungin</drug> trough concentrations.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Butalbital",
    "entity2": "alcohol",
    "text": "<drug>Butalbital</drug>, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, <drug>alcohol</drug>, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Butalbital",
    "entity2": "chlordiazepoxide",
    "text": "<drug>Butalbital</drug>, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as <drug>chlordiazepoxide</drug>, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "acetaminophen",
    "entity2": "alcohol",
    "text": "Butalbital, <drug>acetaminophen</drug> and caffeine may enhance the effects of: other narcotic analgesics, <drug>alcohol</drug>, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "acetaminophen",
    "entity2": "chlordiazepoxide",
    "text": "Butalbital, <drug>acetaminophen</drug> and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as <drug>chlordiazepoxide</drug>, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "caffeine",
    "entity2": "alcohol",
    "text": "Butalbital, acetaminophen and <drug>caffeine</drug> may enhance the effects of: other narcotic analgesics, <drug>alcohol</drug>, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "caffeine",
    "entity2": "chlordiazepoxide",
    "text": "Butalbital, acetaminophen and <drug>caffeine</drug> may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as <drug>chlordiazepoxide</drug>, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "nevirapine",
    "entity2": "warfarin",
    "text": "The in vitro interaction between <drug>nevirapine</drug> and the antithrombotic agent <drug>warfarin</drug> is complex.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "warfarin",
    "entity2": "nevirapine",
    "text": "When <drug>warfarin</drug> is co-administered with <drug>nevirapine</drug>, anticoagulation levels should be monitored frequently.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Clarithromycin",
    "entity2": "nevirapine",
    "text": "<drug>Clarithromycin</drug> exposure was significantly decreased by <drug>nevirapine</drug>;",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "Nevirapine",
    "entity2": "ketoconazole",
    "text": "<drug>Nevirapine</drug> and <drug>ketoconazole</drug> should not beadministered concomitantly becausedecreases in ketoconazole plasmaconcentrations may reduce the efficacy of the drug.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "lopinavir",
    "entity2": "nevirapine",
    "text": "A dose increase of <drug>lopinavir</drug>/ritonavir to 533/133 mg twice daily with food isrecommended in combination with <drug>nevirapine</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "ritonavir",
    "entity2": "nevirapine",
    "text": "A dose increase of lopinavir/<drug>ritonavir</drug> to 533/133 mg twice daily with food isrecommended in combination with <drug>nevirapine</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "Methadone",
    "entity2": "nevirapine",
    "text": "Methadone levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. <drug>Methadone</drug> maintained patients beginning <drug>nevirapine</drug> therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "Nevirapine",
    "entity2": "rifampin",
    "text": "<drug>Nevirapine</drug> and <drug>rifampin</drug> should not beadministered concomitantly becausedecreases in nevirapine plasmaconcentrations may reduce the efficacy ofthe drug.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "nevirapine",
    "entity2": "methadone",
    "text": "aBased on reports of narcotic withdrawal syndrome in patients treated with <drug>nevirapine</drug> and <drug>methadone</drug> concurrently, and evidence of decreased plasma concentrations of methadone.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "nitazoxanide",
    "entity2": "warfarin",
    "text": "Therefore, caution should be used when administering <drug>nitazoxanide</drug> concurrently with other highly plasma protein-bound drugs with narrow therapeutic indices, as competition for binding sites may occur (e.g., <drug>warfarin</drug>).",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Erythromycin",
    "entity2": "theophylline",
    "text": "<drug>Erythromycin</drug> use in patients who are receiving high doses of <drug>theophylline</drug> may be associated with an increase in serum theophylline levels and potential theophylline toxicity.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "theophylline",
    "entity2": "erythromycin",
    "text": "In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of <drug>theophylline</drug> should be reduced while the patient is receiving concomitant <drug>erythromycin</drug> therapy.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "erythromycin",
    "entity2": "digoxin",
    "text": "Concomitant administration of <drug>erythromycin</drug> and <drug>digoxin</drug> has been reported to result in elevated digoxin serum levels.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "erythromycin",
    "entity2": "ergotamine",
    "text": "Concurrent use of <drug>erythromycin</drug> and <drug>ergotamine</drug> or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "erythromycin",
    "entity2": "dihydroergotamine",
    "text": "Concurrent use of <drug>erythromycin</drug> and ergotamine or <drug>dihydroergotamine</drug> has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Erythromycin",
    "entity2": "triazolam",
    "text": "<drug>Erythromycin</drug> has been reported to decrease the clearance of <drug>triazolam</drug> and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Erythromycin",
    "entity2": "midazolam",
    "text": "<drug>Erythromycin</drug> has been reported to decrease the clearance of triazolam and <drug>midazolam</drug> and thus may increase the pharmacologic effect of these benzodiazepines.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "erythromycin",
    "entity2": "carbamazepine",
    "text": "There have been reports of interactions of <drug>erythromycin</drug> with <drug>carbamazepine</drug>, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "erythromycin",
    "entity2": "cyclosporine",
    "text": "There have been reports of interactions of <drug>erythromycin</drug> with carbamazepine, <drug>cyclosporine</drug>, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "erythromycin",
    "entity2": "tacrolimus",
    "text": "There have been reports of interactions of <drug>erythromycin</drug> with carbamazepine, cyclosporine, <drug>tacrolimus</drug>, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "erythromycin",
    "entity2": "hexobarbital",
    "text": "There have been reports of interactions of <drug>erythromycin</drug> with carbamazepine, cyclosporine, tacrolimus, <drug>hexobarbital</drug>, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "erythromycin",
    "entity2": "phenytoin",
    "text": "There have been reports of interactions of <drug>erythromycin</drug> with carbamazepine, cyclosporine, tacrolimus, hexobarbital, <drug>phenytoin</drug>, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "erythromycin",
    "entity2": "alfentanil",
    "text": "There have been reports of interactions of <drug>erythromycin</drug> with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, <drug>alfentanil</drug>, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "erythromycin",
    "entity2": "cisapride",
    "text": "There have been reports of interactions of <drug>erythromycin</drug> with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, <drug>cisapride</drug>, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "erythromycin",
    "entity2": "disopyramide",
    "text": "There have been reports of interactions of <drug>erythromycin</drug> with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, <drug>disopyramide</drug>, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "erythromycin",
    "entity2": "lovastatin",
    "text": "There have been reports of interactions of <drug>erythromycin</drug> with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, <drug>lovastatin</drug>, bromocriptine, valproate, terfenadine, and astemizole.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "erythromycin",
    "entity2": "bromocriptine",
    "text": "There have been reports of interactions of <drug>erythromycin</drug> with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, <drug>bromocriptine</drug>, valproate, terfenadine, and astemizole.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "erythromycin",
    "entity2": "valproate",
    "text": "There have been reports of interactions of <drug>erythromycin</drug> with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, <drug>valproate</drug>, terfenadine, and astemizole.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "erythromycin",
    "entity2": "terfenadine",
    "text": "There have been reports of interactions of <drug>erythromycin</drug> with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, <drug>terfenadine</drug>, and astemizole.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "erythromycin",
    "entity2": "astemizole",
    "text": "There have been reports of interactions of <drug>erythromycin</drug> with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and <drug>astemizole</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Erythromycin",
    "entity2": "terfenadine",
    "text": "<drug>Erythromycin</drug> has been reported to significantly alter the metabolism of nonsedating antihistamines <drug>terfenadine</drug> and astemizole when taken concomitantly.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Erythromycin",
    "entity2": "astemizole",
    "text": "<drug>Erythromycin</drug> has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and <drug>astemizole</drug> when taken concomitantly.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "terfenadine",
    "entity2": "erythromycin",
    "text": "In addition, deaths have been reported rarely with concomitant administration of <drug>terfenadine</drug> and <drug>erythromycin</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "erythromycin",
    "entity2": "cisapride",
    "text": "There have been postmarketing reports of drug interactions when <drug>erythromycin</drug> is coadministered with <drug>cisapride</drug>, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "cisapride",
    "entity2": "erythromycin",
    "text": "There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of <drug>cisapride</drug> by <drug>erythromycin</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "lovastatin",
    "entity2": "erythromycin",
    "text": "Patients receiving concomitant <drug>lovastatin</drug> and <drug>erythromycin</drug> should be carefully monitored;",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "carbenicillin indanyl sodium",
    "entity2": "probenecid",
    "text": "Geocillin (<drug>carbenicillin indanyl sodium</drug>) blood levels may be increased and prolonged by concurrent administration of <drug>probenecid</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "caffeine",
    "entity2": "cimetidine",
    "text": "Based on adult data, lower doses of <drug>caffeine</drug> may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., <drug>cimetidine</drug> and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "caffeine",
    "entity2": "ketoconazole",
    "text": "Based on adult data, lower doses of <drug>caffeine</drug> may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and <drug>ketoconazole</drug>) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "caffeine",
    "entity2": "phenobarbital",
    "text": "Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher <drug>caffeine</drug> doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., <drug>phenobarbital</drug> and phenytoin).",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "caffeine",
    "entity2": "phenytoin",
    "text": "Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher <drug>caffeine</drug> doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and <drug>phenytoin</drug>).",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Caffeine",
    "entity2": "ketoprofen",
    "text": "<drug>Caffeine</drug> administered concurrently with <drug>ketoprofen</drug> reduced the urine volume in 4 healthy volunteers.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "glimepiride",
    "entity2": "magnesium/choline salicylate",
    "text": "Before taking <drug>glimepiride</drug>, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as <drug>magnesium/choline salicylate</drug> (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "glimepiride",
    "entity2": "salsalate",
    "text": "Before taking <drug>glimepiride</drug>, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), <drug>salsalate</drug> (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "glimepiride",
    "entity2": "choline salicylate",
    "text": "Before taking <drug>glimepiride</drug>, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), <drug>choline salicylate</drug> (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "glimepiride",
    "entity2": "Arthropan",
    "text": "Before taking <drug>glimepiride</drug>, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (<drug>Arthropan</drug>), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "glimepiride",
    "entity2": "magnesium salicylate",
    "text": "Before taking <drug>glimepiride</drug>, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), <drug>magnesium salicylate</drug> (Magan), or bismuth subsalicylate (Pepto-Bismol);",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "glimepiride",
    "entity2": "bismuth subsalicylate",
    "text": "Before taking <drug>glimepiride</drug>, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or <drug>bismuth subsalicylate</drug> (Pepto-Bismol);",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "tetracycline",
    "entity2": "bismuth subsalicylate",
    "text": "Absorption of <drug>tetracycline</drug> is impaired by <drug>bismuth subsalicylate</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "carbamazepine",
    "entity2": "doxycycline",
    "text": "Barbiturates, <drug>carbamazepine</drug>, and phenytoin decrease the half-life of <drug>doxycycline</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "phenytoin",
    "entity2": "doxycycline",
    "text": "Barbiturates, carbamazepine, and <drug>phenytoin</drug> decrease the half-life of <drug>doxycycline</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "tetracycline",
    "entity2": "methoxyflurane",
    "text": "The concurrent use of <drug>tetracycline</drug> and Penthrane (<drug>methoxyflurane</drug>) has been reported to result in fatal renal toxicity.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "probenecid",
    "entity2": "cefdinir",
    "text": "Probenecid: As with other b-lactam antibiotics, <drug>probenecid</drug> inhibits the renal excretion of <drug>cefdinir</drug>, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "cefdinir",
    "entity2": "iron",
    "text": "Iron Supplements and Foods Fortified With Iron Concomitant administration of <drug>cefdinir</drug> with a therapeutic iron supplement containing 60 mg of elemental <drug>iron</drug> (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "cefdinir",
    "entity2": "iron",
    "text": "Iron Supplements and Foods Fortified With Iron Concomitant administration of <drug>cefdinir</drug> with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental <drug>iron</drug> reduced extent of absorption by 80% and 31%, respectively.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "cefdinir",
    "entity2": "iron",
    "text": "The reddish color is due to the formation of a nonabsorbable complex between <drug>cefdinir</drug> or its breakdown products and <drug>iron</drug> in the gastrointestinal tract.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "norfloxacin",
    "entity2": "theophylline",
    "text": "There have been reports of theophylline-related side effects in patients on concomitant therapy with <drug>norfloxacin</drug> and <drug>theophylline</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "cyclosporine",
    "entity2": "norfloxacin",
    "text": "Elevated serum levels of cyclosporine have been reported with concomitant use of <drug>cyclosporine</drug> with <drug>norfloxacin</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "norfloxacin",
    "entity2": "warfarin",
    "text": "Quinolones, including <drug>norfloxacin</drug>, may enhance the effects of oral anticoagulants, including <drug>warfarin</drug> or its derivatives or similar agents.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "norfloxacin",
    "entity2": "glyburide",
    "text": "The concomitant administration of quinolones including <drug>norfloxacin</drug> with <drug>glyburide</drug> (a sulfonylurea agent) has, on rare occasions, resulted in severe hypoglycemia.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "probenecid",
    "entity2": "norfloxacin",
    "text": "Diminished urinary excretion of norfloxacin has been reported during the concomitant administration of <drug>probenecid</drug> and <drug>norfloxacin</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "nitrofurantoin",
    "entity2": "Norfloxacin",
    "text": "The concomitant use of nitrofurantoin is not recommended since <drug>nitrofurantoin</drug> may antagonize the antibacterial effect of <drug>Norfloxacin</drug> in the urinary tract.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "iron",
    "entity2": "norfloxacin",
    "text": "Multivitamins, or other products containing <drug>iron</drug> or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of <drug>norfloxacin</drug>, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "zinc",
    "entity2": "norfloxacin",
    "text": "Multivitamins, or other products containing iron or <drug>zinc</drug>, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of <drug>norfloxacin</drug>, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "sucralfate",
    "entity2": "norfloxacin",
    "text": "Multivitamins, or other products containing iron or zinc, antacids or <drug>sucralfate</drug> should not be administered concomitantly with, or within 2 hours of, the administration of <drug>norfloxacin</drug>, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "Didanosine",
    "entity2": "norfloxacin",
    "text": "Videx (<drug>Didanosine</drug>) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of <drug>norfloxacin</drug>, because these products may interfere with absorption resulting in lower serum and urine levels of norfloxacin.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Corticotropin",
    "entity2": "diuretic",
    "text": "<drug>Corticotropin</drug> may accentuate the electrolyte loss associated with <drug>diuretic</drug> therapy.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "buprenorphine",
    "entity2": "benzodiazepines",
    "text": "There have been a number of reports in the post-marketing experience of coma and death associated with the concomitant intravenous misuse of <drug>buprenorphine</drug> and <drug>benzodiazepines</drug> by addicts.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "butorphanol",
    "entity2": "alcohol",
    "text": "Concurrent use of <drug>butorphanol</drug> with central nervous system depressants (e.g., <drug>alcohol</drug>, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "butorphanol",
    "entity2": "erythromycin",
    "text": "It is not known if the effects of <drug>butorphanol</drug> are altered by concomitant medications that affect hepatic metabolism of drugs (<drug>erythromycin</drug>, etc.), but physicians should be alert to the possibility that a smaller initial dose and longer intervals between doses may be needed.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Colchicine",
    "entity2": "vitamin B12",
    "text": "<drug>Colchicine</drug> para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of <drug>vitamin B12</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "para-aminosalicylic acid",
    "entity2": "vitamin B12",
    "text": "Colchicine <drug>para-aminosalicylic acid</drug> and heavy alcohol intake for longer than 2 weeks may produce malabsorption of <drug>vitamin B12</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "alcohol",
    "entity2": "vitamin B12",
    "text": "Colchicine para-aminosalicylic acid and heavy <drug>alcohol</drug> intake for longer than 2 weeks may produce malabsorption of <drug>vitamin B12</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "eszopiclone",
    "entity2": "ethanol",
    "text": "CNS-Active Drugs Ethanol An additive effect on psychomotor performance was seen with coadministration of <drug>eszopiclone</drug> and <drug>ethanol</drug> 0.70 g/kg for up to 4 hours after ethanol administration.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "eszopiclone",
    "entity2": "olanzapine",
    "text": "Olanzapine: Coadministration of <drug>eszopiclone</drug> 3 mg and <drug>olanzapine</drug> 10 mg produced a decrease in DSST scores.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "eszopiclone",
    "entity2": "ketoconazole",
    "text": "The AUC of <drug>eszopiclone</drug> was increased 2.2-fold by coadministration of <drug>ketoconazole</drug>, a potent inhibitor of CYP3A4, 400 mg daily for 5 days.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "zopiclone",
    "entity2": "rifampicin",
    "text": "Drugs That Induce CYP3A4 (Rifampicin) Racemic <drug>zopiclone</drug> exposure was decreased 80% by concomitant useof <drug>rifampicin</drug>, a potent inducer of CYP3A4.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "bosentan",
    "entity2": "cyclosporine A",
    "text": "Steady-state <drug>bosentan</drug> plasma concentrations were 3- to 4-fold higher than in the absence of <drug>cyclosporine A</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "bosentan",
    "entity2": "cyclosporine A",
    "text": "The concomitant administration of <drug>bosentan</drug> and <drug>cyclosporine A</drug> is contraindicated.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "bosentan",
    "entity2": "cyclosporine A",
    "text": "Co-administration of <drug>bosentan</drug> decreased the plasma concentrations of <drug>cyclosporine A</drug> (a CYP3A4 substrate) by approximately 50%.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "tacrolimus",
    "entity2": "bosentan",
    "text": "Co-administration of <drug>tacrolimus</drug> and <drug>bosentan</drug> resulted in markedly increased plasma concentrations of bosentan in animals.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "tacrolimus",
    "entity2": "bosentan",
    "text": "Caution should be exercised if <drug>tacrolimus</drug> and <drug>bosentan</drug> are used together.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "bosentan",
    "entity2": "glyburide",
    "text": "Co-administration of <drug>bosentan</drug> decreased the plasma concentrations of <drug>glyburide</drug> by approximately 40%.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "bosentan",
    "entity2": "ketoconazole",
    "text": "Ketoconazole: Co-administration of <drug>bosentan</drug> 125 mg b.i.d. and <drug>ketoconazole</drug>, a potent CYP3A4 inhibitor, increased the plasma concentrations of bosentan by approximately 2-fold.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "bosentan",
    "entity2": "simvastatin",
    "text": "Simvastatin and Other Statins: Co-administration of <drug>bosentan</drug> decreased the plasma concentrations of <drug>simvastatin</drug> (a CYP3A4 substrate), and its active  -hydroxy acid metabolite, by approximately 50%.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Bosentan",
    "entity2": "lovastatin",
    "text": "<drug>Bosentan</drug> is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as <drug>lovastatin</drug> and atorvastatin.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Bosentan",
    "entity2": "atorvastatin",
    "text": "<drug>Bosentan</drug> is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and <drug>atorvastatin</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "bosentan",
    "entity2": "S-warfarin",
    "text": "Warfarin: Co-administration of <drug>bosentan</drug> 500 mg b.i.d. for 6 days decreased the plasma concentrations of both <drug>S-warfarin</drug> (a CYP2C9 substrate) and R-warfarin (a CYP3A4 substrate) by 29 and 38%, respectively.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "bosentan",
    "entity2": "R-warfarin",
    "text": "Warfarin: Co-administration of <drug>bosentan</drug> 500 mg b.i.d. for 6 days decreased the plasma concentrations of both S-warfarin (a CYP2C9 substrate) and <drug>R-warfarin</drug> (a CYP3A4 substrate) by 29 and 38%, respectively.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Cimetidine",
    "entity2": "altretamine",
    "text": "Concurrent administration of HEXALEN and antidepressants of the MAO inhibitor class may cause severe orthostatic hypotension.<drug>Cimetidine</drug>, an inhibitor of microsomal drug metabolism, increased <drug>altretamine</drug>s half-life and toxicity in a rat model.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "pyridoxine",
    "entity2": "cisplatin",
    "text": "however, it adversely affected response duration suggesting that <drug>pyridoxine</drug> should not be administered with HEXALEN and/or <drug>cisplatin</drug>.1",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Probenecid",
    "entity2": "acetaminophen",
    "text": "Probenecid : <drug>Probenecid</drug> is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., <drug>acetaminophen</drug>, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Probenecid",
    "entity2": "acyclovir",
    "text": "Probenecid : <drug>Probenecid</drug> is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, <drug>acyclovir</drug>, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Probenecid",
    "entity2": "aminosalicylic acid",
    "text": "Probenecid : <drug>Probenecid</drug> is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, <drug>aminosalicylic acid</drug>, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Probenecid",
    "entity2": "bumetanide",
    "text": "Probenecid : <drug>Probenecid</drug> is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, <drug>bumetanide</drug>, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Probenecid",
    "entity2": "clofibrate",
    "text": "Probenecid : <drug>Probenecid</drug> is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, <drug>clofibrate</drug>, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Probenecid",
    "entity2": "methotrexate",
    "text": "Probenecid : <drug>Probenecid</drug> is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, <drug>methotrexate</drug>, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Probenecid",
    "entity2": "famotidine",
    "text": "Probenecid : <drug>Probenecid</drug> is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, <drug>famotidine</drug>, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Probenecid",
    "entity2": "furosemide",
    "text": "Probenecid : <drug>Probenecid</drug> is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, <drug>furosemide</drug>, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Probenecid",
    "entity2": "theophylline",
    "text": "Probenecid : <drug>Probenecid</drug> is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, <drug>theophylline</drug>, and zidovudine).",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Probenecid",
    "entity2": "zidovudine",
    "text": "Probenecid : <drug>Probenecid</drug> is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and <drug>zidovudine</drug>).",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "Zidovudine",
    "entity2": "probenecid",
    "text": "<drug>Zidovudine</drug> should either be temporarily discontinued or decreased by 50% when coadministered with <drug>probenecid</drug> on the day of VISTIDE infusion.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Quinidine",
    "entity2": "digoxin",
    "text": "<drug>Quinidine</drug>, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum <drug>digoxin</drug> concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "verapamil",
    "entity2": "digoxin",
    "text": "Quinidine, <drug>verapamil</drug>, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum <drug>digoxin</drug> concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "amiodarone",
    "entity2": "digoxin",
    "text": "Quinidine, verapamil, <drug>amiodarone</drug>, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum <drug>digoxin</drug> concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "propafenone",
    "entity2": "digoxin",
    "text": "Quinidine, verapamil, amiodarone, <drug>propafenone</drug>, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum <drug>digoxin</drug> concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "indomethacin",
    "entity2": "digoxin",
    "text": "Quinidine, verapamil, amiodarone, propafenone, <drug>indomethacin</drug>, itraconazole, alprazolam, and spironolactone raise the serum <drug>digoxin</drug> concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "itraconazole",
    "entity2": "digoxin",
    "text": "Quinidine, verapamil, amiodarone, propafenone, indomethacin, <drug>itraconazole</drug>, alprazolam, and spironolactone raise the serum <drug>digoxin</drug> concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "alprazolam",
    "entity2": "digoxin",
    "text": "Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, <drug>alprazolam</drug>, and spironolactone raise the serum <drug>digoxin</drug> concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "spironolactone",
    "entity2": "digoxin",
    "text": "Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and <drug>spironolactone</drug> raise the serum <drug>digoxin</drug> concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Erythromycin",
    "entity2": "digoxin",
    "text": "<drug>Erythromycin</drug> and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase <drug>digoxin</drug> absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "clarithromycin",
    "entity2": "digoxin",
    "text": "Erythromycin and <drug>clarithromycin</drug> (and possibly other macrolide antibiotics) and tetracycline may increase <drug>digoxin</drug> absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "tetracycline",
    "entity2": "digoxin",
    "text": "Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and <drug>tetracycline</drug> may increase <drug>digoxin</drug> absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Propantheline",
    "entity2": "digoxin",
    "text": "<drug>Propantheline</drug> and diphenoxylate, by decreasing gut motility, may increase <drug>digoxin</drug> absorption.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "diphenoxylate",
    "entity2": "digoxin",
    "text": "Propantheline and <drug>diphenoxylate</drug>, by decreasing gut motility, may increase <drug>digoxin</drug> absorption.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "kaolin",
    "entity2": "digoxin",
    "text": "Antacids, <drug>kaolin</drug>-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal <drug>digoxin</drug> absorption, resulting in unexpectedly low serum concentrations.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "sulfasalazine",
    "entity2": "digoxin",
    "text": "Antacids, kaolin-pectin, <drug>sulfasalazine</drug>, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal <drug>digoxin</drug> absorption, resulting in unexpectedly low serum concentrations.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "neomycin",
    "entity2": "digoxin",
    "text": "Antacids, kaolin-pectin, sulfasalazine, <drug>neomycin</drug>, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal <drug>digoxin</drug> absorption, resulting in unexpectedly low serum concentrations.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "cholestyramine",
    "entity2": "digoxin",
    "text": "Antacids, kaolin-pectin, sulfasalazine, neomycin, <drug>cholestyramine</drug>, certain anticancer drugs, and metoclopramide may interfere with intestinal <drug>digoxin</drug> absorption, resulting in unexpectedly low serum concentrations.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "metoclopramide",
    "entity2": "digoxin",
    "text": "Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and <drug>metoclopramide</drug> may interfere with intestinal <drug>digoxin</drug> absorption, resulting in unexpectedly low serum concentrations.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Rifampin",
    "entity2": "digoxin",
    "text": "<drug>Rifampin</drug> may decrease serum <drug>digoxin</drug> concentration, especially in patients with renal dysfunction, by increasing the non-renal clearance of digoxin.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "alcohol",
    "entity2": "bromocriptine mesylate",
    "text": "The risk of using bromocriptine mesylate in combination with other drugs has not been systematically evaluated, but <drug>alcohol</drug> may potentiate the side effects of <drug>bromocriptine mesylate</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "bromocriptine mesylate",
    "entity2": "haloperidol",
    "text": "Compounds in these categories result in a decreased efficacy of <drug>bromocriptine mesylate</drug>: phenothiazines, <drug>haloperidol</drug>, metoclopramide, pimozide.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "bromocriptine mesylate",
    "entity2": "metoclopramide",
    "text": "Compounds in these categories result in a decreased efficacy of <drug>bromocriptine mesylate</drug>: phenothiazines, haloperidol, <drug>metoclopramide</drug>, pimozide.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "bromocriptine mesylate",
    "entity2": "pimozide",
    "text": "Compounds in these categories result in a decreased efficacy of <drug>bromocriptine mesylate</drug>: phenothiazines, haloperidol, metoclopramide, <drug>pimozide</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "dopamine",
    "entity2": "propranolol",
    "text": "Cardiac effects of <drug>dopamine</drug> are antagonized by beta-adrenergic blocking agents, such as <drug>propranolol</drug> and metoprolol.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "dopamine",
    "entity2": "metoprolol",
    "text": "Cardiac effects of <drug>dopamine</drug> are antagonized by beta-adrenergic blocking agents, such as propranolol and <drug>metoprolol</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "haloperidol",
    "entity2": "dopamine",
    "text": "Butyrophenones (such as <drug>haloperidol</drug>) and phenothiazines can suppress the <drug>dopamine</drug>rgic renal and mesenteric vasodilation induced with low dose dopamine infusion.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Cyclopropane",
    "entity2": "dopamine",
    "text": "<drug>Cyclopropane</drug> or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as <drug>dopamine</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "dopamine HCl",
    "entity2": "cyclopropane",
    "text": "Therefore, EXTREME CAUTION should be exercised when administering <drug>dopamine HCl</drug> to patients receiving <drug>cyclopropane</drug> or halogenated hydrocarbon anesthetics.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "dopamine",
    "entity2": "propranolol",
    "text": "It has been reported that results of studies in animals indicate that <drug>dopamine</drug>-induced ventricular arrhythmias during anesthesia can be reversed by <drug>propranolol</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "phenytoin",
    "entity2": "dopamine HCl",
    "text": "Administration of <drug>phenytoin</drug> to patients receiving <drug>dopamine HCl</drug> has been reported to lead to hypotension and bradycardia.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "dopamine HCl",
    "entity2": "phenytoin",
    "text": "It is suggested that in patients receiving <drug>dopamine HCl</drug>, alternatives to <drug>phenytoin</drug> should be used if anticonvulsant therapy is needed.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "terfenadine",
    "entity2": "Itraconazole",
    "text": "Coadministration of <drug>terfenadine</drug> with <drug>Itraconazole</drug> has led to elevated plasma concentrations of terfenadine, resulting in rare instances of life- threatening cardiac dysrhythmias and one death.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "ketoconazole",
    "entity2": "astemizole",
    "text": "Another oral azole antifungal, <drug>ketoconazole</drug>, inhibits the metabolism of <drug>astemizole</drug>, resulting in elevated plasma concentrations of astemizole and its active metabolite desmethylastermizole which may prolong QT intervals.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "itraconazole",
    "entity2": "astemizole",
    "text": "In vitro data suggest that <drug>itraconazole</drug>, when compared to ketoconazole, has a less pronounced effect on the biotransformation system responsible for the metabolism of <drug>astemizole</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "astemizole",
    "entity2": "itraconazole",
    "text": "Based on the chemical resemblance of itraconazole and ketoconazole, coadministration of <drug>astemizole</drug> with <drug>itraconazole</drug> is contraindicated.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "ketoconazole",
    "entity2": "cisapride",
    "text": "Human pharmacokinetics data indicate that oral <drug>ketoconazole</drug> potently inhibits the metabolism of <drug>cisapride</drug> resulting in an eight-fold increase in the mean AUC of cisapride.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "ketoconazole",
    "entity2": "cisapride",
    "text": "Data suggest that coadministration of oral <drug>ketoconazole</drug> and <drug>cisapride</drug> can result in prolongation of the QT interval on the ECG.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "itraconazole",
    "entity2": "cisapride",
    "text": "In vitro data suggest that <drug>itraconazole</drug> also markedly inhibits the biotransformation system mainly responsible for the metabolism of <drug>cisapride</drug>;",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "Itraconazole",
    "entity2": "cisapride",
    "text": "therefore concomitant administration of <drug>Itraconazole</drug> with <drug>cisapride</drug> is contraindicated.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Itraconazole",
    "entity2": "midazolam",
    "text": "Coadministration of <drug>Itraconazole</drug> with oral <drug>midazolam</drug> or triazolam has resulted in elevated plasma concentrations of the latter two drugs.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Itraconazole",
    "entity2": "triazolam",
    "text": "Coadministration of <drug>Itraconazole</drug> with oral midazolam or <drug>triazolam</drug> has resulted in elevated plasma concentrations of the latter two drugs.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Itraconazole",
    "entity2": "cyclosporine",
    "text": "Coadministration of <drug>Itraconazole</drug> and <drug>cyclosporine</drug>, tacrolimus or digoxin has led to increased plasma concentrations of the latter three drugs.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Itraconazole",
    "entity2": "tacrolimus",
    "text": "Coadministration of <drug>Itraconazole</drug> and cyclosporine, <drug>tacrolimus</drug> or digoxin has led to increased plasma concentrations of the latter three drugs.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Itraconazole",
    "entity2": "digoxin",
    "text": "Coadministration of <drug>Itraconazole</drug> and cyclosporine, tacrolimus or <drug>digoxin</drug> has led to increased plasma concentrations of the latter three drugs.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "Cyclosporine",
    "entity2": "Itraconazole",
    "text": "<drug>Cyclosporine</drug>, tacrolimus and digoxin concentrations should be monitored at the initiation of <drug>Itraconazole</drug> therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "tacrolimus",
    "entity2": "Itraconazole",
    "text": "Cyclosporine, <drug>tacrolimus</drug> and digoxin concentrations should be monitored at the initiation of <drug>Itraconazole</drug> therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "digoxin",
    "entity2": "Itraconazole",
    "text": "Cyclosporine, tacrolimus and <drug>digoxin</drug> concentrations should be monitored at the initiation of <drug>Itraconazole</drug> therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Itraconazole",
    "entity2": "phenytoin",
    "text": "When <drug>Itraconazole</drug> was coadministered with <drug>phenytoin</drug>, rifampin, or H2antagonists, reduced plasma concentrations of itraconazole were reported.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Itraconazole",
    "entity2": "rifampin",
    "text": "When <drug>Itraconazole</drug> was coadministered with phenytoin, <drug>rifampin</drug>, or H2antagonists, reduced plasma concentrations of itraconazole were reported.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Itraconazole",
    "entity2": "phenytoin",
    "text": "Although no studies have been conducted, concomitant administration of <drug>Itraconazole</drug> and <drug>phenytoin</drug> may alter the metabolism of phenytoin;",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "phenytoin",
    "entity2": "Itraconazole",
    "text": "therefore, plasma concentrations of <drug>phenytoin</drug> should also be monitored when it is given concurrently with <drug>Itraconazole</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "Itraconazole",
    "entity2": "isoniazid",
    "text": "Itraconazole plasma concentrations should be monitored when <drug>Itraconazole</drug> and <drug>isoniazid</drug> are coadministered.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Itraconazole",
    "entity2": "quinidine",
    "text": "Tinnitus and decreased hearing have been reported in patients concomitantly receiving <drug>Itraconazole</drug> and <drug>quinidine</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "gemifloxacin",
    "entity2": "aluminum",
    "text": "The absorption of oral <drug>gemifloxacin</drug> is significantly reduced by the concomitant administration of an antacid containing <drug>aluminum</drug> and magnesium.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "gemifloxacin",
    "entity2": "magnesium",
    "text": "The absorption of oral <drug>gemifloxacin</drug> is significantly reduced by the concomitant administration of an antacid containing aluminum and <drug>magnesium</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Argatroban",
    "entity2": "warfarin",
    "text": "However, the concomitant use of <drug>Argatroban</drug> and <drug>warfarin</drug> (5-7.5 mg initial oral dose followed by 2.5-6 mg/day orally for 6-10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR).",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Cholestyramine",
    "entity2": "warfarin",
    "text": "<drug>Cholestyramine</drug> resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, <drug>warfarin</drug>, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Cholestyramine",
    "entity2": "propranolol",
    "text": "<drug>Cholestyramine</drug> resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or <drug>propranolol</drug> (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Cholestyramine",
    "entity2": "tetracycline",
    "text": "<drug>Cholestyramine</drug> resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as <drug>tetracycline</drug> penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Cholestyramine",
    "entity2": "penicillin G",
    "text": "<drug>Cholestyramine</drug> resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline <drug>penicillin G</drug>, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Cholestyramine",
    "entity2": "phenobarbital",
    "text": "<drug>Cholestyramine</drug> resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, <drug>phenobarbital</drug>, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Cholestyramine",
    "entity2": "thyroxine",
    "text": "<drug>Cholestyramine</drug> resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and <drug>thyroxine</drug> preparations, estrogens and progestins, and digitalis.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "heparin sodium",
    "entity2": "dicumarol",
    "text": "Therefore, when <drug>heparin sodium</drug> is given with <drug>dicumarol</drug> or warfarin sodium, a period of at least 5 hours after the last intravenous dose or 24 hours after the last subcutaneous dose should elapse before blood is drawn if a valid prothrombin time is to be obtained.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "heparin sodium",
    "entity2": "warfarin sodium",
    "text": "Therefore, when <drug>heparin sodium</drug> is given with dicumarol or <drug>warfarin sodium</drug>, a period of at least 5 hours after the last intravenous dose or 24 hours after the last subcutaneous dose should elapse before blood is drawn if a valid prothrombin time is to be obtained.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "acetylsalicylic acid",
    "entity2": "heparin sodium",
    "text": "Platelet inhibitors: Drugs such as <drug>acetylsalicylic acid</drug>, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving <drug>heparin sodium</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "dextran",
    "entity2": "heparin sodium",
    "text": "Platelet inhibitors: Drugs such as acetylsalicylic acid, <drug>dextran</drug>, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving <drug>heparin sodium</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "phenylbutazone",
    "entity2": "heparin sodium",
    "text": "Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, <drug>phenylbutazone</drug>, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving <drug>heparin sodium</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "ibuprofen",
    "entity2": "heparin sodium",
    "text": "Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, <drug>ibuprofen</drug>, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving <drug>heparin sodium</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "indomethacin",
    "entity2": "heparin sodium",
    "text": "Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, <drug>indomethacin</drug>, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving <drug>heparin sodium</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "dipyridamole",
    "entity2": "heparin sodium",
    "text": "Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, <drug>dipyridamole</drug>, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving <drug>heparin sodium</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "hydroxychloroquine",
    "entity2": "heparin sodium",
    "text": "Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, <drug>hydroxychloroquine</drug> and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving <drug>heparin sodium</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "heparin",
    "entity2": "antithrombin III",
    "text": "The anticoagulant effect of <drug>heparin</drug> is enhanced by concurrent treatment with <drug>antithrombin III</drug> (human) in patients with hereditary antithrombin III deficiency.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "heparin",
    "entity2": "antithrombin III",
    "text": "Thus in order to avoid bleeding, reduced dosage of <drug>heparin</drug> is recommended during treatment with <drug>antithrombin III</drug> (human).",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "nicotine",
    "entity2": "heparin sodium",
    "text": "Drugs Decreasing Heparin Effect: Digitalis, tetracyclines, <drug>nicotine</drug>, or antihistamines may partially counteract the anticoagulant action of <drug>heparin sodium</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Flurbiprofen",
    "entity2": "propranolol",
    "text": "<drug>Flurbiprofen</drug> pretreatment attenuated the hypotensive effect of a single dose of <drug>propranolol</drug> but not atenolol.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "Flurbiprofen",
    "entity2": "propranolol",
    "text": "<drug>Flurbiprofen</drug> did not affect the pharmacokinetic profile of either drug, and the mechanism under lying the interference with <drug>propranolol</drug>s hypotensive effect is unknown.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "flurbiprofen",
    "entity2": "cimetidine",
    "text": "Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of <drug>flurbiprofen</drug> resulted with <drug>cimetidine</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "flurbiprofen",
    "entity2": "furosemide",
    "text": "Diuretics: Studies in normal volunteers have shown that <drug>flurbiprofen</drug> like other nonsteroidal anti-inflammatory drugs, can interfere with the effects of <drug>furosemide</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "flurbiprofen",
    "entity2": "furosemide",
    "text": "Patients receiving <drug>flurbiprofen</drug> and <drug>furosemide</drug> or other diuretics should be observed closely to determine if the desired effect is obtained.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "citalopram",
    "entity2": "cimetidine",
    "text": "Cimetidine - In subjects who had received 21 days of 40 mg/day racemic <drug>citalopram</drug>, combined administration of 400 mg/day <drug>cimetidine</drug> for 8 days resulted in an increase in citalopram AUC and Cmax of 43% and 39%, respectively.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "lithium",
    "entity2": "escitalopram",
    "text": "Because <drug>lithium</drug> may enhance the serotonergic effects of <drug>escitalopram</drug>, caution should be exercised when LEXAPRO and lithium are coadministered.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "pimozide",
    "entity2": "citalopram",
    "text": "Pimozide and Celexa - In a controlled study, a single dose of <drug>pimozide</drug> 2 mg co-administered with racemic <drug>citalopram</drug> 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "sumatriptan",
    "entity2": "fluoxetine",
    "text": "If concomitant treatment with <drug>sumatriptan</drug> and an SSRI (e.g., <drug>fluoxetine</drug>, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "sumatriptan",
    "entity2": "fluvoxamine",
    "text": "If concomitant treatment with <drug>sumatriptan</drug> and an SSRI (e.g., fluoxetine, <drug>fluvoxamine</drug>, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "sumatriptan",
    "entity2": "paroxetine",
    "text": "If concomitant treatment with <drug>sumatriptan</drug> and an SSRI (e.g., fluoxetine, fluvoxamine, <drug>paroxetine</drug>, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "sumatriptan",
    "entity2": "sertraline",
    "text": "If concomitant treatment with <drug>sumatriptan</drug> and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, <drug>sertraline</drug>, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "sumatriptan",
    "entity2": "citalopram",
    "text": "If concomitant treatment with <drug>sumatriptan</drug> and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, <drug>citalopram</drug>, escitalopram) is clinically warranted, appropriate observation of the patient is advised.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "sumatriptan",
    "entity2": "escitalopram",
    "text": "If concomitant treatment with <drug>sumatriptan</drug> and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, <drug>escitalopram</drug>) is clinically warranted, appropriate observation of the patient is advised.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "carbamazepine",
    "entity2": "escitalopram",
    "text": "Although trough citalopram plasma levels were unaffected, given the enzyme-inducing properties of carbamazepine, the possibility that <drug>carbamazepine</drug> might increase the clearance of <drug>escitalopram</drug> should be considered if the two drugs are coadministered.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "citalopram",
    "entity2": "ketoconazole",
    "text": "Ketoconazole - Combined administration of racemic <drug>citalopram</drug> (40 mg) and <drug>ketoconazole</drug> (200 mg) decreased the Cmax and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "escitalopram",
    "entity2": "desipramine",
    "text": "However, there are limited in vivo data suggesting a modest CYP2D6 inhibitory effect for escitalopram, i.e., coadministration of <drug>escitalopram</drug> (20 mg/day for 21 days) with the tricyclic antidepressant <drug>desipramine</drug> (single dose of 50 mg), a substrate for CYP2D6, resulted in a 40% increase in Cmax and a 100% increase in AUC of desipramine.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "escitalopram",
    "entity2": "citalopram",
    "text": "Concomitant Administration with Racemic Citalopram Citalopram - Since <drug>escitalopram</drug> is the active isomer of racemic <drug>citalopram</drug> (Celexa), the two agents should not be coadministered.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "lorazepam",
    "entity2": "alcohol",
    "text": "Tablets: The benzodiazepines, including <drug>lorazepam</drug>, produce CNS-depressant effects when administered with such medications as barbiturates or <drug>alcohol</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Lorazepam",
    "entity2": "ethyl alcohol",
    "text": "Injection: <drug>Lorazepam</drug> injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with <drug>ethyl alcohol</drug>, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "scopolamine",
    "entity2": "lorazepam",
    "text": "Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When <drug>scopolamine</drug> is used concomitantly with injectable <drug>lorazepam</drug>, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "nelfinavir",
    "entity2": "didanosine",
    "text": "therefore, <drug>nelfinavir</drug> should be administered (with food) one hour after or more than two hours before <drug>didanosine</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "reserpine",
    "entity2": "beta-blocking",
    "text": "Catecholamine-depleting drugs (e.g., <drug>reserpine</drug>) may have an additive effect when given with <drug>beta-blocking</drug> agents.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Clozapine",
    "entity2": "alcohol",
    "text": "Given the primary CNS effects of <drug>Clozapine</drug>, caution is advised in using it concomitantly with other CNS-active drugs or <drug>alcohol</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Clozapine",
    "entity2": "atropine",
    "text": "<drug>Clozapine</drug> may potentiate the hypotensive effects of antihypertensive drugs and the anticholinergic effects of <drug>atropine</drug>-type drugs.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Phenytoin",
    "entity2": "Clozapine",
    "text": "<drug>Phenytoin</drug>, nicotine, and rifampin may decrease <drug>Clozapine</drug> plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "nicotine",
    "entity2": "Clozapine",
    "text": "Phenytoin, <drug>nicotine</drug>, and rifampin may decrease <drug>Clozapine</drug> plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "rifampin",
    "entity2": "Clozapine",
    "text": "Phenytoin, nicotine, and <drug>rifampin</drug> may decrease <drug>Clozapine</drug> plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Cimetidine",
    "entity2": "Clozapine",
    "text": "<drug>Cimetidine</drug>, caffeine, and erythromycin may increase plasma levels of <drug>Clozapine</drug>, potentially resulting in adverse effects.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "caffeine",
    "entity2": "Clozapine",
    "text": "Cimetidine, <drug>caffeine</drug>, and erythromycin may increase plasma levels of <drug>Clozapine</drug>, potentially resulting in adverse effects.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "erythromycin",
    "entity2": "Clozapine",
    "text": "Cimetidine, caffeine, and <drug>erythromycin</drug> may increase plasma levels of <drug>Clozapine</drug>, potentially resulting in adverse effects.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "Clozapine",
    "entity2": "carbamazepine",
    "text": "Although concomitant use of <drug>Clozapine</drug> and <drug>carbamazepine</drug> is not recommended, it should be noted that discontinuation of concomitant carbamazepine administration may result in an increase in Clozapine plasma levels.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "carbamazepine",
    "entity2": "Clozapine",
    "text": "Although concomitant use of Clozapine and carbamazepine is not recommended, it should be noted that discontinuation of concomitant <drug>carbamazepine</drug> administration may result in an increase in <drug>Clozapine</drug> plasma levels.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Paroxetine",
    "entity2": "clozapine",
    "text": "<drug>Paroxetine</drug> produced only minor changes in the levels of <drug>clozapine</drug> and its metabolites.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "clozapine",
    "entity2": "paroxetine",
    "text": "However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when <drug>clozapine</drug> was taken with <drug>paroxetine</drug>, fluoxetine, and sertraline.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "clozapine",
    "entity2": "fluoxetine",
    "text": "However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when <drug>clozapine</drug> was taken with paroxetine, <drug>fluoxetine</drug>, and sertraline.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "clozapine",
    "entity2": "sertraline",
    "text": "However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when <drug>clozapine</drug> was taken with paroxetine, fluoxetine, and <drug>sertraline</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "Clozapine",
    "entity2": "fluvoxamine",
    "text": "Therefore, such combined treatment should be approached with caution and patients should be monitored closely when <drug>Clozapine</drug> is combined with these drugs, particularly with <drug>fluvoxamine</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "clozapine",
    "entity2": "carbamazepine",
    "text": "Therefore, co-administration of <drug>clozapine</drug> with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, <drug>carbamazepine</drug>, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "clozapine",
    "entity2": "propafenone",
    "text": "Therefore, co-administration of <drug>clozapine</drug> with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., <drug>propafenone</drug>, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "clozapine",
    "entity2": "flecainide",
    "text": "Therefore, co-administration of <drug>clozapine</drug> with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, <drug>flecainide</drug> and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "clozapine",
    "entity2": "encainide",
    "text": "Therefore, co-administration of <drug>clozapine</drug> with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and <drug>encainide</drug>), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "clozapine",
    "entity2": "quinidine",
    "text": "Therefore, co-administration of <drug>clozapine</drug> with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., <drug>quinidine</drug>), should be approached with caution.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Edetate calcium disodium",
    "entity2": "zinc insulin",
    "text": "Steroids enhance the renal toxicity of edetate calcium disodium in animals. 7 <drug>Edetate calcium disodium</drug> interferes with the action of <drug>zinc insulin</drug> preparations by chelating the zinc. 7",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "ketoconazole",
    "entity2": "erlotinib",
    "text": "Co-treatment with the potent CYP3A4 inhibitor <drug>ketoconazole</drug> increases <drug>erlotinib</drug> AUC by 2/3.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "rifampicin",
    "entity2": "erlotinib",
    "text": "Pre-treatment with the CYP3A4 inducer <drug>rifampicin</drug> decreased <drug>erlotinib</drug> AUC by about 2/3.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "probenecid",
    "entity2": "penciclovir",
    "text": "Concurrent use with <drug>probenecid</drug> or other drugs significantly eliminated by active renal tubular secretion may result in increased plasma concentrations of <drug>penciclovir</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "ketoconazole",
    "entity2": "budesonide",
    "text": "Concomitant oral administration of <drug>ketoconazole</drug> (a known inhibitor of CYP3A4 activity in the liver and in the intestinal mucosa) caused an eight-fold increase of the systemic exposure to oral <drug>budesonide</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "ketoconazole",
    "entity2": "budesonide",
    "text": "If treatment with inhibitors of CYP3A4 activity (such as <drug>ketoconazole</drug>, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the <drug>budesonide</drug> dose should be considered.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "intraconazole",
    "entity2": "budesonide",
    "text": "If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, <drug>intraconazole</drug>, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the <drug>budesonide</drug> dose should be considered.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "ritonavir",
    "entity2": "budesonide",
    "text": "If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, <drug>ritonavir</drug>, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the <drug>budesonide</drug> dose should be considered.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "indinavir",
    "entity2": "budesonide",
    "text": "If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, <drug>indinavir</drug>, saquinavir, erythromycin, etc.) is indicated, reduction of the <drug>budesonide</drug> dose should be considered.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "saquinavir",
    "entity2": "budesonide",
    "text": "If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, <drug>saquinavir</drug>, erythromycin, etc.) is indicated, reduction of the <drug>budesonide</drug> dose should be considered.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "erythromycin",
    "entity2": "budesonide",
    "text": "If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, <drug>erythromycin</drug>, etc.) is indicated, reduction of the <drug>budesonide</drug> dose should be considered.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Grepafloxacin",
    "entity2": "caffeine",
    "text": "Caffeine Theobromine <drug>Grepafloxacin</drug>, like other quinolones, may inhibit the metabolism of <drug>caffeine</drug> and theobromine.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Grepafloxacin",
    "entity2": "theobromine",
    "text": "Caffeine Theobromine <drug>Grepafloxacin</drug>, like other quinolones, may inhibit the metabolism of caffeine and <drug>theobromine</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Grepafloxacin",
    "entity2": "theophylline",
    "text": "Theophylline: <drug>Grepafloxacin</drug> is a competitive inhibitor of the metabolism of <drug>theophylline</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "grepafloxacin",
    "entity2": "theophylline",
    "text": "Serum theophylline concentrations increase when <drug>grepafloxacin</drug> is initiated in a patient maintained on <drug>theophylline</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "theophylline",
    "entity2": "grepafloxacin",
    "text": "When initiating a multi-day course of grepafloxacin in a patient maintained on theophylline, the <drug>theophylline</drug> maintenance dose should be halved for the period of concurrent use of <drug>grepafloxacin</drug> and monitoring of serum theophylline concentrations should be initiated as a guide to further dosage adjustments.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "grepafloxacin",
    "entity2": "theophylline",
    "text": "Drugs Metabolized by Cytochrome P450 Enzymes The drug interaction study evaluating the effect of grepafloxacin on theophylline indicates that <drug>grepafloxacin</drug> inhibits <drug>theophylline</drug> metabolism, which is mediated by CYP1A2.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Dipyridamole",
    "entity2": "adenosine",
    "text": "Adenosine: <drug>Dipyridamole</drug> has been reported to increase the plasma levels and cardiovascular effects of <drug>adenosine</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "triacetyloleandomycin",
    "entity2": "ergotamine",
    "text": "The effects of ERGOMAR may be potentiated by <drug>triacetyloleandomycin</drug> which inhibits the metabolism of <drug>ergotamine</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "colestipol hydrochloride",
    "entity2": "propranolol",
    "text": "Repeated doses of <drug>colestipol hydrochloride</drug> given prior to a single dose of <drug>propranolol</drug> in human trials have been reported to decrease propranolol absorption.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "chlorothiazide",
    "entity2": "colestipol hydrochloride",
    "text": "Studies in humans show that the absorption of <drug>chlorothiazide</drug> as reflected in urinary excretion is markedly decreased even when administered one hour before <drug>colestipol hydrochloride</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "tetracycline",
    "entity2": "colestipol hydrochloride",
    "text": "The absorption of <drug>tetracycline</drug>, furosemide, penicillin G, hydrochlorothiazide, and gemfibrozil was significantly decreased when given simultaneously with <drug>colestipol hydrochloride</drug>;",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "furosemide",
    "entity2": "colestipol hydrochloride",
    "text": "The absorption of tetracycline, <drug>furosemide</drug>, penicillin G, hydrochlorothiazide, and gemfibrozil was significantly decreased when given simultaneously with <drug>colestipol hydrochloride</drug>;",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "penicillin G",
    "entity2": "colestipol hydrochloride",
    "text": "The absorption of tetracycline, furosemide, <drug>penicillin G</drug>, hydrochlorothiazide, and gemfibrozil was significantly decreased when given simultaneously with <drug>colestipol hydrochloride</drug>;",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "hydrochlorothiazide",
    "entity2": "colestipol hydrochloride",
    "text": "The absorption of tetracycline, furosemide, penicillin G, <drug>hydrochlorothiazide</drug>, and gemfibrozil was significantly decreased when given simultaneously with <drug>colestipol hydrochloride</drug>;",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "gemfibrozil",
    "entity2": "colestipol hydrochloride",
    "text": "The absorption of tetracycline, furosemide, penicillin G, hydrochlorothiazide, and <drug>gemfibrozil</drug> was significantly decreased when given simultaneously with <drug>colestipol hydrochloride</drug>;",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "colestipol hydrochloride",
    "entity2": "digoxin",
    "text": "Particular caution should be observed with digitalis preparations since there are conflicting results for the effect of <drug>colestipol hydrochloride</drug> on the availability of <drug>digoxin</drug> and digitoxin.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "colestipol hydrochloride",
    "entity2": "digitoxin",
    "text": "Particular caution should be observed with digitalis preparations since there are conflicting results for the effect of <drug>colestipol hydrochloride</drug> on the availability of digoxin and <drug>digitoxin</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "irbesartan",
    "entity2": "aliskiren",
    "text": "Co-administration of <drug>irbesartan</drug> reduced <drug>aliskiren</drug> Cmax up to 50% after multiple dosing.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "atorvastatin",
    "entity2": "aliskiren",
    "text": "Co-administration of <drug>atorvastatin</drug> resulted in about a 50% increase in <drug>aliskiren</drug> Cmax and AUC after multiple dosing.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "ketoconazole",
    "entity2": "aliskiren",
    "text": "Ketoconazole: Co-administration of 200 mg twice-daily <drug>ketoconazole</drug> with <drug>aliskiren</drug> resulted in an approximate 80% increase in plasma levels of aliskiren.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "aliskiren",
    "entity2": "furosemide",
    "text": "Furosemide: When <drug>aliskiren</drug> was co-administered with <drug>furosemide</drug>, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "diflunisal",
    "entity2": "indomethacin",
    "text": "In normal volunteers receiving indomethacin, the administration of <drug>diflunisal</drug> decreased the renal clearance and significantly increased the plasma levels of <drug>indomethacin</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "atropine",
    "entity2": "pralidoxime",
    "text": "When <drug>atropine</drug> and <drug>pralidoxime</drug> are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "pralidoxime",
    "entity2": "atropine",
    "text": "When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because <drug>pralidoxime</drug> may potentiate the effect of <drug>atropine</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "atropine",
    "entity2": "pralidoxime",
    "text": "The following precautions should be kept in mind in the treatment of anticholinesterase poisoning although they do not bear directly on the use of <drug>atropine</drug> and <drug>pralidoxime</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "erythromycin",
    "entity2": "loratadine",
    "text": "Plasma concentrations (AUC 0-24 hrs) of <drug>erythromycin</drug> decreased 15% with coadministration of <drug>loratadine</drug> relative to that observed with erythromycin alone.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "phenytoin",
    "entity2": "calcitriol",
    "text": "Phenytoin/Phenobarbital: The coadministration of <drug>phenytoin</drug> or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of <drug>calcitriol</drug>/ergocalcitriol by accelerating metabolism.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "phenobarbital",
    "entity2": "calcitriol",
    "text": "Phenytoin/Phenobarbital: The coadministration of phenytoin or <drug>phenobarbital</drug> will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of <drug>calcitriol</drug>/ergocalcitriol by accelerating metabolism.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "amphotericin B",
    "entity2": "hydrocortisone",
    "text": "In addition, there have been cases reported in which concomitant use of <drug>amphotericin B</drug> and <drug>hydrocortisone</drug> was followed by cardiac enlargement and congestive heart failure.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "ketoconazole",
    "entity2": "corticosteroid",
    "text": "In addition, <drug>ketoconazole</drug> alone can inhibit adrenal <drug>corticosteroid</drug> synthesis and may cause adrenal insufficiency during corticosteroid withdrawal.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "phenytoin",
    "entity2": "dexamethasone",
    "text": "Phenytoin: In post-marketing experience, there have been reports of both increases and decreases in <drug>phenytoin</drug> levels with <drug>dexamethasone</drug> co-administration, leading to alterations in seizure control.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "valdecoxib",
    "entity2": "phenytoin",
    "text": "Anticonvulsants (Phenytoin): Steady state plasma exposure (AUC) of <drug>valdecoxib</drug> (40 mg BID for 12 days) was decreased by 27% when co-administered with multiple doses (300 mg QD for 12 days) of <drug>phenytoin</drug> (a CYP 3A4 inducer).",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "valdecoxib",
    "entity2": "phenytoin",
    "text": "Patients already stabilized on <drug>valdecoxib</drug> should be closely monitored for loss of symptom control with <drug>phenytoin</drug> coadministration.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "valdecoxib",
    "entity2": "dextromethorphan",
    "text": "Coadministration with <drug>valdecoxib</drug> (40 mg BID for 7 days) resulted in a significant increase in <drug>dextromethorphan</drug> plasma levels suggesting that, at these doses, valdecoxib is a weak inhibitor of 2D6.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "dextromethorphan",
    "entity2": "valdecoxib",
    "text": "Even so <drug>dextromethorphan</drug> plasma concentrations in the presence of high doses of <drug>valdecoxib</drug> were almost 5-fold lower than those seen in CYP 2D6 poor metabolizers suggesting that dose adjustment is not necessary.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Valdecoxib",
    "entity2": "lithium",
    "text": "Lithium: <drug>Valdecoxib</drug> 40 mg BID for 7 days produced significant decreases in <drug>lithium</drug> serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to lithium alone.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Valdecoxib",
    "entity2": "R-warfarin",
    "text": "<drug>Valdecoxib</drug> caused a statistically significant increase in plasma exposures of <drug>R-warfarin</drug> and S-warfarin (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of warfarin.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Valdecoxib",
    "entity2": "S-warfarin",
    "text": "<drug>Valdecoxib</drug> caused a statistically significant increase in plasma exposures of R-warfarin and <drug>S-warfarin</drug> (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of warfarin.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Valdecoxib",
    "entity2": "warfarin",
    "text": "<drug>Valdecoxib</drug> caused a statistically significant increase in plasma exposures of R-warfarin and S-warfarin (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of <drug>warfarin</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "valdecoxib",
    "entity2": "ketoconazole",
    "text": "Concomitant single dose administration of <drug>valdecoxib</drug> 20 mg with multiple doses of <drug>ketoconazole</drug> and fluconazole produced a significant increase in exposure of valdecoxib.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "valdecoxib",
    "entity2": "fluconazole",
    "text": "Concomitant single dose administration of <drug>valdecoxib</drug> 20 mg with multiple doses of ketoconazole and <drug>fluconazole</drug> produced a significant increase in exposure of valdecoxib.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "valdecoxib",
    "entity2": "fluconazole",
    "text": "Plasma exposure (AUC) to <drug>valdecoxib</drug> was increased 62% when coadministered with <drug>fluconazole</drug> and 38% when coadministered with ketoconazole.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "valdecoxib",
    "entity2": "ketoconazole",
    "text": "Plasma exposure (AUC) to <drug>valdecoxib</drug> was increased 62% when coadministered with fluconazole and 38% when coadministered with <drug>ketoconazole</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "valdecoxib",
    "entity2": "glyburide",
    "text": "Coadministration of <drug>valdecoxib</drug> (40 mg BID (day 1) and 40 mg QD (days 2-7)) with <drug>glyburide</drug> (10 mg glyburide BID) resulted in 21% increase in glyburide AUC0-12 and a 16% increase in glyburide Cmax leading to a 16% decrease in glucose AUC0-24.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "glyburide",
    "entity2": "valdecoxib",
    "text": "Because changes in glucose concentrations with valdecoxib coadministration were within the normal variability and individual glucose concentrations were above or near 70 mg/dL, dose adjustment for <drug>glyburide</drug> (5 mg QD and 10 mg BID) with <drug>valdecoxib</drug> coadministration (up to 40 mg QD) is not indicated.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "valdecoxib",
    "entity2": "omeprazole",
    "text": "Coadministration with <drug>valdecoxib</drug> increased exposure of <drug>omeprazole</drug> (AUC) by 46%.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "diazepam",
    "entity2": "valdecoxib",
    "text": "Plasma exposure of <drug>diazepam</drug> (10 mg BID) was increased by 28% following administration of <drug>valdecoxib</drug> (40 mg BID) for 12 days, while plasma exposure of valdecoxib (40 mg BID) was not substantially increased following administration of diazepam (10 mg BID) for 12 days.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "valdecoxib",
    "entity2": "diazepam",
    "text": "Although the magnitude of changes in diazepam plasma exposure when coadministered with <drug>valdecoxib</drug> were not sufficient to warrant dosage adjustments, patients may experience enhanced sedative side effects caused by increased exposure of <drug>diazepam</drug> under this circumstance.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "dapsone",
    "entity2": "pyrimethamine",
    "text": "With oral <drug>dapsone</drug> treatment, folic acid antagonists such as <drug>pyrimethamine</drug> have been noted to possibly increase the likelihood of hematologic reactions",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "cyclosporin A",
    "entity2": "etoposide",
    "text": "High-dose <drug>cyclosporin A</drug> resulting in concentrations above 2000 ng/mL administered with oral <drug>etoposide</drug> has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of etoposide compared to etoposide alone.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Oxytocin",
    "entity2": "dinoprost",
    "text": "<drug>Oxytocin</drug> or other oxytocics (concurrent use with <drug>dinoprost</drug> may result in uterine hypertonus, possibly causing uterine rupture or cervical laceration, especially in the absence of adequate cervical dilatation;",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "fluconazole",
    "entity2": "glipizide",
    "text": "The effect of concomitant administration of <drug>fluconazole</drug> and <drug>glipizide</drug> has been demonstrated in a placebo-controlled crossover study in normal volunteers.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "glipizide",
    "entity2": "fluconazole",
    "text": "The mean percentage increase in the <drug>glipizide</drug> AUC after <drug>fluconazole</drug> administration was 56.9% (range: 35 to 81).",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "ethambutol",
    "entity2": "aluminum hydroxide",
    "text": "The results of a study of coadministration of <drug>ethambutol</drug> (50 mg/kg) with an <drug>aluminum hydroxide</drug> containing antacid to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ethambutol of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these antacid products.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "ethambutol",
    "entity2": "aluminum hydroxide",
    "text": "It is recommended to avoid concurrent administration of <drug>ethambutol</drug> with <drug>aluminum hydroxide</drug> containing antacids for at least 4 hours following ethambutol administration.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Lofexidine",
    "entity2": "alcohol",
    "text": "- <drug>Lofexidine</drug> may enhance the CNS depressive effects of <drug>alcohol</drug>, barbiturates and other sedatives",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Dimenhydrinate",
    "entity2": "apomorphine",
    "text": "<drug>Dimenhydrinate</drug> may decrease emetic response to <drug>apomorphine</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Hydrocodone",
    "entity2": "gabapentin",
    "text": "<drug>Hydrocodone</drug> increases <drug>gabapentin</drug> AUC values by 14%.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "cimetidine",
    "entity2": "gabapentin",
    "text": "Cimetidine: In the presence of <drug>cimetidine</drug> at 300 mg QID (N=12) the mean apparent oral clearance of <drug>gabapentin</drug> fell by 14% and creatinine clearance fell by 10%.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "cimetidine",
    "entity2": "gabapentin",
    "text": "Thus <drug>cimetidine</drug> appeared to alter the renal excretion of both <drug>gabapentin</drug> and creatinine, an endogenous marker of renal function.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "gabapentin",
    "entity2": "cimetidine",
    "text": "This small decrease in excretion of <drug>gabapentin</drug> by <drug>cimetidine</drug> is not expected to be of clinical importance.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "norethindrone",
    "entity2": "gabapentin",
    "text": "The Cmax of <drug>norethindrone</drug> was 13% higher when it was coadministered with <drug>gabapentin</drug>;",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "amitriptyline HCl",
    "entity2": "anticholinergic",
    "text": "Hyperpyrexia has been reported when <drug>amitriptyline HCl</drug> is administered with <drug>anticholinergic</drug> agents or with neuroleptic drugs, particularly during hot weather.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "tricyclic antidepressants",
    "entity2": "anticholinergic",
    "text": "Paralytic ileus may occur in patients taking <drug>tricyclic antidepressants</drug> in combination with <drug>anticholinergic</drug>-type drugs.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Cimetidine",
    "entity2": "tricyclic antidepressants",
    "text": "<drug>Cimetidine</drug> is reported to reduce hepatic metabolism of certain <drug>tricyclic antidepressants</drug>, thereby delaying elimination and increasing steady-state concentrations of these drugs.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "tricyclic antidepressants",
    "entity2": "cimetidine",
    "text": "Clinically significant effects have been reported with the <drug>tricyclic antidepressants</drug> when used concomitantly with <drug>cimetidine</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "tricyclic antidepressants",
    "entity2": "cimetidine",
    "text": "Increases in plasma levels of <drug>tricyclic antidepressants</drug>, and in the frequency and severity of side effects, particularly anticholinergic, have been reported when <drug>cimetidine</drug> was added to the drug regimen.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "tricyclic antidepressants",
    "entity2": "cimetidine",
    "text": "Discontinuation of cimetidine in well-controlled patients receiving <drug>tricyclic antidepressants</drug> and <drug>cimetidine</drug> may decrease the plasma levels and efficacy of the antidepressants.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "ethchlorvynol",
    "entity2": "amitriptyline HCl",
    "text": "Transient delirium has been reported in patients who were treated with one gram of <drug>ethchlorvynol</drug> and 75 - 150 mg of <drug>amitriptyline HCl</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "ketoconazole",
    "entity2": "gefitinib",
    "text": "Substances that are potent inhibitors of CYP3A4 activity (eg, <drug>ketoconazole</drug> and itraconazole) decrease <drug>gefitinib</drug> metabolism and increase gefitinib plasma concentrations.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "ketoconazole",
    "entity2": "gefitinib",
    "text": "Substances that are potent inhibitors of CYP3A4 activity (eg, <drug>ketoconazole</drug> and itraconazole) decrease gefitinib metabolism and increase <drug>gefitinib</drug> plasma concentrations.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "itraconazole",
    "entity2": "gefitinib",
    "text": "Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and <drug>itraconazole</drug>) decrease <drug>gefitinib</drug> metabolism and increase gefitinib plasma concentrations.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "itraconazole",
    "entity2": "gefitinib",
    "text": "Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and <drug>itraconazole</drug>) decrease gefitinib metabolism and increase <drug>gefitinib</drug> plasma concentrations.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "clorazepate dipotassium",
    "entity2": "hexobarbital",
    "text": "Animal experience indicates that <drug>clorazepate dipotassium</drug> prolongs the sleeping time after <drug>hexobarbital</drug> or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase inhibition.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "clorazepate dipotassium",
    "entity2": "ethyl alcohol",
    "text": "Animal experience indicates that <drug>clorazepate dipotassium</drug> prolongs the sleeping time after hexobarbital or after <drug>ethyl alcohol</drug>, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase inhibition.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "clorazepate dipotassium",
    "entity2": "chlorpromazine",
    "text": "Animal experience indicates that <drug>clorazepate dipotassium</drug> prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of <drug>chlorpromazine</drug>, but does not exhibit monoamine oxidase inhibition.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "ketoconazole",
    "entity2": "lapatinib",
    "text": "Ketoconazole: In healthy subjects receiving <drug>ketoconazole</drug>, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to <drug>lapatinib</drug> was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "carbamazepine",
    "entity2": "lapatinib",
    "text": "Carbamazepine: In healthy subjects receiving the CYP3A4 inducer, <drug>carbamazepine</drug>, at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) to <drug>lapatinib</drug> was decreased approximately 72%.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "etanercept",
    "entity2": "anakinra",
    "text": "Concurrent administration of <drug>etanercept</drug> (another TNF -blocking agent) and <drug>anakinra</drug> (an interleukin-1 antagonist) has been associated with an increased risk of serious infections, and increased risk of neutropenia and no additional benefit compared to these medicinal products alone.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "carbamazepine",
    "entity2": "ethinyl estradiol",
    "text": "Anticonvulsants (<drug>carbamazepine</drug>, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of <drug>ethinyl estradiol</drug> and/or some progestins, leading to possible decrease in contraceptive effectiveness.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "felbamate",
    "entity2": "ethinyl estradiol",
    "text": "Anticonvulsants (carbamazepine, <drug>felbamate</drug>, phenobarbital, phenytoin, topiramate): Increase the metabolism of <drug>ethinyl estradiol</drug> and/or some progestins, leading to possible decrease in contraceptive effectiveness.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "phenobarbital",
    "entity2": "ethinyl estradiol",
    "text": "Anticonvulsants (carbamazepine, felbamate, <drug>phenobarbital</drug>, phenytoin, topiramate): Increase the metabolism of <drug>ethinyl estradiol</drug> and/or some progestins, leading to possible decrease in contraceptive effectiveness.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "phenytoin",
    "entity2": "ethinyl estradiol",
    "text": "Anticonvulsants (carbamazepine, felbamate, phenobarbital, <drug>phenytoin</drug>, topiramate): Increase the metabolism of <drug>ethinyl estradiol</drug> and/or some progestins, leading to possible decrease in contraceptive effectiveness.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "topiramate",
    "entity2": "ethinyl estradiol",
    "text": "Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, <drug>topiramate</drug>): Increase the metabolism of <drug>ethinyl estradiol</drug> and/or some progestins, leading to possible decrease in contraceptive effectiveness.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Atorvastatin",
    "entity2": "norethindrone",
    "text": "Atorvastatin: <drug>Atorvastatin</drug> increases the AUC for <drug>norethindrone</drug> and ethinyl estradiol.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Atorvastatin",
    "entity2": "ethinyl estradiol",
    "text": "Atorvastatin: <drug>Atorvastatin</drug> increases the AUC for norethindrone and <drug>ethinyl estradiol</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Ethinyl estradiol",
    "entity2": "prednisolone",
    "text": "Prednisolone: <drug>Ethinyl estradiol</drug> may inhibit the metabolism of <drug>prednisolone</drug>, leading to increased plasma concentrations.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Rifampin",
    "entity2": "ethinyl estradiol",
    "text": "Rifampin: <drug>Rifampin</drug> increases the metabolism of <drug>ethinyl estradiol</drug> and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Rifampin",
    "entity2": "norethindrone",
    "text": "Rifampin: <drug>Rifampin</drug> increases the metabolism of ethinyl estradiol and some progestins (<drug>norethindrone</drug>) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Ethinyl estradiol",
    "entity2": "theophylline",
    "text": "Theophylline: <drug>Ethinyl estradiol</drug> may inhibit the metabolism of <drug>theophylline</drug>, leading to increased plasma concentrations.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "digoxin",
    "entity2": "conivaptan",
    "text": "Digoxin: Coadministration of <drug>digoxin</drug>, a P-glycoprotein substrate, with oral <drug>conivaptan</drug> resulted in a reduction in clearance and an increase in digoxin Cmax and AUC values.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "risperidone",
    "entity2": "levodopa",
    "text": "Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, <drug>risperidone</drug>) and isoniazid may reduce the therapeutic effects of <drug>levodopa</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "isoniazid",
    "entity2": "levodopa",
    "text": "Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone) and <drug>isoniazid</drug> may reduce the therapeutic effects of <drug>levodopa</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "levodopa",
    "entity2": "phenytoin",
    "text": "In addition, the beneficial effects of <drug>levodopa</drug> in Parkinsons disease have been reported to be reversed by <drug>phenytoin</drug> and papaverine.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "levodopa",
    "entity2": "papaverine",
    "text": "In addition, the beneficial effects of <drug>levodopa</drug> in Parkinsons disease have been reported to be reversed by phenytoin and <drug>papaverine</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Iron",
    "entity2": "carbidopa",
    "text": "<drug>Iron</drug> salts may reduce the bioavailability of <drug>carbidopa</drug> and levodopa.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Iron",
    "entity2": "levodopa",
    "text": "<drug>Iron</drug> salts may reduce the bioavailability of carbidopa and <drug>levodopa</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "metoclopramide",
    "entity2": "levodopa",
    "text": "Although <drug>metoclopramide</drug> may increase the bioavailability of <drug>levodopa</drug> by increasing gastric emptying, metoclopramide may also adversely affect disease control by its dopamine receptor antagonistic properties.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Folic acid",
    "entity2": "phenobarbital",
    "text": "<drug>Folic acid</drug> in large amounts may counteract the antiepileptic effect of <drug>phenobarbital</drug>, phenytoin and primidone, and increase the frequency of seizures in susceptible pediatric patients.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Folic acid",
    "entity2": "phenytoin",
    "text": "<drug>Folic acid</drug> in large amounts may counteract the antiepileptic effect of phenobarbital, <drug>phenytoin</drug> and primidone, and increase the frequency of seizures in susceptible pediatric patients.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Folic acid",
    "entity2": "primidone",
    "text": "<drug>Folic acid</drug> in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and <drug>primidone</drug>, and increase the frequency of seizures in susceptible pediatric patients.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "leucovorin",
    "entity2": "methotrexate",
    "text": "However, high doses of <drug>leucovorin</drug> may reduce the efficacy of intrathecally administered <drug>methotrexate</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Leucovorin",
    "entity2": "5-fluorouracil",
    "text": "<drug>Leucovorin</drug> may enhance the toxicity of <drug>5-fluorouracil</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Cimetidine",
    "entity2": "nicardipine HCl",
    "text": "Cimetidine: <drug>Cimetidine</drug> increases <drug>nicardipine HCl</drug> plasma levels.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "digoxin",
    "entity2": "nicardipine HCl",
    "text": "Nicardipine HCl usually does not alter the plasma levels of digoxin, however, serum <drug>digoxin</drug> levels should be evaluated after concomitant therapy with <drug>nicardipine HCl</drug> is initiated.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "cyclosporine",
    "entity2": "nicardipine",
    "text": "Plasma concentrations of <drug>cyclosporine</drug> should therefore be closely monitored, and its dosage reduced accordingly, in patients treated with <drug>nicardipine</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Cimetidine",
    "entity2": "epirubicin",
    "text": "<drug>Cimetidine</drug> increased the AUC of <drug>epirubicin</drug> by 50%.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "Epinephrine",
    "entity2": "isoproterenol",
    "text": "<drug>Epinephrine</drug> should not be administered concomitantly with other sympathomimetic drugs (such as <drug>isoproterenol</drug>) because of possible additive effects and increased toxicity.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "epinephrine",
    "entity2": "cyclopropane",
    "text": "Administration of <drug>epinephrine</drug> to patients receiving <drug>cyclopropane</drug> or halogenated hydrocarbon general anesthetics such as halothane which sensitize the myocardium, may induce cardiac arrhythmia..",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "epinephrine",
    "entity2": "halothane",
    "text": "Administration of <drug>epinephrine</drug> to patients receiving cyclopropane or halogenated hydrocarbon general anesthetics such as <drug>halothane</drug> which sensitize the myocardium, may induce cardiac arrhythmia..",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Epinephrine",
    "entity2": "guanethidine",
    "text": "<drug>Epinephrine</drug> may antagonize the neuron blockade produced by <drug>guanethidine</drug> resulting in decreased antihypertensive effect and requiring increased dosage of the latter.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "dolasetron",
    "entity2": "cimetidine",
    "text": "Blood levels of hydrodolasetron increased 24% when <drug>dolasetron</drug> was coadministered with <drug>cimetidine</drug> (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "dolasetron",
    "entity2": "rifampin",
    "text": "Blood levels of hydrodolasetron increased 24% when <drug>dolasetron</drug> was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of <drug>rifampin</drug> (potent inducer of cytochrome P-450) for 7 days.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "dolasetron mesylate",
    "entity2": "atenolol",
    "text": "Clearance of hydrodolasetron decreased by about 27% when <drug>dolasetron mesylate</drug> was administered intravenously concomitantly with <drug>atenolol</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Zalcitabine",
    "entity2": "ZDV",
    "text": "<drug>Zalcitabine</drug> also has no significant effect on the intracellular phosphorylation of <drug>ZDV</drug>, as shown in vitro in peripheral blood mononuclear cells or in two other cell lines (U937 and Molt-4).",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "lamivudine",
    "entity2": "zalcitabine",
    "text": "Lamivudine: In vitro studies in peripheral blood mononuclear cells, U937 and Molt-4 cells revealed that <drug>lamivudine</drug> significantly inhibited <drug>zalcitabine</drug> phosphorylation in a dose dependent manner.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Zalcitabine",
    "entity2": "lamivudine",
    "text": "<drug>Zalcitabine</drug> inhibited <drug>lamivudine</drug> phosphorylation at high concentration ratios (10 and 100);",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "zalcitabine",
    "entity2": "lamivudine",
    "text": "These in vitro studies suggest that concomitant administration of <drug>zalcitabine</drug> and <drug>lamivudine</drug> in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine, which may lead to a decreased antiretroviral effect of zalcitabine.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "zalcitabine",
    "entity2": "lamivudine",
    "text": "Concomitant use of <drug>zalcitabine</drug> and <drug>lamivudine</drug> is not recommended.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "HIVID",
    "entity2": "didanosine",
    "text": "Concomitant use of <drug>HIVID</drug> with <drug>didanosine</drug> is not recommended.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "pentamidine",
    "entity2": "HIVID",
    "text": "Death due to fulminant pancreatitis possibly related to intravenous <drug>pentamidine</drug> and <drug>HIVID</drug> has been reported.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "pentamidine",
    "entity2": "HIVID",
    "text": "If intravenous <drug>pentamidine</drug> is required to treat Pneumocystis carinii pneumonia, treatment with <drug>HIVID</drug> should be interrupted.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "amphotericin",
    "entity2": "HIVID",
    "text": "Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as <drug>amphotericin</drug>, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other <drug>HIVID</drug>-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "amphotericin",
    "entity2": "zalcitabine",
    "text": "Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as <drug>amphotericin</drug>, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of <drug>zalcitabine</drug> (thereby raising systemic exposure).",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "foscarnet",
    "entity2": "HIVID",
    "text": "Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, <drug>foscarnet</drug>, and aminoglycosides may increase the risk of developing peripheral neuropathy or other <drug>HIVID</drug>-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "foscarnet",
    "entity2": "zalcitabine",
    "text": "Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, <drug>foscarnet</drug>, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of <drug>zalcitabine</drug> (thereby raising systemic exposure).",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "probenecid",
    "entity2": "zalcitabine",
    "text": "Probenecid or Cimetidine: Concomitant administration of <drug>probenecid</drug> or cimetidine decreases the elimination of <drug>zalcitabine</drug>, most likely by inhibition of renal tubular secretion of zalcitabine.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "cimetidine",
    "entity2": "zalcitabine",
    "text": "Probenecid or Cimetidine: Concomitant administration of probenecid or <drug>cimetidine</drug> decreases the elimination of <drug>zalcitabine</drug>, most likely by inhibition of renal tubular secretion of zalcitabine.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "zalcitabine",
    "entity2": "magnesium",
    "text": "The clinical significance of this reduction is not known, hence <drug>zalcitabine</drug> is not recommended to be ingested simultaneously with <drug>magnesium</drug>/aluminum-containing antacids.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "zalcitabine",
    "entity2": "aluminum",
    "text": "The clinical significance of this reduction is not known, hence <drug>zalcitabine</drug> is not recommended to be ingested simultaneously with magnesium/<drug>aluminum</drug>-containing antacids.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "zalcitabine",
    "entity2": "metoclopramide",
    "text": "Metoclopramide: Bioavailability is mildly reduced (approximately 10%) when <drug>zalcitabine</drug> and <drug>metoclopramide</drug> are coadministered.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Doxorubicin",
    "entity2": "zalcitabine",
    "text": "Doxorubicin: <drug>Doxorubicin</drug> caused a decrease in <drug>zalcitabine</drug> phosphorylation ( 50% inhibition of total phosphate formation) in U937/Molt 4 cells.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Aprepitant",
    "entity2": "S(-) warfarin",
    "text": "<drug>Aprepitant</drug> has been shown to induce the metabolism of <drug>S(-) warfarin</drug> and tolbutamide, which are metabolized through CYP2C9.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Aprepitant",
    "entity2": "tolbutamide",
    "text": "<drug>Aprepitant</drug> has been shown to induce the metabolism of S(-) warfarin and <drug>tolbutamide</drug>, which are metabolized through CYP2C9.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Aprepitant",
    "entity2": "phenytoin",
    "text": "Coadministration of <drug>Aprepitant</drug> with these drugs or other drugs that are known to be metabolized by CYP2C9, such as <drug>phenytoin</drug>, may result in lower plasma concentrations of these drugs.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Aprepitant",
    "entity2": "dexamethasone",
    "text": "Corticosteroids: Dexamethasone: <drug>Aprepitant</drug>, when given as a regimen of 125mg with <drug>dexamethasone</drug> coadministered orally as 20 mg on Day 1, and Aprepitant when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Aprepitant",
    "entity2": "dexamethasone",
    "text": "Corticosteroids: Dexamethasone: Aprepitant, when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and <drug>Aprepitant</drug> when given as 80 mg/day with <drug>dexamethasone</drug> coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "dexamethasone",
    "entity2": "Aprepitant",
    "text": "The oral <drug>dexamethasone</drug> doses should be reduced by approximately 50% when coadministered with <drug>Aprepitant</drug>, to achieve exposures of dexamethasone similar to those obtained when it is given without Aprepitant.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "dexamethasone",
    "entity2": "Aprepitant",
    "text": "The daily dose of <drug>dexamethasone</drug> administered in clinical studies with <drug>Aprepitant</drug> reflects an approximate 50% reduction of the dose of dexamethasone.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Aprepitant",
    "entity2": "methylprednisolone",
    "text": "<drug>Aprepitant</drug>, when given as a regimen of 125 mg on Day 1 and 80 mg/day on Days 2 and 3, increased the AUC of <drug>methylprednisolone</drug>, a CYP3A4 substrate, by 1.34-fold on Day 1 and by 2.5-fold on Day 3, when methylprednisolone was coadministered intravenously as 125 mg on Day 1 and orally as 40 mg on Days 2 and 3.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "methylprednisolone",
    "entity2": "Aprepitant",
    "text": "The IV <drug>methylprednisolone</drug> dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with <drug>Aprepitant</drug> to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "methylprednisolone",
    "entity2": "Aprepitant",
    "text": "The IV methylprednisolone dose should be reduced by approximately 25%, and the oral <drug>methylprednisolone</drug> dose should be reduced by approximately 50% when coadministered with <drug>Aprepitant</drug> to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "S(-)warfarin",
    "entity2": "Aprepitant",
    "text": "Although there was no effect of Aprepitant on the plasma AUC of R(+) or S(-) warfarin determined on Day 3, there was a 34% decrease in <drug>S(-)warfarin</drug> (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with <drug>Aprepitant</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "warfarin",
    "entity2": "Aprepitant",
    "text": "In patients on chronic <drug>warfarin</drug> therapy, the prothrombin time (INR) should be closely monitored in the 2-week period, particularly at 7 to 10 days, following initiation of the 3-day regimen of <drug>Aprepitant</drug> with each chemotherapy cycle.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "tolbutamide",
    "entity2": "Aprepitant",
    "text": "Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of <drug>tolbutamide</drug> 500 mg was admini,stered orally prior to the administration of the 3-day regimen of <drug>Aprepitant</drug> and on Days 4,8, and 15.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Aprepitant",
    "entity2": "ethinyl estradiol",
    "text": "Oral contraceptives: <drug>Aprepitant</drug>, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of <drug>ethinyl estradiol</drug> and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Aprepitant",
    "entity2": "norethindrone",
    "text": "Oral contraceptives: <drug>Aprepitant</drug>, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of <drug>norethindrone</drug>, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Aprepitant",
    "entity2": "midazolam",
    "text": "Midazolam: <drug>Aprepitant</drug> increased the AUC of <drug>midazolam</drug>, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadministered on Day 1 and Day 5 of a regimen of Aprepitant 125 mg on Day 1 and 80 mg/day on Days 2 through 5.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "midazolam",
    "entity2": "Aprepitant",
    "text": "The potential effects of increased plasma concentrations of <drug>midazolam</drug> or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with <drug>Aprepitant</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "alprazolam",
    "entity2": "Aprepitant",
    "text": "The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (<drug>alprazolam</drug>, triazolam) should be considered when coadministering these agents with <drug>Aprepitant</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "triazolam",
    "entity2": "Aprepitant",
    "text": "The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, <drug>triazolam</drug>) should be considered when coadministering these agents with <drug>Aprepitant</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Aprepitant",
    "entity2": "midazolam",
    "text": "<drug>Aprepitant</drug> increased the AUC of <drug>midazolam</drug> by 25% on Day 4 and decreased the AUC of midazolam by 19% on Day 8 relative to the dosing of Aprepitant on Days 1 through 3.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Aprepitant",
    "entity2": "midazolam",
    "text": "<drug>Aprepitant</drug> increased the AUC of midazolam by 25% on Day 4 and decreased the AUC of <drug>midazolam</drug> by 19% on Day 8 relative to the dosing of Aprepitant on Days 1 through 3.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "Aprepitant",
    "entity2": "ketoconazole",
    "text": "Consequently, concomitant administration of <drug>Aprepitant</drug> with strong CYP3A4 inhibitors (e.g., <drug>ketoconazole</drug>, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "Aprepitant",
    "entity2": "itraconazole",
    "text": "Consequently, concomitant administration of <drug>Aprepitant</drug> with strong CYP3A4 inhibitors (e.g., ketoconazole, <drug>itraconazole</drug>, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "Aprepitant",
    "entity2": "nefazodone",
    "text": "Consequently, concomitant administration of <drug>Aprepitant</drug> with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, <drug>nefazodone</drug>, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "Aprepitant",
    "entity2": "troleandomycin",
    "text": "Consequently, concomitant administration of <drug>Aprepitant</drug> with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, <drug>troleandomycin</drug>, clarithromycin, ritonavir, nelfinavir) should be approached with caution.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "Aprepitant",
    "entity2": "clarithromycin",
    "text": "Consequently, concomitant administration of <drug>Aprepitant</drug> with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, <drug>clarithromycin</drug>, ritonavir, nelfinavir) should be approached with caution.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "Aprepitant",
    "entity2": "ritonavir",
    "text": "Consequently, concomitant administration of <drug>Aprepitant</drug> with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, <drug>ritonavir</drug>, nelfinavir) should be approached with caution.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "Aprepitant",
    "entity2": "nelfinavir",
    "text": "Consequently, concomitant administration of <drug>Aprepitant</drug> with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, <drug>nelfinavir</drug>) should be approached with caution.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "diltiazem",
    "entity2": "aprepitant",
    "text": "Because moderate CYP3A4 inhibitors (e.g., <drug>diltiazem</drug>) result in 2-fold increase in plasma concentrations of <drug>aprepitant</drug>, concomitant administration should also be approached with caution.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Aprepitant",
    "entity2": "rifampin",
    "text": "therefore, coadministration of <drug>Aprepitant</drug> with drugs that strongly induce CYP3A4 activity (e.g., <drug>rifampin</drug>, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Aprepitant",
    "entity2": "phenytoin",
    "text": "therefore, coadministration of <drug>Aprepitant</drug> with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, <drug>phenytoin</drug>) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Aprepitant",
    "entity2": "aprepitant",
    "text": "therefore, coadministration of <drug>Aprepitant</drug> with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of <drug>aprepitant</drug> that may result in decreased efficacy of Aprepitant.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Aprepitant",
    "entity2": "ketoconazole",
    "text": "Ketoconazole: When a single 125-mg dose of <drug>Aprepitant</drug> was administered on Day5 of a 10-day regimen of 400 mg/day of <drug>ketoconazole</drug>, a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of aprepitant increased approximately 3-fold.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Aprepitant",
    "entity2": "rifampin",
    "text": "Rifampin: When a single 375-mg dose of <drug>Aprepitant</drug> was administered on Day9 of a 14-day regimen of 600 mg/day of <drug>rifampin</drug>, a strong CYP3A4 inducer, the AUC of aprepitant decreased approximately 11-fold and the mean terminal half-life decreased approximately 3-fold.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "aprepitant",
    "entity2": "diltiazem",
    "text": "Diltiazem: In patients with mild to moderate hypertension, administration of <drug>aprepitant</drug> once daily, as a tablet formulation comparable to 230 mg of the capsule formulation, with <drug>diltiazem</drug> 120 mg 3 times daily for 5 days, resulted in a 2-fold increase of aprepitant AUC and a simultaneous 1.7-fold increase of diltiazem AUC.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "aprepitant",
    "entity2": "paroxetine",
    "text": "Paroxetine: Coadministration of once daily doses of <drug>aprepitant</drug>, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with <drug>paroxetine</drug> 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both aprepitant and paroxetine.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Warfarin",
    "entity2": "cefixime",
    "text": "<drug>Warfarin</drug> and Anticoagulants: Increased prothrombin time, with or without clinical bleeding, has been reported when <drug>cefixime</drug> is administered concomitantly.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Cimetidine",
    "entity2": "dofetilide",
    "text": "<drug>Cimetidine</drug> at doses of 100 mg BID (OTC dose) resulted in a 13% increase in <drug>dofetilide</drug> plasma levels (500 mcg single dose).",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "verapamil",
    "entity2": "dofetilide",
    "text": "In an analysis of the supraventricular arrhythmia and DIAMOND patient populations, the concomitant administration of <drug>verapamil</drug> with <drug>dofetilide</drug> was associated with a higher occurrence of torsade de pointes.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "HCTZ",
    "entity2": "dofetilide",
    "text": "In patients receiving <drug>HCTZ</drug> alone, <drug>dofetilide</drug> AUC increased by 27% and Cmax by 21%.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "triamterene",
    "entity2": "dofetilide",
    "text": "In addition, drugs that are actively secreted via this route (e.g., <drug>triamterene</drug>, metformin and amiloride) should be co-administered with care as they might increase <drug>dofetilide</drug> levels.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "metformin",
    "entity2": "dofetilide",
    "text": "In addition, drugs that are actively secreted via this route (e.g., triamterene, <drug>metformin</drug> and amiloride) should be co-administered with care as they might increase <drug>dofetilide</drug> levels.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "amiloride",
    "entity2": "dofetilide",
    "text": "In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin and <drug>amiloride</drug>) should be co-administered with care as they might increase <drug>dofetilide</drug> levels.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "digoxin",
    "entity2": "dofetilide",
    "text": "In patients, the concomitant administration of <drug>digoxin</drug> with <drug>dofetilide</drug> was associated with a higher occurrence of torsade de pointes.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "diphenidol",
    "entity2": "apomorphine",
    "text": "apomorphine - prior ingestion of <drug>diphenidol</drug> may decrease the emetic response to <drug>apomorphine</drug> in the treatment of poisoning.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Bismuth subsalicylate",
    "entity2": "enoxacin",
    "text": "Bismuth: <drug>Bismuth subsalicylate</drug>, given concomitantly with <drug>enoxacin</drug> or 60 minutes following enoxacin administration, decreased enoxacin bioavailability by approximately 25%.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "enoxacin",
    "entity2": "bismuth subsalicylate",
    "text": "Thus, concomitant administration of <drug>enoxacin</drug> and <drug>bismuth subsalicylate</drug> should be avoided.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "enoxacin",
    "entity2": "caffeine",
    "text": "In a multiple-dose study, <drug>enoxacin</drug> caused a dose-related increase in the mean elimination half-life of <drug>caffeine</drug>, thereby decreasing the clearance of caffeine by up to 80% and leading to a five-fold increase in the AUC and the half-life of caffeine.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "caffeine",
    "entity2": "enoxacin",
    "text": "Trough plasma enoxacin levels were also 20% higher when <drug>caffeine</drug> and <drug>enoxacin</drug> were administered concomitantly.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "caffeine",
    "entity2": "enoxacin",
    "text": "Caffeine-related adverse effects have occurred in patients consuming <drug>caffeine</drug> while on therapy with <drug>enoxacin</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Enoxacin",
    "entity2": "digoxin",
    "text": "Digoxin: <drug>Enoxacin</drug> may raise serum <drug>digoxin</drug> levels in some individuals.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "enoxacin",
    "entity2": "digoxin",
    "text": "If signs and symptoms suggestive of digoxin toxicity occur when <drug>enoxacin</drug> and <drug>digoxin</drug> are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "enoxacin",
    "entity2": "fenbufen",
    "text": "Non-steroidal anti-inflammatory agents: Seizures have been reported in patients taking <drug>enoxacin</drug> concomitantly with the nonsteroidal anti-inflammatory drug <drug>fenbufen</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "aluminum hydroxide",
    "entity2": "enoxacin",
    "text": "Antacids containing <drug>aluminum hydroxide</drug> and magnesium hydroxide reduce the oral absorption of <drug>enoxacin</drug> by 75%.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "magnesium hydroxide",
    "entity2": "enoxacin",
    "text": "Antacids containing aluminum hydroxide and <drug>magnesium hydroxide</drug> reduce the oral absorption of <drug>enoxacin</drug> by 75%.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "enoxacin",
    "entity2": "ranitidine",
    "text": "The oral bioavailability of <drug>enoxacin</drug> is reduced by 60% with coadministration of <drug>ranitidine</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Enoxacin",
    "entity2": "theophylline",
    "text": "<drug>Enoxacin</drug> interferes with the metabolism of <drug>theophylline</drug> resulting in a 42% to 74% dose-related decrease in theophylline clearance and a subsequent 260% to 350% increase in serum theophylline levels.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "theophylline",
    "entity2": "enoxacin",
    "text": "Theophylline-related adverse effects have occurred in patients when <drug>theophylline</drug> and <drug>enoxacin</drug> were coadministered.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "enoxacin",
    "entity2": "R-warfarin",
    "text": "Warfarin: Quinolones, including <drug>enoxacin</drug>, decrease the clearance of <drug>R-warfarin</drug>, the less active isomer of racemic warfarin.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "warfarin",
    "entity2": "enoxacin",
    "text": "Nevertheless, the prothrombin time or other suitable coagulation test should be monitored when <drug>warfarin</drug> or its derivatives and <drug>enoxacin</drug> are given concomitantly.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "Sulfapyridine",
    "entity2": "Acetaminophen",
    "text": "<drug>Sulfapyridine</drug> may interact with any of the following: - <drug>Acetaminophen</drug> (e.g., Tylenol) (with long-term, high-dose use) or",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "methotrexate",
    "entity2": "sulfapyridine",
    "text": "- Methotrexate (e.g., Mexate) Use of <drug>methotrexate</drug> with <drug>sulfapyridine</drug> may increase the chance of side effects affecting the liver and/or the side effects of methotrexate",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "methyldopa",
    "entity2": "sulfapyridine",
    "text": "- Methyldopa (e.g., Aldomet) Use of <drug>methyldopa</drug> with <drug>sulfapyridine</drug> may increase the chance of side effects affecting the liver and/or the blood",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "phenytoin",
    "entity2": "sulfapyridine",
    "text": "- Phenytoin (e.g., Dilantin) Use of <drug>phenytoin</drug> with <drug>sulfapyridine</drug> may increase the chance of side effects affecting the liver and/or the side effects of phenytoin",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "glyburide",
    "entity2": "ciprofloxacin",
    "text": "A possible interaction between <drug>glyburide</drug> and <drug>ciprofloxacin</drug>, a fluoroquinolone antibiotic, has been reported, resulting in a potentiation of the hypoglycemic action of glyburide.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "moclobemide",
    "entity2": "almotriptan",
    "text": "Monoamine Oxidase Inhibitors: Coadministration of <drug>moclobemide</drug> resulted in a 27% decrease in <drug>almotriptan</drug> clearance and an increase in Cmax of approximately 6%.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "almotriptan",
    "entity2": "verapamil",
    "text": "Verapamil: Coadministration of <drug>almotriptan</drug> and <drug>verapamil</drug> resulted in a 24% increase in plasma concentrations of almotriptan.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "almotriptan",
    "entity2": "ketoconazole",
    "text": "Coadministration of <drug>almotriptan</drug> and the potent CYP3A4 inhibitor <drug>ketoconazole</drug> (400 mg q.d. for 3 days) resulted in an approximately 60% increase in the area under the plasma concentration-time curve and maximal plasma concentrations of almotriptan.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "itraconazole",
    "entity2": "almotriptan",
    "text": "Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., <drug>itraconazole</drug>, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when <drug>almotriptan</drug> is used concomitantly with these medications.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "ritonavir",
    "entity2": "almotriptan",
    "text": "Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, <drug>ritonavir</drug>, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when <drug>almotriptan</drug> is used concomitantly with these medications.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "erythromycin",
    "entity2": "almotriptan",
    "text": "Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and <drug>erythromycin</drug>) has not been studied, increased exposures to almotriptan may be expected when <drug>almotriptan</drug> is used concomitantly with these medications.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "charcoal",
    "entity2": "Acarbose",
    "text": "Intestinal adsorbents (e. g., <drug>charcoal</drug>) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of <drug>Acarbose</drug> and should not be taken concomitantly.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "amylase",
    "entity2": "Acarbose",
    "text": "Intestinal adsorbents (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., <drug>amylase</drug>, pancreatin) may reduce the effect of <drug>Acarbose</drug> and should not be taken concomitantly.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "pancreatin",
    "entity2": "Acarbose",
    "text": "Intestinal adsorbents (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, <drug>pancreatin</drug>) may reduce the effect of <drug>Acarbose</drug> and should not be taken concomitantly.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Acarbose",
    "entity2": "digoxin",
    "text": "<drug>Acarbose</drug> has been shown to change the bioavailabillty <drug>digoxin</drug> when they are co-administered, which may require digoxin dose adjustment.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "metformin",
    "entity2": "Acarbose",
    "text": "However, the peak plasma level of <drug>metformin</drug> was reduced by approximately 20% when taking <drug>Acarbose</drug> due to a slight delay in the absorption of metformin.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Acarbose",
    "entity2": "metformin",
    "text": "However, the peak plasma level of metformin was reduced by approximately 20% when taking <drug>Acarbose</drug> due to a slight delay in the absorption of <drug>metformin</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "PAH",
    "entity2": "procaine",
    "text": "Renal clearance measurements of <drug>PAH</drug> cannot be made with any significant accuracy in patients receiving sulfonamides, <drug>procaine</drug>, or thiazolesulfone.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "PAH",
    "entity2": "thiazolesulfone",
    "text": "Renal clearance measurements of <drug>PAH</drug> cannot be made with any significant accuracy in patients receiving sulfonamides, procaine, or <drug>thiazolesulfone</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Probenecid",
    "entity2": "PAH",
    "text": "<drug>Probenecid</drug> depresses tubular secretion of certain weak acids such as <drug>PAH</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "probenecid",
    "entity2": "PAH",
    "text": "Therefore, patients receiving <drug>probenecid</drug> will have erroneously low ERPF and Tm <drug>PAH</drug> values.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "phenobarbital",
    "entity2": "efavirenz",
    "text": "Drugs which induce CYP3A4 activity (eg, <drug>phenobarbital</drug>, rifampin, rifabutin) would be expected to increase the clearance of <drug>efavirenz</drug> resulting in lowered plasma concentrations.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "rifampin",
    "entity2": "efavirenz",
    "text": "Drugs which induce CYP3A4 activity (eg, phenobarbital, <drug>rifampin</drug>, rifabutin) would be expected to increase the clearance of <drug>efavirenz</drug> resulting in lowered plasma concentrations.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "rifabutin",
    "entity2": "efavirenz",
    "text": "Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin, <drug>rifabutin</drug>) would be expected to increase the clearance of <drug>efavirenz</drug> resulting in lowered plasma concentrations.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "naltrexone",
    "entity2": "Acamprosate",
    "text": "Co-administration of <drug>naltrexone</drug> with <drug>Acamprosate</drug> produced a 25% increase in AUC and a 33% increase in the Cmax of acamprosate.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "probenecid",
    "entity2": "cefprozil",
    "text": "Concomitant administration of <drug>probenecid</drug> doubled the AUC for <drug>cefprozil</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Aminosalicylic acid",
    "entity2": "digoxin",
    "text": "<drug>Aminosalicylic acid</drug> may decrease the amount of <drug>digoxin</drug> (Lanoxin, Lanoxicaps) that gets absorbed into your body.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "digoxin",
    "entity2": "aminosalicylic acid",
    "text": "In the case that you are taking <drug>digoxin</drug> while taking <drug>aminosalicylic acid</drug>, higher doses of digoxin may be needed.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Aminosalicylic acid",
    "entity2": "vitamin B12",
    "text": "<drug>Aminosalicylic acid</drug> may also decrease the absorption of <drug>vitamin B12</drug>, which can lead to a deficiency.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "vitamin B12",
    "entity2": "aminosalicylic acid",
    "text": "Therefore you may need to take a <drug>vitamin B12</drug> supplement while taking <drug>aminosalicylic acid</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "piperacillin",
    "entity2": "vecuronium",
    "text": "Vecuronium: When used in the perioperative period, <drug>piperacillin</drug> has been implicated in the prolongation of the neuromuscular blockade of <drug>vecuronium</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "piperacillin",
    "entity2": "vecuronium",
    "text": "In one controlled clinical study, the ureidopenicillins, including <drug>piperacillin</drug>, were reported to prolong the action of <drug>vecuronium</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Piperacillin sodium",
    "entity2": "methotrexate",
    "text": "Methotrexate: <drug>Piperacillin sodium</drug> may reduce the excretion of <drug>methotrexate</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "piperazine",
    "entity2": "pyrantel",
    "text": "Pyrantel (e.g., Antiminth) - Taking <drug>piperazine</drug> and <drug>pyrantel</drug> together may decrease the effects of piperazine.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "phenobarbital",
    "entity2": "fenoprofen",
    "text": "Chronic administration of <drug>phenobarbital</drug>, a known enzyme inducer, may be associated with a decrease in the plasma half-life of <drug>fenoprofen</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "selegiline hydrochloride",
    "entity2": "fluoxetine",
    "text": "In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., <drug>selegiline hydrochloride</drug>) in combination with serotoninergic agents (e.g., <drug>fluoxetine</drug>, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "selegiline hydrochloride",
    "entity2": "fluvoxamine",
    "text": "In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., <drug>selegiline hydrochloride</drug>) in combination with serotoninergic agents (e.g., fluoxetine, <drug>fluvoxamine</drug>, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "selegiline hydrochloride",
    "entity2": "paroxetine",
    "text": "In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., <drug>selegiline hydrochloride</drug>) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, <drug>paroxetine</drug>, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "selegiline hydrochloride",
    "entity2": "sertraline",
    "text": "In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., <drug>selegiline hydrochloride</drug>) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, <drug>sertraline</drug>, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "selegiline hydrochloride",
    "entity2": "venlafaxine",
    "text": "In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., <drug>selegiline hydrochloride</drug>) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, <drug>venlafaxine</drug>), there have been reports of serious, sometimes fatal, reactions.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Rifampin",
    "entity2": "losartan",
    "text": "<drug>Rifampin</drug>, an inducer of drug metabolism, decreased the concentrations of <drug>losartan</drug> and its active metabolite.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Fluconazole",
    "entity2": "losartan",
    "text": "<drug>Fluconazole</drug>, an inhibitor of P450 2C9, decreased active metabolite concentration and increased <drug>losartan</drug> concentration.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "losartan",
    "entity2": "indomethacin",
    "text": "As with other antihypertensive agents, the antihypertensive effect of <drug>losartan</drug> may be blunted by the non-steroidal anti-inflammatory drug <drug>indomethacin</drug>",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "celecoxib",
    "entity2": "fluconazole",
    "text": "Clinical studies with <drug>celecoxib</drug> have identified potentially significant interactions with <drug>fluconazole</drug> and lithium.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "celecoxib",
    "entity2": "lithium",
    "text": "Clinical studies with <drug>celecoxib</drug> have identified potentially significant interactions with fluconazole and <drug>lithium</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "fluconazole",
    "entity2": "celecoxib",
    "text": "Fluconazole: Concomitant administration of <drug>fluconazole</drug> at 200 mg QD resulted in a two-fold increase in <drug>celecoxib</drug> plasma concentration.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "celecoxib",
    "entity2": "fluconazole",
    "text": "This increase is due to the inhibition of <drug>celecoxib</drug> metabolism via P450 2C9 by <drug>fluconazole</drug> (see CLINICAL PHARMACOLOGY - Pharmacokinetics: Metabolism).",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "etidronate",
    "entity2": "warfarin",
    "text": "There have been isolated reports of patients experiencing increases in their prothrombin times when <drug>etidronate</drug> was added to <drug>warfarin</drug> therapy.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "esomeprazole",
    "entity2": "diazepam",
    "text": "Coadministration of <drug>esomeprazole</drug> 30 mg and <drug>diazepam</drug>, a CYP2C19 substrate, resulted in a 45% decrease in clearance of diazepam.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "esomeprazole",
    "entity2": "ketoconazole",
    "text": "Therefore, <drug>esomeprazole</drug> may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, <drug>ketoconazole</drug>, iron salts and digoxin).",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "esomeprazole",
    "entity2": "iron",
    "text": "Therefore, <drug>esomeprazole</drug> may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, <drug>iron</drug> salts and digoxin).",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "esomeprazole",
    "entity2": "digoxin",
    "text": "Therefore, <drug>esomeprazole</drug> may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and <drug>digoxin</drug>).",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "clarithromycin",
    "entity2": "pimozide",
    "text": "Concomitant administration of <drug>clarithromycin</drug> with <drug>pimozide</drug> is contraindicated.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Dexbrompheniramine",
    "entity2": "alcohol",
    "text": "<drug>Dexbrompheniramine</drug> can interact with <drug>alcohol</drug> or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "neomycin",
    "entity2": "penicillin V",
    "text": "Oral <drug>neomycin</drug> inhibits the gastrointestinal absorption of <drug>penicillin V</drug>, oral vitamin B-12, methotrexate and 5-fluorouracil.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "neomycin",
    "entity2": "vitamin B-12",
    "text": "Oral <drug>neomycin</drug> inhibits the gastrointestinal absorption of penicillin V, oral <drug>vitamin B-12</drug>, methotrexate and 5-fluorouracil.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "neomycin",
    "entity2": "methotrexate",
    "text": "Oral <drug>neomycin</drug> inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, <drug>methotrexate</drug> and 5-fluorouracil.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "neomycin",
    "entity2": "5-fluorouracil",
    "text": "Oral <drug>neomycin</drug> inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and <drug>5-fluorouracil</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "ciprofloxacin",
    "entity2": "caffeine",
    "text": "Some quinolones, including <drug>ciprofloxacin</drug>, have also been shown to interfere with the metabolism of <drug>caffeine</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "ciprofloxacin",
    "entity2": "cyclosporine",
    "text": "Some quinolones, including <drug>ciprofloxacin</drug>, have been associated with transient elevations in serum creatinine in patients receiving <drug>cyclosporine</drug> concomitantly.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "ciprofloxacin",
    "entity2": "glyburide",
    "text": "Glyburide: The concomitant administration of <drug>ciprofloxacin</drug> with the sulfonylurea <drug>glyburide</drug> has, on rare occasions, resulted in severe hypoglycemia.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "methotrexate",
    "entity2": "ciprofloxacin",
    "text": "Methotrexate Renal tubular transport of <drug>methotrexate</drug> may be inhibited by concomitant administration of <drug>ciprofloxacin</drug>, potentially leading to increased plasma levels of methotrexate.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "methotrexate",
    "entity2": "ciprofloxacin",
    "text": "Therefore, patients under <drug>methotrexate</drug> therapy should be carefully monitored when concomitant <drug>ciprofloxacin</drug> therapy is indicated.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "ciprofloxacin",
    "entity2": "magnesium",
    "text": "Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including <drug>ciprofloxacin</drug>, with multivalent cation-containing products such as <drug>magnesium</drug> or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "ciprofloxacin",
    "entity2": "aluminum",
    "text": "Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including <drug>ciprofloxacin</drug>, with multivalent cation-containing products such as magnesium or <drug>aluminum</drug> antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "ciprofloxacin",
    "entity2": "sucralfate",
    "text": "Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including <drug>ciprofloxacin</drug>, with multivalent cation-containing products such as magnesium or aluminum antacids, <drug>sucralfate</drug>, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "ciprofloxacin",
    "entity2": "calcium",
    "text": "Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including <drug>ciprofloxacin</drug>, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing <drug>calcium</drug>, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "ciprofloxacin",
    "entity2": "iron",
    "text": "Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including <drug>ciprofloxacin</drug>, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, <drug>iron</drug>, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "ciprofloxacin",
    "entity2": "zinc",
    "text": "Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including <drug>ciprofloxacin</drug>, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or <drug>zinc</drug> may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "ciprofloxacin",
    "entity2": "ciprofloxacin",
    "text": "Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including <drug>ciprofloxacin</drug>, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of <drug>ciprofloxacin</drug>, resulting in serum and urine levels considerably lower than desired.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "phenytoin",
    "entity2": "ciprofloxacin",
    "text": "Phenytoin: Altered serum levels of <drug>phenytoin</drug> (increased and decreased) have been reported in patients receiving concomitant <drug>ciprofloxacin</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Probenecid",
    "entity2": "ciprofloxacin",
    "text": "Probenecid: <drug>Probenecid</drug> interferes with renal tubular secretion of <drug>ciprofloxacin</drug> and produces an increase in the level of ciprofloxacin in serum.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Probenecid",
    "entity2": "ciprofloxacin",
    "text": "Probenecid: <drug>Probenecid</drug> interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of <drug>ciprofloxacin</drug> in serum.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "ciprofloxacin",
    "entity2": "theophylline",
    "text": "Theophylline: As with some other quinolones, concurrent administration of <drug>ciprofloxacin</drug> with <drug>theophylline</drug> may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "clarithromycin",
    "entity2": "cisapride",
    "text": "Antibiotics: In vitro and/or in vivo data show that <drug>clarithromycin</drug>, erythromycin, and troleandomycin markedly inhibit the metabolism of <drug>cisapride</drug>, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "erythromycin",
    "entity2": "cisapride",
    "text": "Antibiotics: In vitro and/or in vivo data show that clarithromycin, <drug>erythromycin</drug>, and troleandomycin markedly inhibit the metabolism of <drug>cisapride</drug>, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "troleandomycin",
    "entity2": "cisapride",
    "text": "Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and <drug>troleandomycin</drug> markedly inhibit the metabolism of <drug>cisapride</drug>, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "dicyclomine",
    "entity2": "cisapride",
    "text": "Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and <drug>dicyclomine</drug>, would be expected to compromise the beneficial effects of <drug>cisapride</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "nefazodone",
    "entity2": "cisapride",
    "text": "Antidepressants: In vitro data indicate that <drug>nefazodone</drug> inhibits the metabolism of <drug>cisapride</drug>, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "fluconazole",
    "entity2": "cisapride",
    "text": "Antifungals: In vitro and/or in vivo data indicate that <drug>fluconazole</drug>, itraconazole, and oral ketoconazole markedly inhibit the metabolism of <drug>cisapride</drug>, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "itraconazole",
    "entity2": "cisapride",
    "text": "Antifungals: In vitro and/or in vivo data indicate that fluconazole, <drug>itraconazole</drug>, and oral ketoconazole markedly inhibit the metabolism of <drug>cisapride</drug>, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "ketoconazole",
    "entity2": "cisapride",
    "text": "Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral <drug>ketoconazole</drug> markedly inhibit the metabolism of <drug>cisapride</drug>, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "ketoconazole",
    "entity2": "cisapride",
    "text": "Human pharmacokinetic data indicate that oral <drug>ketoconazole</drug> markedly inhibits the metabolism of <drug>cisapride</drug>, resulting in a mean eight-fold increase in AUC of cisapride.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "cisapride",
    "entity2": "ketoconazole",
    "text": "A study in 14 normal male and female volunteers suggests that coadministration of <drug>cisapride</drug> and <drug>ketoconazole</drug> can result in prolongation of the QT interval on the ECG.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Cimetidine",
    "entity2": "cisapride",
    "text": "H2 Receptor Antagonists: <drug>Cimetidine</drug> coadministration leads to an increased peak plasma concentration and AUC of <drug>cisapride</drug>, there is no effect on cisapride absorption when it is coadministered with ranitidine.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "cimetidine",
    "entity2": "cisapride",
    "text": "The gastrointestinal absorption of <drug>cimetidine</drug> and ranitidine is accelerated when they are coadministered with <drug>cisapride</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "ranitidine",
    "entity2": "cisapride",
    "text": "The gastrointestinal absorption of cimetidine and <drug>ranitidine</drug> is accelerated when they are coadministered with <drug>cisapride</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "indinavir",
    "entity2": "cisapride",
    "text": "Protease Inhibitors: In vitro data indicate that <drug>indinavir</drug> and ritonavir markedly inhibit the metabolism of <drug>cisapride</drug> which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "ritonavir",
    "entity2": "cisapride",
    "text": "Protease Inhibitors: In vitro data indicate that indinavir and <drug>ritonavir</drug> markedly inhibit the metabolism of <drug>cisapride</drug> which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "Cisapride",
    "entity2": "quinidine",
    "text": "<drug>Cisapride</drug> should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as <drug>quinidine</drug> and procainamide) and Class III (such as sotalol);",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "Cisapride",
    "entity2": "procainamide",
    "text": "<drug>Cisapride</drug> should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and <drug>procainamide</drug>) and Class III (such as sotalol);",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "Cisapride",
    "entity2": "sotalol",
    "text": "<drug>Cisapride</drug> should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as <drug>sotalol</drug>);",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "dantrolene sodium",
    "entity2": "verapamil",
    "text": "It is recommended that the combination of intravenous <drug>dantrolene sodium</drug> and calcium channel blockers, such as <drug>verapamil</drug>, not be used together during the management of malignant hyperthermia crisis until the relevance of these findings to humans is established.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "dantrolene",
    "entity2": "vecuronium",
    "text": "Administration of <drug>dantrolene</drug> may potentiate <drug>vecuronium</drug>-induced neuromuscular block.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "amiodarone",
    "entity2": "indinavir",
    "text": "A case report of one patient taking <drug>amiodarone</drug> 200 mg and <drug>indinavir</drug> 800 mg three times a day resulted in increases in amiodarone concentrations from 0.9 mg/L to 1.3 mg/L.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "ciprofloxacin",
    "entity2": "magnesium",
    "text": "Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of <drug>ciprofloxacin</drug> are decreased when administered with antacids containing <drug>magnesium</drug>, calcium, or aluminum.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "ciprofloxacin",
    "entity2": "calcium",
    "text": "Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of <drug>ciprofloxacin</drug> are decreased when administered with antacids containing magnesium, <drug>calcium</drug>, or aluminum.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "ciprofloxacin",
    "entity2": "aluminum",
    "text": "Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of <drug>ciprofloxacin</drug> are decreased when administered with antacids containing magnesium, calcium, or <drug>aluminum</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "ciprofloxacin",
    "entity2": "didanosine",
    "text": "The AUC of ciprofloxacin was decreased an average of 15-fold in 12 healthy subjects given <drug>ciprofloxacin</drug> and <drug>didanosine</drug>-placebo tablets concurrently.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "ciprofloxacin",
    "entity2": "didanosine",
    "text": "In a single subject given one dose of <drug>ciprofloxacin</drug> 2 hours after a dose of <drug>didanosine</drug>-placebo tablets, a greater than 50% reduction in the AUC of ciprofloxacin was observed.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "terfenadine",
    "entity2": "dirithromycin",
    "text": "in one man, the C max of terfenadine was 8.1 ng/mL with terfenadine alone and 7.2 ng/mL with <drug>terfenadine</drug> plus <drug>dirithromycin</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "terfenadine",
    "entity2": "dirithromycin",
    "text": "The mean QT c interval (msec) was 369 with terfenadine alone and 367 with <drug>terfenadine</drug> plus <drug>dirithromycin</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "erythromycin",
    "entity2": "terfenadine",
    "text": "Thus, the interaction observed between <drug>erythromycin</drug> and <drug>terfenadine</drug> is not expected for dirithromycin.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "Erythromycin",
    "entity2": "triazolam",
    "text": "Triazolam: <drug>Erythromycin</drug> has been reported to decrease the clearance of <drug>triazolam</drug> and, thus, may increase the pharmacologic effect of triazolam.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Erythromycin",
    "entity2": "triazolam",
    "text": "Triazolam: <drug>Erythromycin</drug> has been reported to decrease the clearance of triazolam and, thus, may increase the pharmacologic effect of <drug>triazolam</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "erythromycin",
    "entity2": "digoxin",
    "text": "Digoxin: Concomitant administration of <drug>erythromycin</drug> and <drug>digoxin</drug> has been reported to result in elevated digoxin serum levels.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "erythromycin",
    "entity2": "ergotamine",
    "text": "Ergotamine: Concurrent use of <drug>erythromycin</drug> and <drug>ergotamine</drug> or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "erythromycin",
    "entity2": "dihydroergotamine",
    "text": "Ergotamine: Concurrent use of <drug>erythromycin</drug> and ergotamine or <drug>dihydroergotamine</drug> has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "erythromycin",
    "entity2": "cyclosporine",
    "text": "Other drugs Drug interactions have been reported with concomitant administration of <drug>erythromycin</drug> and other medications, including <drug>cyclosporine</drug>, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "erythromycin",
    "entity2": "hexobarbital",
    "text": "Other drugs Drug interactions have been reported with concomitant administration of <drug>erythromycin</drug> and other medications, including cyclosporine, <drug>hexobarbital</drug>, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "erythromycin",
    "entity2": "carbamazepine",
    "text": "Other drugs Drug interactions have been reported with concomitant administration of <drug>erythromycin</drug> and other medications, including cyclosporine, hexobarbital, <drug>carbamazepine</drug>, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "erythromycin",
    "entity2": "alfentanil",
    "text": "Other drugs Drug interactions have been reported with concomitant administration of <drug>erythromycin</drug> and other medications, including cyclosporine, hexobarbital, carbamazepine, <drug>alfentanil</drug>, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "erythromycin",
    "entity2": "disopyramide",
    "text": "Other drugs Drug interactions have been reported with concomitant administration of <drug>erythromycin</drug> and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, <drug>disopyramide</drug>, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "erythromycin",
    "entity2": "phenytoin",
    "text": "Other drugs Drug interactions have been reported with concomitant administration of <drug>erythromycin</drug> and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, <drug>phenytoin</drug>, bromocriptine, valproate, astemizole, and lovastatin.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "erythromycin",
    "entity2": "bromocriptine",
    "text": "Other drugs Drug interactions have been reported with concomitant administration of <drug>erythromycin</drug> and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, <drug>bromocriptine</drug>, valproate, astemizole, and lovastatin.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "erythromycin",
    "entity2": "valproate",
    "text": "Other drugs Drug interactions have been reported with concomitant administration of <drug>erythromycin</drug> and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, <drug>valproate</drug>, astemizole, and lovastatin.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "erythromycin",
    "entity2": "astemizole",
    "text": "Other drugs Drug interactions have been reported with concomitant administration of <drug>erythromycin</drug> and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, <drug>astemizole</drug>, and lovastatin.",
    "source": "DrugBank"
  },
  {
    "_id": 3,
    "label_name": "int",
    "entity1": "erythromycin",
    "entity2": "lovastatin",
    "text": "Other drugs Drug interactions have been reported with concomitant administration of <drug>erythromycin</drug> and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and <drug>lovastatin</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "bupropion",
    "entity2": "carbamazepine",
    "text": "While not systematically studied, certain drugs may induce the metabolism of <drug>bupropion</drug> (e.g., <drug>carbamazepine</drug>, phenobarbital, phenytoin).",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "bupropion",
    "entity2": "phenobarbital",
    "text": "While not systematically studied, certain drugs may induce the metabolism of <drug>bupropion</drug> (e.g., carbamazepine, <drug>phenobarbital</drug>, phenytoin).",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "bupropion",
    "entity2": "phenytoin",
    "text": "While not systematically studied, certain drugs may induce the metabolism of <drug>bupropion</drug> (e.g., carbamazepine, phenobarbital, <drug>phenytoin</drug>).",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "bupropion",
    "entity2": "desipramine",
    "text": "In a study of 15 male subjects (ages 19 to 35 years) who were extensive metabolizers of the CYP2D6 isoenzyme, daily doses of <drug>bupropion</drug> given as 150 mg twice daily followed by a single dose of 50 mg <drug>desipramine</drug> increased the Cmax, AUC, and t1/2 of desipramine by an average of approximately 2-, 5- and 2-fold, respectively.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "bupropion",
    "entity2": "nortriptyline",
    "text": "Therefore, co-administration of <drug>bupropion</drug> with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., <drug>nortriptyline</drug>, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "bupropion",
    "entity2": "imipramine",
    "text": "Therefore, co-administration of <drug>bupropion</drug> with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, <drug>imipramine</drug>, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "bupropion",
    "entity2": "desipramine",
    "text": "Therefore, co-administration of <drug>bupropion</drug> with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, <drug>desipramine</drug>, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "bupropion",
    "entity2": "paroxetine",
    "text": "Therefore, co-administration of <drug>bupropion</drug> with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, <drug>paroxetine</drug>, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "bupropion",
    "entity2": "fluoxetine",
    "text": "Therefore, co-administration of <drug>bupropion</drug> with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, <drug>fluoxetine</drug>, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "bupropion",
    "entity2": "sertraline",
    "text": "Therefore, co-administration of <drug>bupropion</drug> with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, <drug>sertraline</drug>), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "bupropion",
    "entity2": "haloperidol",
    "text": "Therefore, co-administration of <drug>bupropion</drug> with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., <drug>haloperidol</drug>, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "bupropion",
    "entity2": "risperidone",
    "text": "Therefore, co-administration of <drug>bupropion</drug> with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, <drug>risperidone</drug>, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "bupropion",
    "entity2": "thioridazine",
    "text": "Therefore, co-administration of <drug>bupropion</drug> with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, <drug>thioridazine</drug>), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "bupropion",
    "entity2": "metoprolol",
    "text": "Therefore, co-administration of <drug>bupropion</drug> with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., <drug>metoprolol</drug>), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "bupropion",
    "entity2": "propafenone",
    "text": "Therefore, co-administration of <drug>bupropion</drug> with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., <drug>propafenone</drug>, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "bupropion",
    "entity2": "flecainide",
    "text": "Therefore, co-administration of <drug>bupropion</drug> with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, <drug>flecainide</drug>), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "bupropion",
    "entity2": "phenelzine",
    "text": "MAO Inhibitors: Studies in animals demonstrate that the acute toxicity of <drug>bupropion</drug> is enhanced by the MAO inhibitor <drug>phenelzine</drug> .",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "bupropion",
    "entity2": "levodopa",
    "text": "Levodopa and Amantadine: Limited clinical data suggest a higher incidence of adverse experiences in patients receiving <drug>bupropion</drug> concurrently with either <drug>levodopa</drug> or amantadine.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "bupropion",
    "entity2": "amantadine",
    "text": "Levodopa and Amantadine: Limited clinical data suggest a higher incidence of adverse experiences in patients receiving <drug>bupropion</drug> concurrently with either levodopa or <drug>amantadine</drug>.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "cinacalcet",
    "entity2": "amitriptyline",
    "text": "Amitriptyline: Concurrent administration of 25 mg or 100 mg <drug>cinacalcet</drug> with 50 mg <drug>amitriptyline</drug> increased amitriptyline exposure and nortriptyline (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "ketoconazole",
    "entity2": "cinacalcet",
    "text": "Co-administration of <drug>ketoconazole</drug>, a strong inhibitor of CYP3A4, increased <drug>cinacalcet</drug> exposure following a single 90 mg dose of Sensipar by 2.3 fold.",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Cyclopentolate",
    "entity2": "carbachol",
    "text": "<drug>Cyclopentolate</drug> may interfere with the anti-glaucoma action of <drug>carbachol</drug> or pilocarpine;",
    "source": "DrugBank"
  },
  {
    "_id": 0,
    "label_name": "effect",
    "entity1": "Cyclopentolate",
    "entity2": "pilocarpine",
    "text": "<drug>Cyclopentolate</drug> may interfere with the anti-glaucoma action of carbachol or <drug>pilocarpine</drug>;",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "calcium",
    "entity2": "L-lysine",
    "text": "Concomitant use of <drug>calcium</drug> supplements and <drug>L-lysine</drug> may increase calcium absorption",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "fenofibrate",
    "entity2": "pravastatin",
    "text": "Concomitant administration of <drug>fenofibrate</drug> (equivalent to 145mg TRICOR) with <drug>pravastatin</drug> (40 mg) once daily for 10 days has been shown to increase the mean Cmax and AUC values for pravastatin by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3 -hydroxy-iso-pravastatin by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively in 23 healthy adults.",
    "source": "DrugBank"
  },
  {
    "_id": 1,
    "label_name": "mechanism",
    "entity1": "fenofibrate",
    "entity2": "atorvastatin",
    "text": "Concomitant administration of <drug>fenofibrate</drug> (equivalent to 145 mg TRICOR) with <drug>atorvastatin</drug> (20 mg) once daily for 10 days resulted in approximately 17% decrease (range from 67% decrease to 44% increase) in atorvastatin AUC values in 22 healthy males.",
    "source": "DrugBank"
  },
  {
    "_id": 2,
    "label_name": "advise",
    "entity1": "Auranofin",
    "entity2": "penicillamine",
    "text": "<drug>Auranofin</drug> should not be used together with <drug>penicillamine</drug> (Depen, Cuprimine), another arthritis medication.",
    "source": "DrugBank"
  }
]